



Invited Review

Glioblastoma multiforme (GBM): An overview of current therapies and mechanisms of resistance



Wei Wu ^{a,1}, Jessica L. Klockow ^{b,1}, Michael Zhang ^{a,c}, Famyrah Lafortune ^a, Edwin Chang ^a, Linchun Jin ^d, Yang Wu ^e, Heike E. Daldrup-Link ^{a,*}

^a Department of Radiology, Molecular Imaging Program at Stanford, Stanford University, Stanford, CA 94305, USA

^b Department of Radiation Oncology, Stanford University, Stanford, CA 94305, USA

^c Department of Neurosurgery, Stanford University, Stanford, CA 94305, USA

^d Lillian S. Wells Department of Neurosurgery, University of Florida, Gainesville, FL 32611, USA

^e Department of Neuropathology, Institute of Pathology, Technical University of Munich, Munich, Bayern 81675, Germany

ARTICLE INFO

ABSTRACT

Keywords:

Glioblastoma

Radiotherapy

Chemotherapy

Targeted therapy

Nanotherapy

Immunotherapy

Chemical compounds studied in this article:

Temozolomide (PubChem CID: 5394)

Carmustine (PubChem CID: 2578)

Lomustine (PubChem CID: 3950)

Cediranib (PubChem CID: 9933475)

Erlotinib (PubChem CID: 176870)

Gefitinib (PubChem CID: 123631)

Veliparib (PubChem CID: 11960529)

Olaparib (PubChem CID: 23725625)

Niraparib (PubChem CID: 24958200)

Irinotecan (PubChem CID: 60838)

Glioblastoma multiforme (GBM) is a WHO grade IV glioma and the most common malignant, primary brain tumor with a 5-year survival of 7.2%. Its highly infiltrative nature, genetic heterogeneity, and protection by the blood brain barrier (BBB) have posed great treatment challenges. The standard treatment for GBMs is surgical resection followed by chemoradiotherapy. The robust DNA repair and self-renewing capabilities of glioblastoma cells and glioma initiating cells (GICs), respectively, promote resistance against all current treatment modalities. Thus, durable GBM management will require the invention of innovative treatment strategies. In this review, we will describe biological and molecular targets for GBM therapy, the current status of pharmacologic therapy, prominent mechanisms of resistance, and new treatment approaches. To date, medical imaging is primarily used to determine the location, size and macroscopic morphology of GBM before, during, and after therapy. In the future, molecular and cellular imaging approaches will more dynamically monitor the expression of molecular targets and/or immune responses in the tumor, thereby enabling more immediate adaptation of tumor-tailored, targeted therapies.

1. Introduction

1.1. The epidemiology and etiology of GBM

Glioblastoma multiforme (GBM) is a WHO grade IV brain tumor which represents one of the most lethal human cancers. The incidence of GBM increases with age and shows the highest incidence in the 75–84-year old age group in the United States [1]. The incidence is higher in men than women, as well as in Caucasians than in other ethnicities [2]. According to gene profile analysis and genetic modeling of GBM in mice, there is evidence that GBM is derived from neural stem cells (NSCs), NSC-derived astrocytes, and oligodendrocyte precursor cells (OPCs) [3].

GBM tumors derived from different cellular origins show different behaviors in animal models [3] (Fig. 1). Exposure of the central nervous system (CNS) to ionizing radiation has been associated with an increased risk to develop malignant brain gliomas, excess relative risk (ERR) estimates for brain/CNS tumors ranged per Gy from 0.19 (95% confidence interval [CI]: 0.03, 0.85) to 5.6 (95% CI: 3.0, 9.4) [4].

1.2. The ongoing challenges of GBM treatment

Standard therapy for GBM encompasses surgical resection followed by chemoradiotherapy, using temozolomide (TMZ) [5]. However, 5-year survival is only 7.2% in the United States according to CBTRUS

* Correspondence to: 725 Welch Road, Rm 1665, Stanford, CA 94305, USA.

E-mail address: heiked@stanford.edu (H.E. Daldrup-Link).

¹ Co-first author.

Statistical Report 2020 [6]. Despite maximal surgical resection and aggressive adjuvant therapy, almost all GBM tumors locally recur after treatment [7]. Ongoing challenges to GBM treatment include its incomplete resection, high degree of genetic heterogeneity, exclusive blood brain barrier (BBB), and immunosuppressive microenvironment.

1.2.1. High infiltration

The highly infiltrative nature of GBM makes complete resection at the cellular level nearly impossible [8]. Also, abundant hypoxic regions provide perivascular niches for glioma initiating cells (GICs). These self-renewing cells can yield potentially more aggressive recurrent tumors that are radioresistant and chemoresistant [9,10].

1.2.2. Intertumor and intratumor heterogeneity

Large intertumor and intratumor heterogeneity have complicated targeted therapy development [11]. Based on their genetic and epigenetic markers, GBMs were previously classified by The Cancer Genome Atlas (TCGA) into four clusters: mesenchymal, classical, proneural, and neural [12,13]. Mesenchymal GBMs are characterized by the neurofibromin 1 (NF1) tumor suppressor gene mutation as well as by frequent mutations in the PTEN and TP53 tumor suppressor genes. The classical subtype is highly proliferative and characterized by EGFR amplification, but no TP53 mutation. Meanwhile proneural GBM is frequently associated with TP53 mutation, and uniquely with IDH1 and PDGFRA mutations. The neural subtype is characterized by many genes which also exist in the brain's normal noncancerous neurons [12,14]. Another GBM tumor transcriptome analysis described only three subtypes: proneural, classical, mesenchymal. The authors proposed that the neural subtype may be due to contamination of the original samples with non-tumor cells [13,15]. The mesenchymal and classical subtypes are typically more aggressive tumors, while the proneural subtype is less aggressive and more often seen in younger patients [13]. The proneural-to-mesenchymal phenotype transition is associated with GBM resistance [16]. Even though TCGA has categorized GBM into four subgroups, recent studies show that different GBM subgroups vary spatially and temporally within the same tumor [17]. Patel et al. showed with single cell RNA sequencing that a single tumor can include a diversity of cells that comprise all the GBM subgroups [18] (Fig. 1).

1.2.3. Blood brain barrier (BBB)

Another challenge to GBM treatment is delivering chemotherapeutic drugs across the blood brain barrier (BBB). The BBB is a protective boundary between the circulatory system and the extracellular space of the central nervous system. The BBB is mainly composed of endothelial cells that form a tight barrier along the wall of blood vessels and selectively limit the compounds that can cross into the parenchyma [19]. Tight junctions are less than 1 nm in size and prohibit penetration of >98% of small molecules. Unlike in healthy brain tissue, the BBB in GBM exhibits enhanced permeability due to poorly formed, leaky blood vessels, upregulated transporter proteins, and downregulated tight junction proteins [20,21]. However, the disruption of the BBB is not

uniform throughout a given tumor, with some areas exhibiting blood vessels with higher permeability and other tumor areas with more intact vessels and/or vascular shunts. Even if a chemotherapeutic drug managed to extravasate into the tumor tissue, it can often not gain therapeutic levels in tumor cells due to upregulation of efflux pumps by glioblastoma cells [22]. Ultimately there remains a substantial proportion of GBM with locoregional intact BBB and upregulated efflux pumps [23,24].

1.2.4. Immunosuppressive microenvironment

The microenvironment of GBM creates treatment challenges. Some authors refer to GBM with an immunosuppressive microenvironment as "cold tumors". These tumors lack pre-existing tumor T cell infiltration which results in tumor resistance to immune checkpoint inhibitors [25]. These tumors are further characterized by their lack of tumor antigens, defects in antigen presentation, and high accumulation of immunosuppressive cells [26,27]. Treatment with immune checkpoint inhibitors shows limited efficacy [28]. In contrast, "hot tumors" are infiltrated with swarms of T cells, and thus more immunogenic. Turning "cold" to "hot" may be achieved by combinatorial approaches that boost anti-tumor immunity [27].

Given the genomic complexity and global alterations of multiple signaling pathways in GBM, consistent effort has been put forth to improve systemic therapies for glioblastoma. In the following sections, we will address how pharmacologic therapies have evolved, how mechanisms of resistance develop, and how new strategies have emerged.

2. GBM traditional therapy and resistance

2.1. Traditional therapy

2.1.1. Surgical resection

Surgical resection of brain tumors was revolutionized in the late 1980s and early 1990s with the development of frameless stereotaxy. It enabled the very precise placement of surgical instruments using image guidance and has been modernized with new imaging technologies [29]. Additionally, cerebral cortical stimulation has enabled intraoperative localization of eloquent cortex regions of the brain that need be avoided during surgery. This technique, or "brain mapping" accounts for individual variations in anatomy or tissue reorganization to remove tumor in areas of great functional importance and that are responsible for quality of life [30,31].

The extent of tumor resection has been positively correlated with survival time, with gross total resection (GTR) being desirable when possible [1, 32–36]. There are, however, major challenges to achieving GTR, including successful identification of tumor margins as well as avoiding adjacent eloquent cortex. Even though the tumor margins can be roughly determined through imaging, GBM grows with microscopic, finger-like projections, imperceptible to presurgical or even intraoperative imaging techniques [37].




Fig. 1. Cellular origin and heterogeneity of glioblastoma multiform (GBM). GBM tumors originate from three types of cells in the brain parenchyma: neural stem cells (NSCs), NSC-derived astrocytes, and oligodendrocyte precursor cells (OPCs). GBM is characterized by extensive intertumor and intratumor heterogeneity, and has, therefore, been divided into four sub-groups: mesenchymal, classical, proneural, and neural.

Imaging is an increasingly important tool for GBM resection [29]. Images can guide biopsies [38–40], identify tumor margins [41–43], and localize critical brain structures that need to be spared [44]. Computed tomography (CT) is valuable for emergent imaging, while MRI is the gold standard for brain tumor imaging due to its higher anatomical resolution and higher soft tissue contrast. Depending on the MRI contrast and pulse sequence used, important features of the tumor and brain tissue can be elucidated including blood vessels, tumor necrosis, and hemorrhage (T1-weighted with contrast), cerebrospinal fluid (T2-weighted), blood perfusion (dynamic susceptibility contrast (DSC)), dynamic contrast enhanced (DCE) and arterial spin labeling (ASL) [45, 46]. Some studies have advocated supramaximal resection, thereby resecting beyond the T1 contrast enhancing portion [47].

Both intraoperative fluorescence imaging and MR imaging can help to address the challenging phenomenon of “brain shift” or movement of the brain during surgery, which can lead to discrepancies between the location of the tumor and critical brain structures on preoperative imaging studies and in the operating room. Some shifts can be up to 2 cm in distance and result from causes that are physical (e.g., patient position, gravity), surgical (types of equipment used, tissue/fluid loss during procedure), or biological (e.g., tumor type/location, drugs used to manage intracranial pressure). Unfortunately, this phenomenon worsens with increasing duration of the surgery and cannot be corrected for using neuronavigational devices that derive stereotactic capabilities from pre-operative MRI images [48].

Fluorescent imaging has been performed with fluorescein, indocyanine green (ICG), and 5-aminolevulinic acid (5-ALA) [49–52]. Fluorescein is of historical relevance, as it is one of the first intraoperative imaging adjuncts. While fluorescein does not typically cross an intact the BBB, it does penetrate high grade gliomas (HGGs) in areas of enhanced permeability [53]. Likewise, ICG has been of historical value, primarily for angiography and vessel delineation rather than parenchymal margins. Currently, 5-aminolevulinic acid (5-ALA) has become the standard of care among intraoperative fluorescent agents and has received regulatory approval in the US and Europe [49]. 5-ALA is a precursor to heme that can cross the BBB and converts to the fluorescent compound protoporphyrin IX in the mitochondria. The mechanisms underlying its accumulation in brain tumors are still not well understood. It exhibits higher specificity over fluorescein (67% vs 33%) [54]. Studies have also shown that GTR or near-GTR rate is higher in patients that underwent fluorescence-guided surgery with 5-ALA compared to patients that were operated under white light only (65% vs 36%) [50]. Additional clinical trials are now being performed using IRDye800CW and ZW800-1 for targeted imaging [55,56],

Intraoperative MRI and ultrasound (iMRI and iUS, respectively) help surgeons identify residual cancer in surgeries [57,58]. The surgeon resects a brain tumor, then performs a contrast-enhanced MRI in the operating room on an intraoperative MRI scanner. If residual enhancing tissue is found, then this residual tissue is removed in the same surgery.

2.1.2. Chemotherapy

2.1.2.1. Cytotoxic chemotherapy. The standard post-surgical treatment regimen includes 6 weeks of concomitant TMZ (75 mg/m^2) and radiation followed by adjuvant TMZ ($150\text{--}200 \text{ mg/m}^2$) for 5 days every 28 days for six cycles [59]. TMZ, the most widely used chemotherapeutic drug for GBM, is a small molecular alkylating agent that directly damages tumors by methylating the purine bases of DNA [60]. The key cytotoxic action is through formation of O⁶-methylguanine lesions which results in apoptosis, autophagy, and cellular senescence [61–64]. In addition, it was discovered that TMZ has radiation-sensitizing properties. It increases the likelihood of radiation-induced DNA double strand breaks and cell death when the drug is administered at the same time as radiation therapy [65].

The most common side effect from TMZ is hematologic toxicity [66].

Thrombocytopenia has been identified in 10–20% of patients. In a Phase II clinical trial, the addition of a thrombopoietin receptor agonist, Romiplostim to adjuvant CCRT (concurrent chemoradiation therapy) has increased the rate of completed regimens [67]. Non-hematologic toxicities from TMZ are less common and include nausea, anorexia, fatigue, and hepatotoxicity [68].

Several nitrosourea reagents have also been explored for GBM treatment. Carmustine (also known as BCNU) is a small nitrogen mustard compound and alkylating agent. It induces interstrand cross-links between the guanine and cytosine bases in DNA [69]. Carmustine rose to prominence with the advent of Gliadel® wafers, which are FDA (U.S. Food and Drug Administration Agency)-approved biodegradable discs that are intraoperatively placed in the resection cavity to provide a slow release of drug over two weeks [70]. The alkylating therapeutic effects of carmustine can be reversed by the enzyme alkyl guanine transferase (AGT). Therefore, carmustine is sometimes used in concert with AGT inhibitors to ensure therapeutic efficacy [71]. Side effects include abnormal wound healing and intracranial infections since the wafers present as foreign bodies [72]. Another alkylating anti-tumor reagent is lomustine. Due to its high lipophilicity and small size, lomustine can cross the BBB. Thus, lomustine can be given orally [73]. Fotemustine, another molecule in this family of drugs, has been used for melanoma and is now tested for its efficacy with recurrent glioblastoma [74].

2.1.2.2. Anti-angiogenic chemotherapy. Bevacizumab is a humanized monoclonal antibody with anti-angiogenic properties and is administered intravenously. It binds to and inhibits vascular endothelial growth factor A (VEGF-A) which initiates growth of new blood vessels when bound to its receptor. The levels of VEGF-A in GBM are estimated to be approximately 30 times higher than in low grade astrocytomas making it an attractive therapeutic target. While bevacizumab appears to improve progression-free survival, it does not significantly improve overall survival for patients with newly diagnosed glioblastoma [75]. Therefore, it is predominantly used to treat recurrent glioblastomas. The use of bevacizumab with irinotecan a small molecular prodrug that is converted a topoisomerase I inhibitor, is being explored [76,77]. Bevacizumab's side effects most commonly include hypertension and leukopenia [74,78].

2.1.3. Radiation therapy (RT)

Radiation therapy can be utilized in several forms (e.g., x-ray photons, gamma photons, protons), but not all have become validated for standard of care (Table 1). Conceptually, it can be administered to help provide local control for the microscopic disease unaddressed by surgical resection. In CCRT, patients receive 3D conformal RT which uses x-ray photons that are directed at the tumor target from several different angles. CT and MRI images are used to plan the delivery of the therapeutic dose to the tumor site. Radiation therapy is usually distributed over 6 weeks in 2 gray (Gy) fractions for a total dose of 40–60 Gy [79]. A typical device for RT possesses elaborate multi-leaf collimators which allow very specific shaped beams to target the tumor and provide a small (1–2 cm) margin around the periphery. Treatment with x-rays confers low linear energy transfer which results in both direct and indirect biological damage. Direct damage to DNA makes up approximately one-third of the treatment effect, and indirect effects (namely, ionization of water to produce free radicals which damage DNA), make up approximately two-thirds [80].

Conformal RT has been preferred in the clinic over whole brain radiation since recurrent gliomas tends to appear within 2 cm from the original tumor site in 80–90% of cases [81]. Thus, conformal RT is designed to target the majority of residual GBM cells while sparing healthy brain tissue and thereby, minimize cognitive side effects. Intensity-modulated RT also uses multi-leafed collimators, but can redistribute ionizing radiation across the target depending on its

Table 1

Summary of therapeutic strategies to treat GBM.

Treatment	Biological action	Notes
Image-guided surgery		
Intraoperative ultrasonography	tumor removal	Routine clinical use. Used in ORs for maximal safe resection of brain tumors since the 1980s
Intraoperative MRI	tumor removal	Routine clinical use. The first iMRI system was installed in 1994 at Brigham and Women's Hospital
Intraoperative fluorescence imaging	tumor removal	New clinical use. In 2017, Gleolan® (5-aminolevulinic acid) was FDA-approved for intraoperative fluorescence imaging
Chemotherapy (small molecules)		
Temozolomide	alkylates DNA base pairs	Routine clinical use. Approved by the FDA in 1999 as a monotherapy and again in 2005 for use in newly diagnosed GBM concomitantly with radiotherapy and as maintenance treatment
Carmustine (BCNU)	alkylates DNA base pairs	Routine clinical use. Gliadel® wafers were approved by the FDA for recurrent GBM in 1997 and for the newly diagnosed high-grade gliomas (III and IV) in 2003
Lomustine (CCNU)	alkylates DNA base pairs	Routine clinical use. FDA approved in 2014 for patients with brain tumors following surgery and/or radiotherapy
Fotemustine	alkylates DNA base pairs	Approved in Europe but not in the US. Phase II clinical trials have shown therapeutic benefit in recurrent GBM
Radiation therapy (RT)		
2D conventional RT	creates DNA double-strand breaks and ROS	Routine clinical use. Largely being phased out for brain RT. Still used in some instances of uncomplicated bone metastases
3D conformal RT	creates DNA double-strand breaks and ROS	Routine clinical use. Good for advanced and inoperable tumors; used post-operatively
Intensity-modulated RT	creates DNA double-strand breaks and ROS	Routine clinical use as adjuvant therapy after surgical tumor resection
Stereotactic radiosurgery (SRS)	creates DNA double-strand breaks and ROS	Routine clinical use with either a gamma emitter (e.g., Gamma Knife) or a linear accelerator (e.g., Cyber Knife)
Brachytherapy	creates DNA double-strand breaks and ROS	Clinical adoption is slow due to adverse events and risk of exposure to people in close proximity to the patient
Particle RT (Proton therapy)	creates DNA double-strand breaks and ROS	FDA approved but reimbursement for the procedure is low. Phase II clinical trials are underway to evaluate the efficacy of proton versus photon irradiation (NCT02179086, NCT01854554)
Inhibitor therapy		
Bevacizumab (mAb)	inhibits VEGF-A	Routine clinical use. FDA approved for recurrent GBM in 2009
Irinotecan (CPT-11) (small molecule)	inhibits topoisomerase I	Phase I/II trials for recurrent GBM showed mixed results. Phase II clinical trials for combination therapies are under way for recurrent and pediatric GBM (NCT04267978, NCT02192359)
Veliparib (ABT-888) (small molecule)	inhibits PARP	Phase II trials in adults with recurrent (NCT01026493) and new (NCT00770471, NCT02152982) GBM showed limited benefit. A phase I/II study of veliparib with RT and TMZ in children with diffuse intrinsic pontine glioma reported little to no survival benefit (NCT01514201)
Olaparib (AZD-2281, MK-7339) (small molecule)	inhibits PARP	Phase II trials in recurrent GBM are ongoing (NCT03212274). Olaparib exacerbated hematological toxicities when used with TMZ in patients with recurrent GBM (NCT01390571). Further studies are warranted to understand potential clinical benefit
Niraparib (MK-4827) (small molecule)	inhibits PARP	A phase I trial evaluated niraparib and TMZ in advanced cancer but with few GBM patients (NCT01294735). A phase II trial evaluating niraparib with TTFs in recurrent GBM is underway (NCT04221503). May be good treatment option for tumors over-expressing EGFR
Pamiparib (BGB-290) (small molecule)	inhibits PARP	Phase I/II trials are underway studying pamiparib with TMZ in new and recurrent GBM (NCT03914742, NCT03150862)
Cediranib (AZD-2171) (small molecule)	inhibits VEGFR	Phase II-III trials in recurrent GBM showed little to no benefit. Some studies may be underpowered or lack proper patient selection (NCT00777 153, NCT01310855, NCT00305656). A phase II trial is comparing cediranib and olaparib to bevacizumab for recurrent GBM (NCT02974621)
Gossypol (AT-101) (small molecule)	binds with and inhibits Bcl-2, Bcl-xL and Mcl-1	Phase II trials were performed in recurrent and new GBM (NCT00390403, NCT00540722). Very little follow-up data exists
Cabozantinib (XL-184) (small molecule)	tyrosine kinase inhibitor	Phase II trial in adult patients with recurrent GBM showed modest clinical activity (NCT00704288). Phase II trial in pediatric patients with recurrent or progressive high grade gliomas is ongoing (NCT02885324)
Erlotinib	EGFR inhibitor	Phase II studies in recurrent GBM as monotherapy (NCT00337883,) and in combination with other therapies (NCT00039494, NCT00445588, NCT00525525 NCT00335764). Also evaluated in new GBM (NCT00187 486, NCT00720356). Clinical results have not confirmed benefit
Gefitinib	EGFR inhibitor	Phase II trials in new and recurrent GBM for both adult and pediatric patients (NCT00052208, NCT00014170, NCT00025675, NCT00042991)
Depatuxizumab mafodotin (ABT-414)	Ab targets EGFR and drug inhibits tubulin	Phase III trial was halted when no survival benefit for new GBM patients could be demonstrated over placebo plus TMZ/radiation (NCT02573324)
Imatinib	multi-targeted tyrosine kinase inhibitor	Phase II trials in new and recurrent GBM showed no clinical activity. Drug has poor BBB penetration
Dasatinib	multi-targeted tyrosine kinase inhibitor	Phase I/II clinical trials in recurrent GBM failed to show treatment efficacy and have been limited by toxicity, especially when used in combination with a second chemotherapy (NCT00948389, NCT00423735).
Sorafenib	multi-targeted protein kinase inhibitor	Clinical trials to date have not been promising. Ongoing phase I/II trial evaluating sorafenib + everolimus (NCT01434602) and sorafenib, valproic acid, and sildenafil (NCT01817751) in recurrent high grade gliomas

(continued on next page)

Table 1 (continued)

Treatment	Biological action	Notes
Sunitinib	multi-targeted protein kinase inhibitor	Several phase II clinical trials have not shown anti-glioma effects. There are no ongoing clinical trials known currently.
Temsirolimus (CCI-779)	inhibits mTOR	Phase I/II trials as a mono- and co-therapy mostly for recurrent GBM (NCT00329719, NCT00112736, NCT00022724). Little added benefit
Everolimus	inhibits mTOR	Underway: Phase II trial evaluating combination with sorafenib (NCT01434602), Phase I trial evaluating combination with ribociclib in children (NCT03355794)
Nanotherapy		
2B3-101 PEGylated liposomes	Target GSH/GSH transporters	Phase I/IIa trial to explore the preliminary antitumor activity of 2B3-101 in brain metastases or recurrent malignant glioma (NCT01386580)
SGT-53 Cationic liposomes	Target Scfv/Tfr	Phase II trial of combined temozolamide and SGT-53 for treatment of recurrent glioblastoma (NCT02340156).
Liposomal irinotecan	convection enhanced delivery (CED)	Phase II trial of convection-enhanced, image-assisted delivery of liposomal-irinotecan in recurrent high grade glioma (NCT02022644)
Immunotherapy		
Cemiplimab	checkpoint inhibitor that binds to PD-1	Phase II trials are underway for recurrent (NCT04006119) and newly diagnosed (NCT03491683) GBM
Nivolumab	checkpoint inhibitor that binds to PD-1	Phase III trials are underway for recurrent (NCT02017717) and newly diagnosed (NCT02617589, NCT02667587) GBM
Rindopepitum peptide vaccine DCVax®-L	targets EGFR deletion mutation EGFRvIII DCs are primed to recognize tumor-specific antigens	Phase III clinical trial is ongoing (NCT01480479) Ongoing phase III clinical trial (NCT00045968)
VB-111 (Ofranergene obadenovec) gene therapy using an adenovirus type 5 vector	Virus carries a trans-gene for chimeric death receptor that connects Fas to hTNF receptor 1.	Phase I/II trials showed statistically significant improvement for VB-111 monotherapy in recurrent GBM (NCT01260506). Phase III trial using dual administration of VB-111 and bevacizumab failed to improve outcomes in recurrent GBM. (NCT02511405)
CAR T cell therapy	T cells are engineered to express receptors against specific tumor markers	There are currently 19 clinical trials listed under clinical-trials.gov, including ongoing studies NCT04385173, NCT04077866, NCT04045847, NCT04045847, NCT04214392, NCT04003649, NCT02937844, NCT03392545, NCT02208362, NCT0338923
Misc. therapies		
Laser interstitial thermal therapy (LITT)	thermal ablation of tumor tissue	Studied for its applications toward tumor therapy and treatment of radiation necrosis. Current clinical trials: NCT02970448 (Phase I: LITT + chemoradiation for new HGGs), NCT03341806 (Phase 1: LITT + avelumab for recurrent GBM), NCT04699773/ NCT04181684 (LITT + hypofractionated RT for new/recurrent GBM)
Tumor Treating Fields (TTF)	disrupts mitotic cell division	May be good for recurrent GBM, inoperable tumors, and/or effective supplement to chemo/radiotherapy

location and sensitivity [82]. This strategy has the added complexity of employing several collimated beams in order to avoid injury to critical structures including the cornea, optic nerves, and brainstem [83].

Another form of focal radiation includes stereotactic radiosurgery (SRS) where even larger radiation doses can be applied by delivering multiple non-parallel, converging radiation beams. The dose is given in fewer fractions [1–5] and at higher doses per fraction (15 + Gy). The gamma radiation is derived from a cobalt-60 source and directed at the tumor through collimators [84]. The heat transfer properties of gamma rays enable high doses of radiation to be delivered very specifically at the tumor target while sparing adjacent healthy tissues [85]. SRS has been commonly used for brain metastases, particularly to avoid the cognitive side effects of whole brain RT, and may be appropriate in some cases of GBM [86].

Brachytherapy is being explored and involves local implantation of one or more radioactive vectors into the tumor bed at the time of surgery. The most common isotopes used for brachytherapy in brain tumors are iodine-125 ($t_{1/2} = 59.5$ days) and iridium-192 ($t_{1/2} = 73.8$ days) [87]. Unfortunately, two major trials by Laperriere et al. and Selker et al. did not show a statistically significant differences in survival between patients receiving brachytherapy and those that did not [88,89]. Another Phase I trial was halted early due to high toxicity [90]. Adverse effects have included symptomatic radiation necrosis, vascular injury, and radiation exposure to close contacts [91].

Charged heavy proton radiotherapies such as carbon ion irradiation spares normal tissue and concentrates energy deposition on the tumor [92]. This disrupts GIC viability [93] through the induction of pro-apoptotic pathways and thereby provides an antiangiogenic and immunopermissive tumor environment [94]. Tumor regression and long-term local control were identified in xenograft mouse models and a

clinical study of 50 patients with grade III and IV glioma measured an 18-month overall survival of 73% with dose equivalents of ≥ 60 gray appearing to be safe [93,95]. Indeed, combination therapies of carbon proton irradiation with TMZ treatment led to enhanced overall survival and progression-free survival compared to patients subjected to combination of TMZ with photon-induced irradiation [95].

An important impediment of effective RT is the hypoxic tumor environment. Oxygen generally enhances the response of cells to low linear energy transfer radiation. When tissue is irradiated and DNA radicals form, oxygen can react with the radicals to create permanent cell damage. In hypoxic tumor environments, the damaged DNA has added time to repair and reduce radiation injury [80]. Hypoxic tissue is thought to require approximately three times the radiation dose to achieve the same therapeutic benefit [96].

2.2. GBM therapy resistance

2.2.1. DNA repair mechanism

2.2.1.1. Methyl guanine methyl transferase (MGMT). TMZ causes tumor cytotoxicity by transferring methyl groups to DNA (70% at N⁷-guanine sites, 10% at N³-adenine sites and 5% at O⁶-guanine sites) [97]. The O⁶ site alkylation on guanine leads to attachment of a thymine rather than a cytosine during the DNA replication process. The altered configuration is the primary cause of cell death [98]. This alkylation damage can be reversed by the DNA repair enzyme MGMT (O⁶-methylguanine-DNA methyltransferase) by removing O⁶-methylguanine adducts. Thus, the methylation status of the MGMT gene promoter has great clinical significance [99,100]. MGMT promoter methylation is more prevalent in recurrent GBMs compared to primary GBMs (75% vs. 36%) [101]. The

level of MGMT protein expression has been associated with the efficacy of alkylating drugs to cancer cells in glioma tumor models [98,102]. GBM with MGMT promoter methylation (evaluated by methylation-specific PCR (MS-PCR)) and its subsequent loss of MGMT protein expression (measured by immunohistochemical staining) showed better response to TMZ therapy [103]. MGMT inactivation or silencing is associated with significantly improved overall survival and progression-free survival (PFS) [104–106]. The role of TMZ in CCRT has made MGMT one of the most pertinent prognostic markers.

Understanding the regulation of MGMT may improve the development of targeted therapies. An important gene related to MGMT expression is p53, a negative regulator of MGMT in GBM tumors [107–109]. Clinically, GBM patients with lower MGMT expression have better prognoses with proneural phenotypes expressing p53 [110]. The proline-rich domain of p53 has been confirmed to be non-essential for MGMT-dependent DNA repair [111]. However, p53 may down-regulate MGMT via interaction with the Sp1 transcription factor [112]. This was supported when BACH overexpression competitively interfered with p53 and Sp1 binding, and antagonized MGMT expression [108]. Sp1 is an imperative nuclear transcription factor, which suggests the role of transcriptional factors in regulating MGMT expression. In silico analysis by Transcription Elements Search System (TESS, <http://www.cbil.upenn.edu/tess>) identified putative consensus sequences for the binding of nuclear transcription factors in the promoter region of MGMT. These include Sp1, NF-κB, CEBP, AP-1, AP-2 and NF-IL6 at CpG dinucleotides. The literature has also supported Sp1 [112–114], AP-1 [102,115], NF-κB [116,117] in the activated transcription of MGMT. Thus, methylation of CpG dinucleotides may hinder the binding of these transcription and compress the transcriptional activation of the MGMT gene [102,118,119]. Other transcription factors, such as hypoxia-inducible factor-1 (HIF-1), when activated in the hypoxic GICs niche, will enhance MGMT expression [120–122].

Besides transcriptional factors, epigenetic modifications of MGMT have also shown a relevant role in MGMT regulation [123,124]. Acetylation of lysine residues on histones H3 and H4 (H3Ac and H4Ac) is correlated with high MGMT expression [125] while di-methylation of lysine 9 of histone 3 (H3me2K9) leads to silencing of MGMT expression [102].

Thus, targeting transcriptional factors or epigenetic modifications related to MGMT activation may be options in GBM therapy.

2.2.1.2. Mismatch repair (MMR). O⁶-methylguanine (O⁶-MeG) generated by therapeutic alkylating agents is the dominant cytotoxic lesion. It can either be removed by MGMT or tolerated by MMR deficiency, to induce prominent therapy resistance [126]. MMR addresses inappropriate nucleotide base pairing to maintain DNA replication fidelity. MMR is collectively achieved by several proteins including MLH1, MLH3, MSH2, MSH3, MSH6, PMS1, and PMS2 [127]. Outside the context of TMZ treatment, MMR deficiency or epigenetic silencing of MMR gene expression leads to cancer development [128,129]. MMR deficiency results in strong resistance to the alkylating agents, such as the alkylating agents N-methyl-N'-nitro-N-nitrosoguanidine (MNNG), TMZ, or procarbazine. When MGMT is not present to remove the methyl group, thymine is erroneously inserted opposite O6-MeG by DNA polymerase. The O6-MeG:T mismatch is recognized by the MMR complex, and bound by MutS α (an MSH2•MSH6 heterodimer), subsequently, a gap is generated in a new stretch of single-stranded DNA, DNA polymerase once again inserts thymine to complete mismatch repair. It is highly likely that the futile repair generates double strand breaks leading to cell cycle arrest and cell death [130].

Perazzoli et al. noticed an interesting inverse correlation between MGMT and MMR [131]. *In vitro* studies investigating an MGMT-methylated GBM cell line (U251), which survived TMZ treatment, ultimately developed MMR deficiency [132]. Studies from TCGA suggest that at least one of the MMR genes – MLH1, MSH2, MSH6 or

PMS2 – possess a methylated MGMT promoter [133]. MSH6 inactivation exhibited a crucial role in conferring tolerant tumor cell growth. It has been shown that a modest decrease of MMR components MSH2 and MSH6 is associated with TMZ sensitivity [134]. Sun et al reported that a large cohort of GBM clinical samples have enhanced expression of MMR genes especially MSH6 after long-term TMZ treatment [135]. Whether the incidence of MSH6 mutation is induced by therapy is still unknown and remains controversial. The German Glioma network noticed significantly lower MSH2, MSH6, and PMS2 protein expression in recurrent GBM compared to primary GBM tumors [136], which is in line with some additional investigations [137]. Meanwhile, recurrent GBM tumors frequently possess MMR6 mutations coinciding with microsatellite instability [138].

2.2.2. Glioma initiating cells (GICs)

A subpopulation of cells in GBM described as “cancer stem cell (CSC)” or “glioma initiating cells (GICs)” is speculated to possess specific characteristics that support tumor development, recurrence, and therapeutic resistance [10,139,140]. GICs are believed to be a distinct subgroup of cells, that can undergo self-renewal and initiate tumorigenesis. Singh et al. first described a population of CD133+ cells, but not CD133- cells, that initiated tumor growth in NOD-SCID (non-obese diabetic, severe combined immunodeficient) mouse brains [141]. Although CD133 is a recognized marker of GICs, it is also expressed in normal neural stem cells [142]. Therefore, multiple surface markers are needed to characterize GICs. Other recognized markers of GICs include CD44 and ATP binding cassette transporters [143–145]. We further elaborate on the molecular mechanisms of resistance in GICs.

2.2.2.1. Enhanced DNA repair capacity. In addition to protective responses by MGMT and MMR expression following chemotherapy, GICs may exhibit sensitizing mechanisms to radiation [146]. Checkpoint kinases (Chks), in particular Chk1 and Chk2, play primary roles in cell cycle control. In response to DNA damage, Chk1 signal will be activated and holds the cells in the G2 phase until DNA is repaired and ready for the mitotic phase, whereas Chk2 is activated under double stranded break (DSB) and prevents cells from dividing in an uncontrolled manner. Bao et al reported that GBM displayed aberrant DNA damage response to radiotherapy. They observed that the addition of specific inhibitors of Chk1 and Chk2 checkpoint kinases restored the radiosensitivity of GICs [147]. More recently, Ahmed, et al. observed that GICs have a prolonged cell cycle arrest at the G2 phase and noted that the inhibition of the Chk1 pathway induced double stranded breaks under ionizing radiation, in an ATM- and ATR-dependent manner [148].

The polycomb group protein, BMI1, also shows enhanced expression in CD133+ GBM cells, BMI1 coprecipitated with DNA DSB response proteins, and preferentially associated with NHEJ repair proteins. This interaction enormously improved DNA damage response to radiation and cell viability [149].

Additionally, homologous recombination (HR) defects can contribute concurrently to the radioresistance of GICs. The inhibition of DNA repair protein RAD51 homolog 1 (RAD51) has been found to delay G2 cell cycle arrest, thereby sensitizing GICs to radiation [150]. Due to the prominent cellular DNA damage response of GICs, targeting DNA repair pathways may provide a beneficial therapeutic approach for eliminating GICs.

2.2.2.2. ATP binding cassette (ABC) transporter. ABC transporters are ubiquitous and one of the largest transmembrane protein pump families. Normally, ABC transporters move endogenous bile acids, cholesterol, ions, and peptides across cell membranes. GICs express high levels of ABC transporters that are normally inactive in mature cells. In GICs, overexpression of ABC transporters further hinders drug delivery. ABC transporters promote therapy resistance by promoting efflux of exogenous compounds, such as TMZ, at the cellular and BBB level, in order to

detoxify cells [151,152].

ABC transporters include 49 members classified into seven gene subfamilies, designated ABCA–G. Thus far, ABCB1 (MDR1), ABCC1 (MRP1), and ABCG2 (BCRP1) are the most well-known pumps that have been identified in tumor stem-like cells. ABCG2 was first identified and associated with subpopulations of cells that are stem-like and multidrug resistant [153]. ABCC1 is assumed to be another cause for GBM recurrence since the blockage of ABCC1 improved therapeutic response in GBMs [154,155]. GICs are enriched in hypoxic niches of the tumor [156]. Low oxygen levels further promote the expression of MGMT, ABCC1 and ABCB1, and thereby lead to chemoresistance [157]. Very recently, Lee, et al., proposed ABCB5 as a new marker for CD133+ GICs in chemoresistant GBM. The knockdown of ABCB5 inhibited GBM proliferation and sensitized the GBM cells to TMZ treatment [158].

Multiple pathways (SHH, Wnt- β -catenin pathway, Bcl-2, Akt, survivin, etc.) have been associated with the role of ABC transporters in therapy resistant GICs [151], which suggests that the ABC transporter is yet another target for which new therapies could be developed.

2.2.2.3. Hypoxia and autophagy. Tumor hypoxia is consistently associated with poor prognosis across multiple cancer types [159–161]. GBM is characterized by extensive tissue hypoxia [162] and the hypoxic microenvironment has been regarded as an indispensable environmental cue for the preservation of GICs [120]. In response to the reduction of oxygen tension, hypoxia-inducible factor 1 (HIF-1) is stabilized to maintain GICs and promote their tumorigenic ability [163, 164]. In tumor tissue, microvascular thromboses congest vessels, further boosting intratumoral hypoxia. GICs can be found in the perivascular niche and the tumor core region, where are usually less oxygenated (1.25% O₂) than peritumoral areas (2.5% O₂) [165]. The poorly oxygenated tumor tissue creates a perfect GIC niche and can stimulate downstream oncogenic pathways resulting in heterogeneity, invasiveness, and therapy resistance. Overall, the density and aggressiveness of GICs are negatively correlated with oxygen tension.

Several studies suggest that autophagy is induced by hypoxia as a cytoprotective mechanism, which is complementary to the ubiquitin system [166,167]. Autophagy is a survival-promoting process that contributes to the clearance of damaged proteins and organelles to maintain cellular homeostasis and genomic integrity. Moreover, it has been shown that autophagy supports cellular metabolism by generating metabolic precursors such as amino acids and lipids, which further supports the function of autophagy as an adaptive mechanism responding to metabolic stress [168,169]. In GBM, protective autophagy is triggered in GICs when challenged by cytotoxic therapies [168,169].

It has been of great interest to investigate how autophagy sustains tumor growth and contributes to therapy resistance. Gene-9/Syntenin (MDA-9) is associated with advanced tumor grades in various cancer types. A recent study showed that MDA-9 is critical to maintaining GICs by regulating essential autophagy-related molecules, including BCL-2 and EGFR [170]. Huang et al. found that radiotherapy increases the level of MST4, which phosphorylates ATG4B and leads to autophagy. The inhibition of ATG4B significantly improved the survival benefit in radiation-treated mice [171]. Inhibition of autophagy increased the massive accumulation of lipid peroxides and enhanced the sensitivity of GBM to TMZ treatment, which indicates initiation of ferroptosis in GICs [172]. However, we observed an opposite role of autophagy. Aldehyde dehydrogenase 1A3 (ALDH1A3) has been regarded as a biomarker for various kinds of cancer stem cells, including GICs. We found that ALDH1A3 confers chemoresistance to GICs by deactivating toxic active aldehydes produced by lipid peroxidation under low concentrations of TMZ treatment. However, under high concentrations (500 μ M) of TMZ, autophagy is induced, ALDH1A3 binds to p62 (an autophagic substrate) and is degraded along with ubiquitin cargo, ultimately enhancing the susceptibility of GICs to TMZ [173,174].

The autophagy inhibitor chloroquine could reduce GBM resistance to

anti-angiogenic therapy [175]. It also has been shown that chloroquine-treated patients have better median survival in adjuvant settings in a phase III clinical trial [176]. Although the role of autophagy in GBM progression is controversial, nevertheless, it provides a new insight for targeted therapy and conquering therapy resistance of GICs.

2.2.2.4. Epigenetic regulation. There is growing evidence that non-genetic determinants, associated with epigenetic modifications, contribute to functional heterogeneity and maintenance of GIC hierarchies [177–180]. Epigenetic regulation includes alterations in the chromatin structure as well as DNA methylation and post translational histone modification or even changes in noncoding RNAs including long noncoding RNAs and miRNAs [181,182]. Specifically, the subpopulation of CD133+ cells, which are generally regarded as GICs, were found to be H3K9me2 negative, while the majority of cancer cells expressed strong H3K9me2. This data indicates that H3K9me2 is an important switch for maintaining stemness of GICs by regulating CD133 [183]. In a study based on histone modification expression analysis of 230 tumor samples, patients were divided into 10 separate prognostic groups. The 10 groups showed significantly different progression-free ($P < 0.0001$) and overall survival ($P < 0.0001$), demonstrating that aberrant histone modifications are critical prognostic factors for GBMs [184].

Epigenetic deregulation of multiple GIC-related pathways enables cancer cells to gain self-renewal and drug resistance properties. Wnt- β -catenin signaling can be activated by DNA methylation and aberrant histone modifications [185]. Wnt- β -catenin signaling stabilized the epigenetic regulator KDM4C, and enhanced tumorigeneses and survival of human GBM cells [186]. Another pathway that regularly interacts with epigenetic regulators is Notch signaling. DNA methylation of NOTCH1 and NOTCH3 inhibits GBM cell proliferation [187]. Another study used sodium butyrate (NaB), a DNA methylating agent, to induce GBM apoptosis by decreasing HEY1 expression, suggesting that promoter methylation may regulate Notch signaling [188]. In parallel to Wnt- β -catenin and Notch signaling, GICs also have high Sonic Hedgehog (SHH) signaling which is associated with better epigenetic memory. Hedgehog signaling can be epigenetically triggered in CSCs by Shh promoter hypomethylation and HDAC1 expression induction [179]. BRD4, a well-characterized "epigenetic reader", is also a critical regulator of GLI1 and GLI2 transcription [189]. Lysine acetyltransferase 2B (PCAF/KAT2B) is another epigenetic modulator which is important in regulating SHH signaling in GBM [190]. Collectively, a sophisticated network of signaling pathways can be deregulated as a result of aberrant epigenetic modifications in GICs. These genetic alterations uphold the stemness of GICs and promote tumor progression (Fig. 2).

A better understanding of the mechanisms underlying GICs therapy resistance would improve the development of more effective therapies against GBM.

3. New therapies

Despite aggressive therapeutic measures, GBMs invariably continue to grow. Therefore, a broad search is underway for new and targeted therapies, such as inhibitors of specific molecular processes, nanoparticle carriers, and immunotherapy (Table 1 and Fig. 3).

3.1. Inhibitor therapy

Targeted inhibitors have been an additional therapeutic strategy for treating GBM [193]. Inhibitors usually target a single biomarker or family of biomarkers that are markedly upregulated in malignant over healthy tissues. In general, inhibitors are developed either for extracellular targets like cell surface receptors or intracellular targets involved in signaling and activation of oncogenic pathways [193]. These therapies have been tested alone and as a co-treatment with established therapeutics like TMZ or bevacizumab with varying but usually limited

benefit.

3.1.1. PARP inhibitors

Poly (ADP ribose) polymerase (PARP) is a family of 17 nuclear enzymes that catalyze the cleavage of NAD⁺ molecules leading to the addition of ADP-ribose to acceptor proteins [194]. The PARP1 enzyme is a prognostic marker and its elevated expression is associated with poor survival in some cancer patients [194]. PARP is important for repair of DNA nicks, cell death, and genomic stability [195]. Cancer therapies like radiation and alkylating agents rely on DNA breaks for their anti-tumor effect. Small molecule PARP inhibitors have been developed to improve the clinical efficacy of these therapies [196]. PARP inhibitors can cause direct cytotoxic effects and potentiate the efficacy of alkylating agents. There is evidence to suggest that PARP inhibitors are most effective for GBM tumors with hypermethylated MGMT gene. In addition, PARP inhibitors can increase tumor sensitivity to TMZ chemotherapy, if the tumor has not previously been exposed to TMZ [196,197]. In addition to enhancing chemotherapy, PARP inhibitors synergize with radiation therapy because PARP1 activity increases 500-fold in the presence of DNA damage [198,199]. While several PARP inhibitors have been tested in vitro, only a few have been evaluated in GBM patients. A Veliparib-TMZ treatment regimen was evaluated in patients with recurrent GBM who had been previously treated with TMZ. Combination of TMZ and ABT-888 (veliparib) did not significantly improve PFS6 for either the bevacizumab-naïve or bevacizumab-failure patients [200].

Similarly, co-treatment of children with diffuse intrinsic pontine glioma with veliparib, RT and TMZ did not show survival benefits [201]. A phase I trial evaluating the safety and tolerability of cotreatment with olaparib and TMZ showed modest activity. Encouragingly, olaparib was found to have penetrated brain tumors both at the core and at the margins suggesting that the BBB was penetrated [202]. Additional PARP inhibitors meriting further clinical study include niraparib and talazoparib [203–205]. Many of these inhibitors show limited BBB penetration in preclinical models but evidence suggests the preclinical data might not faithfully predict clinical results [202,204,206]. The true benefit, if any, of PARP inhibitor therapy for GBM patients remains to be determined.

3.1.2. Protein kinase inhibitors

Protein kinases are involved in biochemical phosphate transfer reactions. Receptor tyrosine kinases are a family of high affinity cell surface receptors that have an extracellular domain with a ligand-binding site for many polypeptides, including growth factors and cytokines [207]. Receptor tyrosine kinase pathways are known oncogenic drivers for malignant cancers [208]. Several tyrosine kinase receptors, including vascular endothelial growth factor receptor (VEGFR), platelet derived growth factor (PDGF), fibroblast growth factor receptor (FGFR), and epidermal growth factor receptor (EGFR), are mutated and/or upregulated in GBM and have become attractive targets for novel therapy development [209–213]. GBM is known to have high levels of VEGF




Fig. 2. The molecular mechanisms of resistance in glioma initiating cells (GICs). GBM is characterized by extensive intratumoral hypoxia. GIC niches are most commonly to be found in tumor core regions that are less-oxygenated. GICs are generally resistant to therapies and mostly due to following mechanisms: (1) Enhanced DNA repair capacity. Cell cycle arrest at G2 phase in GICs allows the DNA repair and further enter mitotic phase. (2) GICs express higher level of ABC transporters which promote efflux of therapeutic compounds. (3) The poorly oxygenated tumor tissue creates perfect GIC niches, which induce autophagy to maintain cellular homeostasis. Protective autophagy can also be triggered in GICs when challenged by cytotoxic therapies. (4) Epigenetic modifications contribute to functional heterogeneity and maintenance of GIC hierarchies. Multiple GICs-related signaling pathways (Wnt/β-catenin, Sonic Hedgehog (SHH), Notch) can be epigenetically regulated to gain self-renewing capabilities and drug resistance properties [179,191,192].

expression resulting in highly angiogenic tumors and abnormal vessel formation [214]. Inhibition of VEGFR or its substrates aims to stymie the growth of new blood vessels and starve the tumor of needed nutrients. Cediranib, an inhibitor of VEGF receptor tyrosine kinases has been evaluated in recurrent GBM as a monotherapy [215] or in combination with cilengitide [216], lomustine [217] or gefitinib [218], but has yet to receive FDA approval. Cediranib has the advantage of oral administration, targeting of multiple tyrosine kinases, and the ability to target intracellular VEGF receptors [215]. Cediranib has been shown to help normalize tumor vascularization in a subset of patients which improved perfusion, oxygenation, and response to therapy. These patients had higher overall survival (OS) than the non-responding cohort [219]. It was also recently discovered that cediranib sensitizes tumors to PARP inhibitors by downregulating homology-directed DNA repair [220]. This discovery may encourage further investigations of combined anti-angiogenic and PARP inhibitor chemotherapies. Unfortunately, to date, the use of anti-angiogenic therapies for GBM has shown limited efficacy in clinical trials. One reason may include inadequate patient selection [221]. Lu-Emerson, et al., summarized results from recent anti-angiogenic trials for GBM and how to use biomarkers to select for patients in future trials [222].

Erlotinib is an inhibitor of EGFR and has been approved to treat non-small cell lung and pancreatic cancers. It garnered excitement as a possible therapy for GBM in the early 2000s with encouraging in vitro results. However, several clinical trials have failed to reproduce the positive results obtained in initial experimental studies or improve survival of patients with GBM [223–227]. Gefitinib, another EGFR inhibitor, has similarly been tested with and without other therapies. A phase II trial showed some evidence of activity of gefitinib for recurrent GBM in a subset of patients. However, survival was worse for the majority of patients compared to treatment with TMZ at the first sign of relapse [228]. Other clinical trials using gefitinib alone or with co-treatments have shown no significant improvements over currently approved therapies [229–231]. While most clinicians agree that combination therapies will be needed to treat recurrent GBM, there has been little further investigation of these two EGFR inhibitors in recent years.

There are also a number of small molecular multi-targeted protein kinase inhibitors that have been evaluated in new and recurrent GBM. Imatinib was evaluated in phase II clinical trials in newly diagnosed

GBM (inoperable or not fully resected) and recurrent GBM, with and without concurrent radiation, but showed no clinical activity [232–234]. Imatinib was well-tolerated but suffered from poor BBB penetration, even after radiation therapy. Again, it is possible that lack of proper patient selection for tumors overexpressing the targeted protein kinases may have contributed to the trial's unfavorable results. Phase II trials of imatinib with the addition of hydroxyurea, which inhibits ribonucleotide reductase, again showed little to no anti-tumor activity [235–237]. Dasatinib is another small molecular multi-targeted tyrosine kinase inhibitor. An early phase I/II clinical trial in recurrent GBM demonstrated toxicity issues and was underpowered such that clinical efficacy could not be determined [238]. A trial evaluating the efficacy of adding dasatinib to bevacizumab did not have any added treatment benefit in patients with recurrent GBM compared to bevacizumab alone [239]. Dasatinib was also tested in pediatric patients with progressive/recurrent GBM or diffuse intrinsic pontine gliomas with crizotinib, an oral c-Met inhibitor, but was poorly tolerated such that further investigation was discouraged in this patient population [240]. Co-administration of dasatinib with lomustine (CCNU) unfortunately led to significant hematological toxicity [241]. Sorafenib is another multi-targeted protein kinase inhibitor that has been tested in GBM patients [242]. Several studies have evaluated the use of sorafenib with TMZ. Only one of these studies met its primary endpoint with 26% of patients achieving PFS at 6 months [243]. The remaining trials with TMZ, bevacizumab, or erlotinib demonstrated safety of the combined therapy but no significant therapeutic efficacy [225, 244–246]. Possible reasons leading to unfavorable study results included extensive prior therapy of some of the study participants and lack of selection of patients with tumors that expressed molecular targets for sorafenib (i.e., VEGFR, Raf-1 and wild-type B-Raf, PDGFR, c-KIT, and Flt-3A). Additional studies combining sorafenib with temsirolimus, an inhibitor of mammalian target of rapamycin (mTOR) or tipifarnib, a farnesyl-transferase inhibitor, led to significant toxicities [247, 248]. Recent evidence suggests that sorafenib may sensitize GBM cells to tumor-treating fields [249]. Sunitinib is a similar multi-targeted protein kinase inhibitor that has been FDA-approved for the treatment of renal cell carcinoma but has failed to show efficacy for recurrent GBM in several clinical trials [250–252]. Cabozantinib, another multi-targeted protein kinase inhibitor approved for the treatment of kidney cancer was evaluated in phase




Fig. 3. New therapies described in this review.

II trials for recurrent GBM and was well-tolerated but did not meet predetermined statistical measures for success. Trials for pediatric patients are underway [253,254].

3.1.3. Miscellaneous inhibitors

Additional molecular targets for inhibitors include myeloid cell leukemia-1 (MCL-1), and topoisomerase I inhibitors. MCL-1 is associated with PTEN deletion/mutation which occurs in 30–60% of GBM patients [255]. Loss of PTEN in GBM cells led to upregulation of MCL-1 which is associated with resistance to apoptosis. There is preclinical evidence that the use of MCL-1 inhibitors in GBM may be an effective therapeutic strategy [255–257]. A few MCL-1 inhibitors have gone to clinical trial (e.g., AZD5991, S64315, AMG 176, and AMG 397) mostly for the treatment of blood cancers but some have been halted due to concerns with cardiac toxicity [256,257]. Gossypol (AT-101), a polyphenolic compound that permeates cells and inhibits several dehydrogenase enzymes, has shown modest benefit in treating recurrent GBM, though few subsequent clinical trials have been initiated [258]. Another biomarker under investigation is mTOR. Temsirolimus and everolimus are small molecular inhibitors that have been developed for mTOR which plays a role in glioma induction, growth, and progression [259]. With these inhibitors, little to no radiographic improvements or benefit to progression-free survival have been observed when used as monotherapy and no added benefit was observed when used with bevacizumab or when compared against TMZ for patients with unmethylated MGMT promoters [260–265]. The addition of everolimus and bevacizumab to radiation and TMZ as first-line treatment for GBM gave similar results compared to other phase II trials where bevacizumab was added to first-line treatment [266]. Additional mTOR inhibitors are currently being evaluated as potential cancer therapies (e.g., AZD-8055, OSI-027, and CC-115) [267]. Irinotecan is a small molecular prodrug that, upon hydrolysis, is converted to SN-38, a topoisomerase I inhibitor [76]. As a monotherapy, irinotecan has shown little to no benefit [268]. It has been shown to have some activity in recurrent GBM although with some toxicity concerns [269–271]. Use of irinotecan with TMZ for newly diagnosed GBM following concurrent chemo-radiation therapy did not improve OS compared to TMZ alone and resulted in significant toxicities [272].

Targeted therapies for GBM have largely failed in clinical trials. A greater emphasis is now being placed on selecting patients whose tumors express the specific biomarkers targeted by the therapy [273,274].

3.2. Immunotherapy

Immunotherapy has seen great success in the treatment of numerous cancers, but GBM has not been among the immunotherapy success stories. Several candidate therapies spanning antibodies and vaccines have reached phase III trials but yielded only modest gains in terms of clinical endpoints and survival. These experiences have underscored that additional interventions may be needed to achieve robust immune activation, potent effector cell activity, and durable treatment response. Here, we describe some of the most advanced immunotherapies studied to date for GBM and the specific mechanisms of resistance that accompany each strategy.

3.2.1. Checkpoint inhibitors

Checkpoint inhibitors are among the most successful innovations in immunotherapy. They are monoclonal antibodies designed to interrupt binding of regulatory receptors on T cells. In the normal cell, downstream signaling by these activated checkpoint receptors exist to prevent excessive inflammation [275]. However, tumor cells can also produce the corresponding ligand, thereby abrogating and eluding an immune response that would lead to tumor clearance. Hence, such receptors are sometimes considered markers of T cell exhaustion, as they are no longer able to mount an immune response despite their successful tumor infiltration [276]. A number of these receptors and inhibitors have since

been identified, with anti-CTLA4 (cytotoxic T-lymphocyte-associated protein 4), anti-PD-1 (programmed cell death protein 1), and anti-PDL1 already being used in the clinic (Fig. 4).

For GBM, the greatest translational success has been seen with anti-PD-1 agents, nivolumab and pembrolizumab. When PD-1 binds to its ligand, there is downregulation of T cell activation [275]. A trial from Dana-Farber Cancer Institute revealed patients who received pembrolizumab prior to surgery showed significant improvement in overall survival [281]. However, in a Phase 3 clinical trial, CheckMate 143, nivolumab monotherapy failed to demonstrate an increase in overall survival versus bevacizumab (9.8 vs 10 months) for recurrent GBM [282]. Additionally, monotherapy was found to be better tolerated than dual therapy with anti-CTLA4. Further findings in phase III trials, CheckMate 498 and CheckMate 548, also did not identify improvement in overall survival for standard therapy with and without anti-PD-1 in patients with MGMT-methylated GBM [283,284].

Several checkpoint inhibitor-specific mechanisms of resistance have been described across cancers and may generalize for GBM. One transcriptome analysis of melanoma biopsies found an “innate PD-1 resistance gene signature” that could predict response to anti-PD-1 [285]. In this study, resistant tumors exhibited increased expression of genes regulating mesenchymal transition, cell adhesion, extracellular matrix remodeling, angiogenesis, and wound healing. Other work in a lung tumor model has shown that anti-inflammatory immune cells in the tumor microenvironment (TME) can decrease the efficacy of checkpoint inhibitors. For example, tumor-associated macrophages (TAMs) have been observed to remove anti-PD1 antibodies bound to CD8+ T cells [286]. Additional preclinical studies on several cell lines have suggested that Treg apoptosis due to TME-related oxidative stress can generate adenosine release and anti-PD-L1 resistance [287].

Various mechanisms also prevent checkpoint inhibitors from generating a robust or durable T cell response. This is, in part, due to impaired epigenetics and memory cell formation, resulting in T cell exhaustion and immune evasion of the tumor [288,289]. Furthermore, several other checkpoint molecules may compensate for blocked PD-1 function [290]. LAG3 is one example found on CD4, CD8, and Tregs. Like PD1, LAG3 normally inhibits T cell receptor activation and cytokine production [291]. TIM3 is another promising checkpoint target, seen during the late stages of disease and T cell exhaustion. Binding to its ligand can lead to effector T cell apoptosis [292]. Both LAG3 and TIM3 inhibitors are being assessed in combination with anti-PD1 in GBM Phase I clinical trials (NCT02658981, NCT03961971). Given the complex interplay of checkpoint regulators, clinical trials have also begun to explore combination therapies.

3.2.2. Vaccines

Vaccines can be largely divided into peptide-based vaccines and cell-based vaccines. While the vehicles may differ, both ultimately require antigen presentation and T cell activation. Much of the early enthusiasm for cancer vaccines has since been redirected due to their limited success. Nevertheless, cancer vaccines have provided important insights on immune responses of GBM and are continuously investigated, especially in conjunction with multimodal treatment regimens.

3.2.2.1. Peptide-based vaccines. The most studied peptide-based vaccine, rindopepitimut, targets the EGFRvIII variant. Wildtype EGFR of the ErbB family of kinase receptors is activated by EGF signal for cell proliferation, cell migration, and apoptosis inhibition [293]. In approximately 20–30% of GBMs, EGFRvIII has a truncated extracellular domain, which prevents binding and leads to constitutive activation. The resulting amino acid sequence spanning across the deleted portion is tumor-specific, not found in any normal tissues [294]. This specific epitope led to the development of rindopepitimut (CDX-110-KLH), a 14 amino acid peptide, enhanced by the keyhole limpet hemocyanin carrier protein.

Rindopepimut underwent several early clinical trials, ultimately reaching a phase III trial (ACT IV) assessing vaccine efficacy in GBM patients with minimal residual disease. The control arm surpassed expectations and was statistically insignificant from rindopepimut, with a median OS of 20.0 and 20.1 months, respectively [295]. The investigators had previously used historical controls during their phase I and II trials, which might have led to an overestimation of rindopepimut's efficacy. Reasons for subsequently noted lower performance of the vaccine in GBM included variable responses to human leukocyte antigen (HLA) haplotype and antigen escape [296]. One study reported that 82% of treated GBMs did not express EGFRvIII at the time of tumor recurrence [297]. Since then, one small phase II trial (ReACT) combined rindopepimut with bevacizumab for recurrent GBM and reported a small survival benefit of the experimental group (12 months) compared to the control group (8.8 months) [298].

3.2.2.2. Cell-based vaccines. Among cell-based vaccines, the DCVax is possibly the most prominent. In this strategy, dendritic cells (DCs) generated *ex vivo* from patient derived peripheral blood are pulsed with different sources of tumor-associated antigens (TAAs), such as autologous tumor lysates, antigen peptide, and TAA-encoding RNA. These naturally-derived, mature DCs showed stronger antigen presentation potential [299]. Moreover, the DCVax enabled customized targeting of multiple tumor antigens for potentially durable response. This approach has been cautiously monitored for the theoretical risk of developing an

immune response to normal tissue antigens [300]. Multiple early clinical trials were able to identify GBM patients for safe DCVax application, culminating in a phase III study. Although the study has yet to be formally completed, median overall survival has been reported at 23.1 months [301].

Several challenges unique to DCs have precluded the efficiency of cell-based vaccines. Interestingly, one group described that mature DCs in melanoma may be more motile and capable of migration to lymph nodes [302]. Additionally, the immune suppressive environment can hinder a desirable DC-NK cross talk, whereby DC maturation leads to enhancement of NK cytotoxicity and IFN- γ production. This has led to consideration of vaccine adjuvants such as, alpha-galactosylceramide or poly(I:C) to enhance NKT and DC activity in GBM treatment [303–305]. Current clinical trials continue to incorporate these adjuvants while optimizing the antigen selection with personalized strategies. In addition, combination strategies with checkpoint inhibitors such as anti-PD-1 are also being considered at the preclinical phase in glioma [306].

3.2.3. Virotherapy

Over the past few decades, virotherapy has evolved from a primarily oncolytic to a broader viro-immunotherapeutic approach. Previously, treatment was designed to infiltrate the tumor, mitigate tumor defenses and induce a rapid, large-scale tumor cell death. Now, the focus of the field has shifted from direct oncolysis (payloads of virus) to




Fig. 4. The inhibition of CTLA-4 and PD-1 in GBM immunotherapy. Dendritic Cells (DCs) traffic between CNS tumors and the cervical lymph nodes to prime T cells against tumor neo-antigens. T cells receive effective activation signals with the engagement of two T cell receptors, antigen-specific T-cell receptor (TCR) and CD28, simultaneously. TCR binds to tumor-associated antigens (TAA) presented on major histocompatibility complex (MHC) molecule while CD28 interact with CD80/CD86(B7-1/2 receptors) costimulatory molecules on the surface of DCs. T cell activation leads to upregulation of checkpoint molecule CTLA-4(cytotoxic T-lymphocyte-associated protein 4). The interaction of CTLA-4 and CD80/CD86 of DCs results in blockage of T cell activation. The effector T cells can proliferate and migrate to the tumor microenvironment, leading to tumor eradication via MHC-I/TCR interaction. Some GBM cells and TAM-BMDMs express high levels of checkpoint molecules including transmembrane protein PD-L1. PD-L1 binds to PD-1 receptors on T cells, which leads to attenuation of TCR and CD28 signals, and subsequently promotes T cell apoptosis and functional exhaustion. Cytotoxic T cell responses are further inhibited by immune-suppressive cytokines by Tregs, astrocytes and neurons [277,278]. Immune checkpoint blockade (ICB) is based on a range of monoclonal antibody-based therapies, especially checkpoint inhibitors that block CTLA-4, PD-1, or PD-L1. Anti-CTLA-4 antibodies restore T cell activation in the lymph nodes, and PD-1/PD-L1 antibodies enhance the functional properties of effector T cells at the tumor site [279,280]. TAM: tumor-associated macrophage, BMDMs: bone marrow-derived macrophages, TCR: antigen-specific T-cell receptor.

immunostimulatory effects to induce long-lasting antitumor immune response [307]. There are a variety of oncolytic viruses that can be armed with immunoregulatory inserts, like IL14, GMCSF, OX40 ligand or INFbeta to increase safety [308–311]. The release of tumor associated antigens or damage-associated molecules can lead to durable and systemic effects, as evidenced in metastatic melanoma [312]. Some parallels have been seen in GBM, where the application of an oncolytic adenovirus has led to CD8 effector T cell activation and downregulation of checkpoint inhibitors [313].

A challenge of therapy with oncolytic viruses is to achieve adequate replication of the virus in the tumor and tumor lysis. Viral vectors must avoid triggering an inflammatory response that would invite early elimination [314]. Combination regimens have been proposed to avoid this premature viral clearance. Chemotherapies, radiation, and steroids are all post-operative steps that can temporarily suppress the innate immunity and support viral infection and dissemination [315,316].

Several virotherapies have been investigated in clinical trials for the treatment of GBM, most notably vocimagene amiretrorepvec (Toca 511), which depends on a non-lytic strategy. In this model, a replicating retrovirus encoded with a cytosine deaminase is injected into the tumor bed with the goal to achieve preferential tumor cell infection over several weeks. At that time, the encoded virus converts a prodrug, Toca FC, to 5-fluorouracil which will in turn impair thymidylate synthase and cell replication [317]. Several weeks later, when viral infection has been achieved, this prodrug-converting enzyme can convert valaciclovir into a nucleotide analogue and interrupt tumor cell replication [318]. Early clinical trials reported a median overall survival of 13.6 months for recurrent or progressive GBM, which is promising when compared to historical controls. Additional viral studies have been performed with alternative vectors as adenovirus, poliovirus, cytomegalovirus and herpes virus [319]. ASPECT is one such Phase III clinical trial for patients with operable high-grade glioma currently underway which assesses the use of an adenovirus encoded with herpes-simplex-virus thymidine kinase [320].

3.2.4. Chimeric antigen receptor T (CAR T) cells

Treatment with CAR T cells involves collection of allogeneic T cells from peripheral blood, ex vivo genetic engineering of the cells to express receptors against specific tumor associated antigens, and adoptive transfer of the tumor-targeted T cells. CAR T cells can bind the tumor antigen without antigen processing and independent of HLA-mediated antigen presentation. Immune cell activation signals are derived from CD3 and co-stimulatory receptors, such as CD28 or TNFRSF9/4–1BB [321]. Several early phase clinical trials with tumor-targeted CAR-T cells have been completed, targeting various tumor antigens such as EGFRvIII, HER2, and IL13R α 2 [322–324] in GBM. It remains to be seen whether there are significant and durable survival benefits for patients with GBM [322,323]. Several other targets for GBM are also actively being evaluated including CD147, also known as extracellular matrix metalloproteinase inducer, as well as B7-H3, an immune checkpoint transmembrane protein overexpressed in GBM [325] (NCT04045847, NCT04385173).

As with other therapies, CAR T cell therapies are subject to many barriers affecting a robust T cell response such as adequate T cell infiltration and activation. Tumor plasticity, antigen loss and heterogeneity continuously counteract CAR T cell therapies [326]. Decreased expression of the target antigen, presence of splice variants and epitope modifications after treatment have all been observed [327]. Additionally, not all tumor cells express the targeted antigen at any given time, while current versions of CAR T cells have a limited receptor repertoire. Recent work has described the expansion into bispecific T cell engager (BiTE) and trivalent CAR T cells, enabling recognition of multiple tumor antigens. Unfortunately, immunosuppressive features of the tumor microenvironment, Tregs and TAMs can counteract the efficacy of CAR T cells or promote T cell exhaustion [328]. Finally, intrinsic pathways can interrupt sustained therapeutic activity of CAR T cells, such as

chronic antigen exposure and tonic CAR signaling, which can also lead to T cell exhaustion.

Overall, many approaches for immunotherapy of GBM rely on activated T cells. Unlike other solid malignancies, GBM treatment is uniquely challenged by its immune-privileged state [326]. Intrinsic characteristics of tumor cells can block this activation, leading to a “cold” tumor [329]. For example, continuous changes in the tumor cell’s mutational profile can lead to loss of neoantigens that are initial targets for therapeutic T-cells [330]. This differs from many hematologic malignancies which exhibit more clonal cell populations [331]. Meanwhile, extrinsic mechanisms can also hinder immune cell infiltration and coordinate an immunosuppressive tumor microenvironment. This can contribute to tumor-promoting resident immune cell populations and secreted factors in the tissue space. While immunotherapy alone fails to provide significant survival benefits for brain cancer patients, accumulating evidence shows that adjuvant radiation can prime and activate immune cells to tumor-derived antigens, induce presentation of neo-antigens in the tumor, and improve immune-suppressive environment, all of which sensitize brain cancers to immunotherapies by converting the immune environment from “cold” to “hot” [278,332] (Fig. 5). We found that irradiation improves IL-8 secretion by tumors, thus, we constructed IL-8 receptor-modified CD70CAR T cells to migrate into the tumor and induce an enhanced antitumor response in GBM [333]. Additionally, Murty et al. found concurrent irradiation improved intravenous adoptive T-cell administration in the treatment of GBM in a preclinical immunocompetent GBM model [334].

3.3. Nanotherapy

Conventional therapies for GBM can only marginally prolong the survival of patients with GBM. The vast majority of patients with GBM will die within 1–2 years after their diagnosis. Some challenges to successful treatment include the difficulty of complete tumor resection, the inefficient delivery of chemotherapeutic drugs, and the incomplete eradication of GICs. To overcome these obstacles, the application of nanoparticulate anti-GBM drugs has been proposed.

3.3.1. Passive tumor targeting: EPR effect

Nanoscale drug systems are based on polymeric micelles, liposomes, inorganic nanoparticles, nanotubes, or dendrimers [335,336] (Fig. 6) with attached or internalized chemotherapeutic drugs, sensitizers, or RNA [337]. A limited permeability of the blood brain barrier (BBB) is the major obstacle in traditional GBM treatment. As a result of the angiogenesis process, the blood vessels in a tumor may develop a leaky endothelium which allows the entry of macromolecules, such as nanoparticles. After intravenous administration, nanoparticles diffuse into tumor tissue. While small molecular drugs extravasate more easily into tumors, they can also diffuse quickly back into the blood. By contrast, the large size of nanomaterials prevents diffusion of extravasated macromolecules back into the blood. This phenomenon is known as the enhanced permeability and retention (EPR) effect [338–340]. The size of macromolecular drugs is critically important to achieve an ideal compromise between vascular extravasation and tumor retention. Xu et al. compared the tumor targeting efficiency of nanoparticles between 3 nm and 30 nm. The study showed that 3 nm nanoparticles exhibited much greater tumor targeting efficiency and penetration compared to the 30 nm nanoparticles [341]. Bort et al developed ultrasmall polysiloxane-based nanoparticles with a hydrodynamic diameter of approximately 4 nm, which extravasated into rodent tumors and have recently been further developed towards a phase I clinical trial in patients with brain metastases [342].

3.3.2. Active tumor targeting

The EPR effect is highly dependent on the permeability of blood vessels within a tumor, to improve tumor targeting, nanoparticle carriers have been decorated with specific antibodies, peptides, or

aptamers, which can be actively targeted to specific surface markers of tumor cells (Fig. 6).

Nanocarriers can transport RNA inhibitors such as siRNAs, miRNAs and LncRNAs [343–347], can be targeted against specific surface markers such as Cx43, CD133, CD44, CD163, CD15, CD49f, CD90 or target signaling pathways such as Hedgehog, Notch, PI3K/Akt/P-TEN/mTOR, cAMP-Epac, NF- κ B, Jak/STAT [337,348,349]. Specific tumor targeting is commonly associated with certain nanocarriers. PEG-modified liposomes allow the attachment of functional groups targeting tumor tissues and reduce uptake by the reticuloendothelial system [350]. In one case, Pep-1-conjugated PEGylated nanoparticles loaded with paclitaxel (Pep-NP-PTX) improved anti-glioma efficacy with a median survival time of 32 days in mouse models, which was significantly longer than that of control mice treated with PTX-NP (23 days) and Taxol® (22 days) [351]. Grafals-Ruiz et al developed gold-liposome nanoparticles conjugated with the brain targeting peptides apolipoprotein E (ApoE) and rabies virus glycoprotein (RVG). Spherical nucleic acids (SNAs)-Liposome-ApoE were able to cross the BBB and showed a high accumulation in brain tumor tissues. Furthermore, SNA-Liposome-ApoE specifically targeted a highly abundant miRNA (miR-92b), which is aberrantly overexpressed in GBM [352]. Belhadj et al developed a multifunctional liposomal glioma-targeted drug delivery system (c(RGDyK)/pHA-LS) modified with cyclic RGD (c(RGDyK)) and p-hydroxybenzoic acid (pHA). In their study, c(RGDyK)/pHA-LS/DOX showed a median survival time of 35 days, which was 2.31-, 1.76- and 1.5-fold higher than that of LS/DOX, c(RGDyK)-LS/DOX, and pHA-LS/DOX, respectively [353].

3.3.3. Stimuli-responsive drug release

Although various delivery platforms, such as PEGylated nanocarriers, have been developed to prolong circulation and improve drug solubility, the delivery efficacy of most nanocarriers is still quite low [354]. Thus, stimuli-responsive nanocarriers are rationally designed to deliver and release drugs by responding to internal stimuli, such as pH,

hypoxia, reactive oxygen species, enzyme activity, etc., or external stimuli, including ultrasound, light (e.g., laser), temperature (i.e., thermal) and magnetic field, etc [336,355] (Fig. 6). can specifically delivery cargos to the tumor microenvironment.

GBMs are characterized by extensive tissue hypoxia and various nanocarriers have been designed to target hypoxic tumors [356]. Liu et al developed hypoxia-responsive ionizable liposomes, which showed enhanced therapeutic efficacy of small interference RNA (siRNA) anti-cancer drugs when exposed to low pH and hypoxic tumor microenvironment in glioma [357]. GBMs are known for their resistance to radiotherapy due to intratumoral hypoxia. Hua et al have designed angiopep-2-lipid-poly-(metronidazoles)n (ALP-(MIs)n) hypoxic radiosensitizer-polyprodrug nanoparticles (NPs), which enhanced the radiotherapy sensitivity of gliomas [358]. Enzyme activity is another internal stimuli to be considered. We developed a cross-linked iron oxide nanoparticle conjugated to azademethylcolchicine (CLIO-ICT), which is specifically activated by the enzyme, matrix-metalloproteinase 14 (MMP-14). Since MMP-14 is highly expressed in GBM, but not in the normal brain or normal visceral organs, it provides cancer-specific therapy with little or no side effects. Upon-cleavage by MMP-14, CLIO-ICT releases azademethylcolchicine in the tumor tissue, which disrupted the tumor vasculature and killed tumor cells and GIC in GBM [359,360]. Our study showed that treatment with CLIO-ICT plus TMZ and irradiation lead to significantly improved tumor growth inhibition and overall survival of mice with GBM when compared to controls that received monotherapy. In addition, the iron core of CLIO-ICT enabled in vivo drug tracking with MR imaging, demonstrating in vivo tumor drug accumulation.

External stimuli also have been studied extensively to improve nanodrug delivery in GBM. Although the BBB is disrupted in GBM patients, overwhelming clinical evidence demonstrates the existence of an intact BBB in all GBM, which limit therapeutics delivery and efficacy [361]. The combination of focused ultrasound (FUS)-BBB opening and externally applied magnetic field (MT) could deliver nanodrugs more




Fig. 5. Immune modulatory effects of radiotherapy. The localized cytotoxic effects of radiation have been shown to cause immunogenic cell death (ICD). Radiation can induce all three arms of ICD: upregulation of the release of adenosine triphosphate (ATP), the extracellular release of “danger signal” high motility group box 1 (HMGB1) and translocation of “eat me” signal calreticulin (CRT) to the cell surface. Additionally, radiation regimens unmask the tumor by upregulating major histocompatibility complex (MHC) on the tumor cell, which enhances neo-antigen presentation in tumor cells for recognition by cytotoxic T-cells. Besides the effects on tumor cells, irradiation also affects tumor-associated stromal cells, such as reactive astrocytes, and the recruitment of microglia, which further contribute to the establishment of radiation-induced immune responses.










Delivery Platforms:**A Gold nanospheres****B Gold nanorods****C Carbon nanotubes****Delivery Mechanism:****Active Targeting of Tumor cells****Stimuli-Responsive Drug Release****External Stimuli****Internal Stimuli****D Nanogels****E Polymeric nanoparticles****F Polymeric micelles****G Liposomes**

Fig. 6. Advanced delivery platforms and delivery mechanisms of nanoparticulate anti-GBM drugs. Nanocarriers have been proposed based on various materials and principles as shown in the figure (a–g). Ligand-installed nanocarriers achieve therapeutic effects by actively targeting the surface marker or signaling pathway of cancer cells. Stimuli-responsive nanocarriers can release drug by responding to internal/external stimuli, which enable specific delivery cargos into the tumor microenvironment.

effectively to deep-seated GBM tumors [362,363]. Most recently, Curley et al. used MRI-FUS and microbubbles to deliver “brain-penetrating” nanoparticle (BPN), which yielded markedly augmented interstitial tumor flow and enhanced BPN penetration in GBM [364]. Fan et al. developed boron-containing polyanion [poly(ethylene glycol)-b-poly((closo-dodecaboranyl)thiomethylstyrene)] (PEG-b-PMBSH) nanoparticles (295 ± 2.3 nm in aqueous media) and coupled them with microbubble-assisted FUS for GBM treatment. They found the combination may improve boron neutron capture therapy (BNCT) in GBM [365]. Li et al. developed polysorbate 80-modified paclitaxel-loaded PLGA nanoparticles (PS-80-PTX-NPs, PPNP), which showed significantly stronger anti-tumor efficacy in the tumor-bearing mice when combined with FUS [366]. Furthermore, magnetic hyperthermia-mediated cancer therapy (MHCT) has shown promising results in the preclinical studies. MHCT has applied magnetic nanoparticles to heat tumor tissues, which is based on an alternating magnetic field (AMF) [367,368]. Gupta et al. have developed manganese-doped magnetic nanoclusters for hyperthermia and photothermal GBM therapy, they observed oxidative stress produced in the cellular environment and confirmed the ROS-dependent apoptosis of GBM cells via the mitochondrial pathway [369]. Mamani et al. found magnetic hyperthermia effectively decreased cell viability (about 20% and 100% after 10- and 30-minutes therapy) with a GBM 3D cells culture model [370].

3.3.4. Different administration routes for drug delivery

An intranasal route of drug administration can enable therapeutic compounds to reach GBM tumors in significantly higher doses than with intravenous administration. Sousa et al. developed BCZ-loaded PLGA nanoparticles and intranasally injected them into a GBM mouse model. The drug was found to be efficiently delivered to the brain with very

limited off-target delivery to visceral organs, such as the lung and liver [371]. Khan et al. established nano-lipid chitosan hydrogel formulations for a nose-to-brain delivery of TMZ. After intranasal administration, TMZ release to GBM was 60% within 24 h and Wistar rats showed an increased drug targeting efficiency (DTE) of 326% and a direct transport percentage (DTP) of 93% compared to the intranasal administration of nano-lipid formulation as a control (DTE, 113.36% and DTP, 71.74%) [372]. Similarly, the concomitant intranasal administration of chitosan nanoparticles attached with a Gal-1 siRNA enhanced the efficacy of anti-PD-1 antibodies with a median survival of 51.5 days, which is significantly higher than the control groups (17.5 and 30 days for untreated mice and anti-PD-1 antibodies alone, respectively) [373].

Intratumor administration can also be effective in cases of a solitary tumor which cannot be surgically removed. The injection can be carried out with a syringe or catheter at the tumor location or with the help of convection enhanced delivery (CED). CED is a technique which can precisely control the infusion rates of anti-GBM compound towards GBM tumors by maintaining a hydrostatic pressure gradient [374]. CED was first introduced in 1994 [375] and applied widely in clinical trials for the non-nano-formulated anti-cancer compounds [376–380]. CED involves drilling a small burr hole into the skull and stereotactically positioning catheters to the interstitial space next to the tumor using image guidance. Once in position, the catheter can deliver many different kinds of therapeutic or imaging contrast agents to the site (e.g., small molecules, proteins, viruses, liposomes, nanoparticles, etc.) [381,382]. This technique ensures delivery to the tumor without needing to bypass the blood-brain barrier (BBB), but it failed mostly due to insufficient drug distribution [383]. Later, it was tested with nano-formulated drugs and showed high retention time in tumors. Polymeric nanoparticles such as poly(lactide-co-glycolide) (PLGA) nanoparticles were used for CED. CED of carboplatin nanoparticles conferred greater tumor cytotoxicity and

reduced neuronal toxicity in rat and porcine models [374]. Finbloom et al found that the CED of virus-like particles (VLPs) and nanophage filamentous rods modified with doxorubicin (DOX) required smaller doses than traditional intravenous routes to achieve comparable survival outcomes [384].

Several potential benefits of anti-GBM nano-drugs have been identified: (1) Improving surgical tumor removal. Most recently, fluorescence guided resection of GBM after intravenous administration of a fluorescent mini nanoimaging agent (NIA) or fluorescent silica coated iron oxide nanoparticles greatly improved the intraoperative delineation of GBM [385,386]. (2) Improving the efficacy of chemotherapy and reducing side effects. As described above, nano-scale drugs have a greater blood circulation half-life and can be predominantly delivered to the tumor via the EPR effect or active delivery systems. Targeting specific markers of tumor cells reduces toxicity to healthy cells and thus decreases side effects [339]. (3) Enhancing the efficacy of radiotherapy. Recent studies have shown that nanodrugs that kill GICs can enhance the efficacy of radiotherapy [360,387]. Radiation therapy could, in turn, enhance nanotherapy by affecting the prevalence and polarization of tumor-associated macrophages [388]. (4) The nanoparticle carrier can be designed to actively induce an immune response [389,390]. Our group showed that the iron oxide nanoparticle ferumoxytol induced pro-inflammatory macrophage polarization and thus inhibited tumor growth[391]. Overall, nanotherapeutics have many advantages for treating GBM, which can enhance the efficacy of traditional therapy.

3.4. Miscellaneous therapies

3.4.1. Laser interstitial thermal therapy (LITT)

LITT is a method for delivering thermal energy to GBM using a stereotactic device with the goal to ablate the tumor tissue. A small burr hole is drilled into the skull through which an optical fiber is threaded and guided to the center of the tumor. The fiber creates heat which burns and kills the tumor tissue. The heat generated can be monitored using MR-thermometry to ensure safe use and no harm to healthy adjacent tissue. Advantages of LITT over standard surgery include the minimally invasive approach and feasibility to treat inoperable tumors. This technology has been used with other types of brain lesions and was particularly useful for high grade gliomas [392]. After treatment with LITT, patients with smaller tumors ($<4 \text{ cm}^3$) demonstrated higher survival rates and fewer perioperative complications compared to patients with larger tumors ($>4 \text{ cm}^3$) [392,393]. Despite promising results, side effects from LITT can include swelling and inflammation which can cause neurological side effects. Traditional surgery also leads to inflammation; however, the effect is mitigated since there is space left where tissue was removed. With LITT, the dead treated tissue is still present. There is still no clear guidance on who should receive this treatment, but it is a useful tool to supplement existing treatment strategies.

3.4.2. Tumor-treating fields (TTFields)

Tumor treating fields are a new treatment modality for GBM. It was approved by the FDA in 2011 for recurrent GBM and in 2015 for newly diagnosed GBM. More recently, TTFields has been approved by the FDA for the treatment of patients with pleural malignant mesothelioma [394]. The treatment requires the patient to wear a device on their shaved head that delivers low-intensity, intermediate frequency, alternating electric fields [395]. The alternating electric fields produce antimitotic effects that are selective for rapidly dividing cells with the maximal benefit occurring when the electric fields are parallel to the axis of cell division [396]. Given that cells in a tumor are turned in many different directions, the treatment is most effective when two or more orthogonal pairs of transducer arrays are used. One major benefit to TTFields is the limited toxicity and mild side effects (usually only skin irritation that can be managed with topical treatments). The greatest determinant of treatment success is patient compliance in wearing the

device since the treatment is only working when the device is worn and the electric fields are “on”. This technology has been slow to gain traction in the clinic possibly due to the sparse scientific literature and variable compliance of patients to shave their head, wearing the device $>75\%$ of the time, and carrying around a large battery pack. However, the benefits of TTFields are clear. In a phase III multi-center clinical trial, it was shown that in a population of nearly 700 patients, those that received TTField therapy in addition to TMZ had a significantly enhanced progression-free survival (~5 months) and significantly enhanced overall survival [397]. Optimization of therapy will come from further examination of the mechanisms of actions of TTFields. For instance, it has been shown that TTFields can disrupt the membrane composition and permeability of cancer cells [398] and this could explain the synergistic effects of combination therapies of TTFields with chemotherapeutics such as Withaferin A [399].

4. Future therapeutic strategies

In 2005, when Stupp et al. demonstrated a major pharmaceutical progress for GBM management by combining radiotherapy and adjuvant TMZ therapy [5]. Since then, there have been advances in understanding genetic drivers of tumor development and progression. Many of these molecular characteristics were included in the World Health Organization (WHO) 2016 updated classification of tumors of the central nervous system including *IDH* mutant/wildtype status, *1p/19q* deletions, *EGFR* amplification, and mutations in *TP53*, *PTEN*, *ATRX*, and *TERT* promoters [400]. There have been improved 2- and 3- year survival rates, but 5-year survival rates remain poor [401]. Advances in precision medicine, surgical techniques, and combination therapies will shape the future directions for GBM treatment.

4.1. Precision medicine

Ideally, a given patient's brain tumor would be screened for specific biomarkers that could be paired with selective drugs. Only patients having high expression of the biomarker would receive a targeted drug. The treatment plan would likely change over time as the tumor evolves and would also look different for patients with different tumor characteristics. For example, O⁶-methylguanine-DNA methyltransferase (MGMT) promoter methylation has already been shown to predict tumor response to TMZ therapy [402]. Exosomes, extracellular vesicles, and microRNA assays are also being used as biomarkers for GBM [403–406]. Intraoperatively, mass spectrometry (MS) can sensitively and specifically identify molecules in the tumor [407], aiding the surgeon in defining the tumor margin and determining the most effective systemic therapy.

GBM is marked by extensive inter- and intra-individual heterogeneity in driver mutations and molecular subtypes [408]. Identification of new biomarkers is also important for treatment of recurrent GBM as 90% of druggable targets are differentially expressed in a recurrent tumor compared to the tumor at initial diagnosis [409]. Patients may need to receive new therapies over the course of their disease. Le Rhun et al. provided an in depth summary of known GBM-specific biomarkers [410]. Many GIC markers are also being explored, including CD133, CD44, CD15, CD70, S100A4, ALDH1A3, NANOG, OCT-4, SOX-2, and NESTIN [411–414].

Tools that aid discovery and understanding of biochemical pathways will likely include new genetic screening techniques [415,416], next generation sequencing and epigenetic studies [417]. In addition, machine learning algorithms and bioinformatics analyses of tumor omics data will enable correlations of complex multi-factorial clinical information with tailored treatment options [418,419]. Machine learning algorithms could be designed to predict responses to treatment and support treatment decisions [420]. Furthermore, organoids gain more and more attention in recent years. Organoids possess greater predictive power compared to assays of single cell monolayers and can be used to

test patient-specific therapies [421,422]. They are especially useful in situations where patient samples are difficult to obtain [423,424]. Some organoid models have even been shown to exhibit stage-specific neural development and yield pathology results similar to resected patient tumors [425].

Unfortunately, targeted therapies in clinical trials have had limited success thus far, partly due to the heterogeneity and plasticity of GBM but also due to practical limitations [193]. A future clinical trial would likely have the following elements: (i) strong evidence of anti-tumor activity in relevant pre-clinical models, (ii) selection of patients with molecular enrichment for the drug target ideally with a non-invasive diagnostic technique, (iii) a drug that by design or by delivery route accounts for the restrictive nature of the BBB, (iv) inclusion of tissue collection or advanced molecular imaging during the treatment for analysis of pharmacodynamic markers, and (v) close integration of advanced imaging technologies and treatment, including advanced imaging biomarkers for improved tumor detection, characterization and treatment monitoring.

4.2. Advances in surgical techniques

Given the importance of complete tumor resection toward positive patient outcomes, advances in surgical techniques and image guidance will be critical for the future of GBM treatment. LITT has shown efficacy in improving quality of life, cognition, and stabilization of Karnofsky Performance Status (KPS) score for patients suffering from radiation necrosis [426]. Appropriate patient selection is important. LITT may not be appropriate for patients who are significantly functionally compromised [393]. The development of novel fluorescent imaging agents and related equipment may improve the surgeon's ability to see and remove the entire tumor. Only 5-aminolevulinic acid (5-ALA) is approved for intraoperative use in GBM resection [49,427,428]. Unfortunately, the US was a full decade behind Europe in approving this clinical imaging agent [49]. In addition, diffusion tensor imaging (DTI)-MRI has also shown promise to visually help locate important motor fibers which can be spared during tumor resection [429]. In addition to improving tumor resection, emphasis should be placed equally on improving safety as new deficits after surgery can eliminate the survival benefits of surgery [430].

4.3. Combination therapies

Unfortunately, current combination therapies for the treatment of GBM are often rendered ineffective because the tumor can find redundant compensatory mechanisms. This was likely the reason why isolated studies that targeted PI3K/AKT/mTOR, p53/RB pathways, or EGFR gene amplification or mutation, have failed to improve outcomes [410]. Therefore, to be successful, novel GBM therapies target distinct biological pathways and include novel methodologies such as electric field, viral, or cell-based therapeutic strategies. Tumor treating fields (TTFields) may be particularly suited for combination therapy [431]. TTFields elicit a therapeutic effect by applying alternating electric fields that alter DNA repair, membrane permeability, and immunological responses [432].

Major considerations for combination therapies are the method of delivery, time of administration, and the order of therapy [433]. Nanocarriers hold promise for delivery of multiple chemical therapeutics and/or a high payload to GBM tumors in a single dose. Nanoparticles are then often phagocytosed by tumor-associated macrophages which can create both limitations and opportunities [434]. Encapsulating several agents in a single nanocarrier can deliver them together [435]. For radiation therapy, fractionated doses are important for normal cell recovery and reoxygenation of acutely hypoxic tissues [436]. In addition to DNA damage induced by radiation, the "abscopal effect" can prime and activate the innate immune system [437–439]. The order of combination therapies also needs to be carefully evaluated. For example, a

first therapy could be used to "prime" the tumor microenvironment and make it more receptive for a subsequent second therapy [440]. "Priming" may include normalizing the vasculature, reducing stress associated with the large solid tumor mass, or degrading the extracellular matrix for better drug penetration [441].

5. Conclusion

GBM continues to be the most lethal tumor type with limited treatment options. Given the genomic complexity and multiple signaling pathways of GBM, a monotherapy will likely not be effective. An effective treatment approach for GBM will require combination therapies targeting distinct oncogenic pathways. A comprehensive understanding of the molecular biology of GBM, along with mechanisms of therapy resistance and effective integration of different therapy approaches will be key for the development of effective therapies. While histology and the identification of chromosomal deletions are important to estimate prognosis and plan targeted therapies, imaging can help in guiding surgeries and monitoring treatment response.

CRediT authorship contribution statement

All authors are involved in the critical review and final acceptance of the submission.

Declaration of interest

None.

Acknowledgments

We would like to dedicate this article to our late chair and long-term mentor Dr. Sanjiv Sam Gambhir, the Virginia and D.K. Ludwig Professor in Cancer Research and Chairman of the Department of Radiology at Stanford University from 2011 to 2020. Dr. Gambhir had dedicated his life to cancer research, with specific focus on glioblastoma. W.W. and H.D.L. are supported by a grant from the ReMission Alliance Against Brain Tumors (PI: Duane Mitchell, University of Florida; PI of subaward to Stanford: H. Daldrup-Link). In addition, H.D.L. is supported by a grant from the National Institute of Child Health and Development (R01HD103638) and the National Cancer Institute (P30CA124435; PI: Steven Artandi). M.Z. is supported by the Stanford Cancer Imaging Training Program (T32CA009695, PI S. Napel, Stanford University).

Graphical abstract, Figs. 1 and 2 were created with BioRender.com. Figs. 4–6 were adapted from "Blockade of CTLA-4 or PD-1 Signaling in Tumor Immunotherapy", "Cold vs Hot Tumors" and "Nanoparticle-Mediated Targeted Drug Delivery to Cancer Stem Cells", respectively, by BioRender.com (2021). Retrieved from <https://app.biorender.com/biorender-templates>.

References

- [1] A. Oszvald, E. Güresir, M. Setzer, H. Vatter, C. Senft, V. Seifert, K. Franz, Glioblastoma therapy in the elderly and the importance of the extent of resection regardless of age, *J. Neurosurg.* 116 (2) (2012) 357–364.
- [2] M.E. Davis, Glioblastoma: overview of disease and treatment, *Clin. J. Oncol. Nurs.* 20 (5 Suppl) (2016) S2–S8.
- [3] M. Yao, S. Li, X. Wu, S. Diao, G. Zhang, H. He, L. Bian, Y. Lu, Cellular origin of glioblastoma and its implication in precision therapy, *Cell Mol. Immunol.* 15 (8) (2018) 737–739.
- [4] M.Z. Braganza, C.M. Kitahara, A. Berrington de Gonzalez, P.D. Inskip, K.J. Johnson, P. Rajaraman, Ionizing radiation and the risk of brain and central nervous system tumors: a systematic review, *Neurooncology* 14 (11) (2012) 1316–1324.
- [5] R. Stupp, W.P. Mason, M.J. van den Bent, M. Weller, B. Fisher, M.J. Taphoorn, K. Belanger, A.A. Brandes, C. Marosi, U. Bogdahn, J. Curschmann, R.C. Janzer, S. K. Ludwin, T. Gorlia, A. Allgeier, D. Lacombe, J.G. Cairncross, E. Eisenhauer, R. O. Mirimanoff, European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups, National Cancer Institute of Canada

- Clinical Trials Group, Radiotherapy plus concomitant and adjuvant temozolamide for glioblastoma, *New Engl. J. Med.* 352 (10) (2005) 987–996.
- [6] Q.T. Ostrom, N. Patil, G. Cioffi, K. Waite, C. Kruchko, J.S. Barnholtz-Sloan, CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2013–2017, *Neurooncology* 22 (12 Suppl 2) (2020) iv1–iv96.
- [7] F. Ringel, H. Pape, M. Sabel, D. Krex, H.C. Bock, M. Misch, A. Weyerbrock, T. Westermaier, C. Senft, P. Schucht, B. Meyer, M. Simon, SN1 Study Group, Clinical benefit from resection of recurrent glioblastomas: results of a multicenter study including 503 patients with recurrent glioblastomas undergoing surgical resection, *Neurooncology* 18 (1) (2016) 96–104.
- [8] M. Lara-Velazquez, R. Al-Kharboosh, S. Jeanneret, C. Vazquez-Ramos, D. Mahato, D. Tavanihaepon, G. Rahmathulla, A. Quinones-Hinojosa, Advances in brain tumor surgery for glioblastoma in adults, *Brain Sci.* 7 (2017) 12.
- [9] D. Garnier, O. Renault, M.C. Alves-Guerra, F. Paris, C. Pecqueur, Glioblastoma stem-like cells, metabolic strategy to kill a challenging target, *Front. Oncol.* 9 (2019) 118.
- [10] B.C. Prager, S. Bhargava, V. Mahadev, C.G. Hubert, J.N. Rich, Glioblastoma stem cells: driving resilience through chaos, *Trends Cancer* 6 (3) (2020) 223–235.
- [11] Y.C.S. Ramon, M. Sese, C. Capdevila, T. Aasen, L. De Mattos-Arruda, S.J. Diaz-Cano, J. Hernández-Losa, J. Castellvi, Clinical implications of intratumor heterogeneity: challenges and opportunities, *J. Mol. Med.* 98 (2) (2020) 161–177.
- [12] R.G. Verhaak, K.A. Hoadley, E. Purdom, V. Wang, Y. Qi, M.D. Wilkerson, C.R. Miller, L. Ding, T. Golub, J.P. Mesirov, G. Alexe, M. Lawrence, M. O'Kelly, P. Tamayo, B.A. Weir, S. Gabriel, W. Winckler, S. Gupta, L. Jakkula, H.S. Feiler, J. G. Hodgson, C.D. James, J.N. Sarkaria, C. Brennan, A. Kahn, P.T. Spellman, R.K. Wilson, T.P. Speed, J.W. Gray, M. Meyerson, G. Getz, C.M. Perou, D.N. Hayes, Cancer Genome Atlas Research Network, Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1, *Cancer Cell* 17 (1) (2010) 98–NF110.
- [13] J. Behnau, G. Finocchiaro, G. Hanna, The landscape of the mesenchymal signature in brain tumours, *Brain* 142 (4) (2019) 847–866.
- [14] D. Sturm, S. Bender, D.T. Jones, P. Lichter, J. Grill, O. Becher, C. Hawkins, J. Majewski, C. Jones, J.F. Costello, A. Iavarone, K. Aldape, C.W. Brennan, N. Jabado, S.M. Pfister, Paediatric and adult glioblastoma: multiform (epi) genomic culprits emerge, *Nat. Rev. Cancer* 14 (2) (2014) 92–107.
- [15] Q. Wang, B. Hu, X. Hu, H. Kim, M. Squatrito, L. Scarpace, A.C. deCarvalho, S. Lyu, P. Li, Y. Li, F. Barthel, H.J. Cho, Y.H. Lin, N. Satani, E. Martinez-Ledesma, S. Zheng, E. Chang, C.E. Gabriel Sauve, A. Olar, Z.D. Lan, G. Finocchiaro, J. J. Phillips, M.S. Berger, K.R. Gabrusiewicz, G. Wang, E. Eskilsson, J. Hu, T. Mikkelsen, R.A. DePinho, F. Müller, A.B. Heimberger, E.P. Sulman, D.H. Nam, R.G.W. Verhaak, Tumor evolution of glioma-intrinsic gene expression subtypes associates with immunological changes in the microenvironment, *Cancer Cell* 33 (1) (2018) 152.
- [16] M. Fedele, L. Cerchia, S. Pegoraro, R. Sgarra, G. Manfioletti, Proneural-mesenchymal transition: phenotypic plasticity to acquire multitherapy resistance in glioblastoma, *Int. J. Mol. Sci.* 20 (2019) 11.
- [17] M.A. Qazi, P. Vora, C. Venugopal, S.S. Sidhu, J. Moffat, C. Swanton, S.K. Singh, Intratumoral heterogeneity: pathways to treatment resistance and relapse in human glioblastoma, *Ann. Oncol.* 28 (7) (2017) 1448–1456.
- [18] A.P. Patel, I. Tiros, J.J. Trombetta, A.K. Shalek, S.M. Gillespie, H. Wakimoto, D. P. Cahill, B.V. Nahed, W.T. Curry, R.L. Martuza, D.N. Louis, O. Rozenblatt-Rosen, M.L. Suva, A. Regev, B.E. Bernstein, Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma, *Science* 344 (6190) (2014) 1396–1401.
- [19] R. Daneman, A. Prat, The blood-brain barrier, *Cold Spring Harb. Perspect. Biol.* 7 (1) (2015), a020412.
- [20] C. Greene, M. Campbell, Tight junction modulation of the blood brain barrier: CNS delivery of small molecules, *Tissue Barriers* 4 (1) (2016), e1138017.
- [21] S. Liebner, R.M. Dijkhuizen, Y. Reiss, K.H. Plate, D. Agalliu, G. Constantin, Functional morphology of the blood-brain barrier in health and disease, *Acta Neuropathol.* 135 (3) (2018) 311–336.
- [22] R.W. Robey, K.M. Pluchino, M.D. Hall, A.T. Fojo, S.E. Bates, M.M. Gottesman, Revisiting the role of ABC transporters in multidrug-resistant cancer, *Nat. Rev. Cancer* 18 (7) (2018) 452–464.
- [23] D. Gomez-Zepeda, M. Taghi, J.M. Schermann, X. Declèves, M.C. Menet, ABC transporters at the blood-brain interfaces, their study models, and drug delivery implications in gliomas, *Pharmaceutics* 12 (2019) 1.
- [24] D. Wang, C. Wang, L. Wang, Y. Chen, A comprehensive review in improving delivery of small-molecule chemotherapeutic agents overcoming the blood-brain/brain tumor barriers for glioblastoma treatment, *Drug Deliv.* 26 (1) (2019) 551–565.
- [25] P. Sharma, J.P. Allison, The future of immune checkpoint therapy, *Science* 348 (6230) (2015) 56–61.
- [26] P. Bonaventura, T. Shekarian, V. Alcazer, J. Valladeau-Guilemond, S. Valsesia-Wittmann, S. Amigorena, C. Caux, S. Depil, Cold tumors: a therapeutic challenge for immunotherapy, *Front Immunol.* 10 (2019) 168.
- [27] M. Lim, Y. Xia, C. Bettegowda, M. Weller, Current state of immunotherapy for glioblastoma, *Nat. Rev. Clin. Oncol.* 15 (7) (2018) 422–442.
- [28] C.G. Brahm, M.E. van Linde, R.H. Enting, M. Schuur, R.H.J. Otten, M. W. Heymans, H.M.W. Verheul, A.M.E. Walenkamp, The current status of immune checkpoint inhibitors in neuro-oncology: a systematic review, *Cancers* (2020) 3.
- [29] D.E. Azagury, M.M. Dua, J.C. Barrese, J.M. Henderson, N.C. Buchs, F. Ris, J. M. Cloyd, J.B. Martinie, S. Razzaque, S. Nicolau, L. Soler, J. Marescaux, B. C. Visser, Image-guided surgery, *Curr. Probl. Surg.* 52 (12) (2015) 476–520.
- [30] C. Watts, N. Sanai, Surgical approaches for the gliomas. *Handbook of Clinical Neurology* vol. 134, Elsevier, 2016, pp. 51–69.
- [31] J.G. Ojemann, J.W. Miller, D.L. Silbergeld, Preserved function in brain invaded by tumor, *Neurosurgery* 39 (2) (1996) 253–258, discussion 258–259.
- [32] M. Lacroix, D. Abi-Said, D.R.ourney, Z.L. Gokaslan, W. Shi, F. DeMonte, F. Lang, I.E. McCutcheon, S.J. Hassenbusch, E. Holland, K. Hess, C. Michael, D. Miller, R. Sawaya, A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival, *J. Neurosurg.* 95 (2) (2001) 190–198.
- [33] N. Sanai, M.S. Berger, Glioma extent of resection and its impact on patient outcome, *Neurosurgery* 62 (4) (2008) 753–764, discussion 264–266.
- [34] N. Sanai, M.-Y. Polley, M.W. McDermott, A.T. Parsa, M.S. Berger, An extent of resection threshold for newly diagnosed glioblastomas, *J. Neurosurg.* 115 (1) (2011) 3–8.
- [35] Y. Ushio, M. Kochi, Y. Hamada J-i, Kai, H. Nakamura, Effect of surgical removal on survival and quality of life in patients with supratentorial glioblastoma, *Neurol. Med. -Chir.* 45 (9) (2005) 454–460, discussion 460–461.
- [36] W. Stummer, H.-J. Reulen, T. Meinel, U. Pichlmeier, W. Schumacher, J.-C. Tonn, V. Rohde, F. Oppel, B. Turowski, C. Woicichowsky, K. Franz, T. Pietsch, ALA-Glioma Study Group, Extent of resection and survival in glioblastoma multiforme: identification of and adjustment for bias, *Neurosurgery* 62 (3) (2008) 564–576, discussion 564–576.
- [37] M.F. Kircher, A. de la Zerda, J.V. Jokerst, C.L. Zavaleta, P.J. Kempen, E. Mittra, K. Pitter, R. Huang, C. Campos, F. Habte, R. Sinclair, C.W. Brennan, I. K. Mellinghoff, E.C. Holland, S.S. Gambhir, A brain tumor molecular imaging strategy using a new triple-modality MRI-photoacoustic-Raman nanoparticle, *Nat. Med.* 18 (5) (2012) 829–834.
- [38] C.M. Moore, N.L. Robertson, N. Arsanious, T. Middleton, A. Villers, L. Klotz, S. S. Taneja, M. Emberton, Image-guided prostate biopsy using magnetic resonance imaging-derived targets: a systematic review, *Eur. Urol.* 63 (1) (2013) 125–140.
- [39] K. Kobayashi, P. Bhargava, S. Raja, F. Nasseri, H.A. Al-Balas, D.D. Smith, S. P. George, M.S. Vij, Image-guided biopsy: what the interventional radiologist needs to know about PET/CT, *RadioGraphics* 32 (5) (2012) 1483–1501.
- [40] V.S. Klimerberg, A. Rivere, Ultrasound image-guided core biopsy of the breast, *Chin. Clin. Oncol.* 5 (3) (2016) 33.
- [41] S. Hu, H. Kang, Y. Baek, G. El Fakhri, A. Kuang, H.S. Choi, Real-Time Imaging Of Brain Tumor For Image-guided Surgery, *Adv. Healthc. Mater.* 7 (16) (2018), e1800066.
- [42] D.G. Barone, T.A. Lawrie, M.G. Hart, Image guided surgery for the resection of brain tumours, *Cochrane Database Syst. Rev.* 1 (2014).
- [43] M.D. Jenkinson, D.G. Barone, A. Bryant, L. Vale, H. Bulbeck, T.A. Lawrie, M. G. Hart, C. Watts, Intraoperative imaging technology to maximise extent of resection for glioma, *Cochrane Database Syst. Rev.* 1 (2018).
- [44] M.A. Whitney, J.L. Crisp, L.T. Nguyen, B. Friedman, L.A. Gross, P. Steinbach, R. Y. Tsien, Q.T. Nguyen, Fluorescent peptides highlight peripheral nerves during surgery in mice, *Nat. Biotechnol.* 29 (4) (2011) 352–356.
- [45] J.E. Villanueva-Meyer, M.C. Mabray, S. Cha, Current clinical brain tumor imaging, *Neurosurgery* 81 (3) (2017) 397–415.
- [46] J.W. Pan, C.H. Moon, H.P. Hetherington, Cerebrospinal fluid-suppressed T2-weighted MR imaging at 7 T for human brain, *Magn. Reson. Med.* 81 (5) (2019) 2924–2936.
- [47] Y.M. Li, D. Suki, K. Hess, R. Sawaya, The influence of maximum safe resection of glioblastoma on survival in 1229 patients: can we do better than gross-total resection? *J. Neurosurg.* 124 (4) (2016) 977–988.
- [48] I.J. Gerard, M. Kersten-Oertel, K. Petrecca, D. Sirhan, J.A. Hall, D.L. Collins, Brain shift in neuronavigation of brain tumors: a review, *Med. Image Anal.* 35 (2017) 403–420.
- [49] C.G. Hadjipanayis, W. Stummer, 5-ALA and FDA approval for glioma surgery, *J. Neurooncol.* 141 (3) (2019) 479–486.
- [50] W. Stummer, U. Pichlmeier, T. Meinel, O.D. Wiestler, F. Zanella, H.-J. Reulen, ALA-Glioma Study Group, Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial, *Lancet Oncol.* 7 (5) (2006) 392–401.
- [51] K.-M. Schebesch, A. Brawanski, C. Hohenberger, J. Hohne, Fluorescein sodium-guided surgery of malignant brain tumors: history, current concepts, and future project, *Turk. Neurosurg.* 26 (2) (2016) 185–194.
- [52] S.S. Cho, R. Salinas, J.Y.K. Lee, Indocyanine-green for fluorescence-guided surgery of brain tumors: evidence, *Tech., Pract. Exp. Front. Surg.* 6 (2019) 11.
- [53] R.J. Diaz, R.R. Dios, E.M. Hattab, K. Burrell, P. Rakopoulos, N. Sabha, C. Hawkins, G. Zadeh, J.T. Rutka, A.A. Cohen-Gadol, Study of the biodistribution of fluorescein in glioma-infiltrated mouse brain and histopathological correlation of intraoperative findings in high-grade gliomas resected under fluorescein fluorescence guidance, *J. Neurosurg.* 122 (6) (2015) 1360–1369.
- [54] A. Della Puppa, M. Munari, M.P. Gardiman, F. Volpin, Combined fluorescence using 5-aminolevulinic acid and fluorescein sodium at glioblastoma border: intraoperative findings and histopathologic data about 3 newly diagnosed consecutive cases, *World Neurosurg.* 122 (2019) e856–e863.
- [55] H. Luo, R. Hernandez, H. Hong, S.A. Graves, Y. Yang, C.G. England, C.P. Theuer, R.J. Nickles, W. Cai, Noninvasive brain cancer imaging with a bispecific antibody fragment, generated via click chemistry, *Proc. Natl. Acad. Sci. U. S. A.* 112 (41) (2015) 12806–12811.
- [56] S.E. Miller, W.S. Tummers, N. Teraphongphom, N.S. van den Berg, A. Hasan, R. D. Ertsey, S. Nagpal, L.D. Recht, E.D. Plowey, H. Vogel, G.R. Harsh, G.A. Grant, G. H. Li, E.L. Rosenthal, First-in-human intraoperative near-infrared fluorescence imaging of glioblastoma using cetuximab-IRDye800, *J. Neurooncol.* 139 (1) (2018) 135–143.
- [57] C. Nimsky, O. Ganslandt, P. Hastreiter, R. Fahlbusch, Intraoperative compensation for brain shift, *Surg. Neurol.* 56 (6) (2001) 357–364.

- [58] S. Ohue, Y. Kumon, S. Nagato, S. Kohno, H. Harada, K. Nakagawa, K. Kikuchi, H. Miki, T. Ohnishi, Evaluation of intraoperative brain shift using an ultrasound-linked navigation system for brain tumor surgery, *Neurol. Med. Chir.* 50 (4) (2010) 291–300.
- [59] R. Stupp, W.P. Mason, M.J. van den Bent, M. Weller, B. Fisher, M.J.B. Taphorn, K. Belanger, A.A. Brandes, C. Marosi, U. Bogdahn, J. Curschmann, R.C. Janzer, S. K. Ludwig, T. Gorlia, A. Allgeier, D. Lacombe, J.G. Cairncross, E. Eisenhauer, R. O. Mirimanoff, European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups, National Cancer Institute of Canada Clinical Trials Group, Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma, *New Engl. J. Med.* 352 (10) (2005) 987–996.
- [60] L.V. Syro, F. Rotondo, M. Camargo, L.D. Ortiz, C.A. Serna, K. Kovacs, Temozolomide and pituitary tumors: current understanding, unresolved issues, and future directions, *Front. Endocrinol.* 9 (2018) 318.
- [61] A.V. Knizhnik, W.P. Roos, T. Nikolova, S. Quirós, K.-H. Tomaszwski, M. Christmann, B. Kaina, Survival and death strategies in glioma cells: autophagy, senescence and apoptosis triggered by a single type of temozolomide-induced DNA damage, *PLoS One* 8 (1) (2013), e55665.
- [62] D. Aasland, L. Götzinger, L. Hauck, N. Berte, J. Meyer, M. Effenberger, S. Schneidewind, E.E. Reuber, W.P. Roos, M.T. Tomicic, B. Kaina, M. Christmann, Temozolomide induces senescence and repression of DNA repair pathways in glioblastoma cells via activation of ATR-CHK1, p21, and NF- κ B, *Cancer Res.* 79 (1) (2019) 99–113.
- [63] B. Kaina, A. Ziouta, K. Ochs, T. Coquerelle, Chromosomal instability, reproductive cell death and apoptosis induced by O6-methylguanine in Mex-, Mex+ and methylation-tolerant mismatch repair compromised cells: facts and models, *Mutat. Res. Fundam. Mol. Mech. Mutagen.* 381 (2) (1997) 227–241.
- [64] W. Meikrantz, M.A. Bergom, A. Memisoglu, L. Samson, D.N.A. O6-alkylguanine, lesions trigger apoptosis, *Carcinogenesis* 19 (2) (1998) 369–372.
- [65] A. Chakravarti, M.G. Erkkinen, U. Nestler, R. Stupp, M. Mehta, K. Aldape, M. R. Gilbert, P.M. Black, J.S. Loeffler, Temozolomide-mediated radiation enhancement in glioblastoma: a report on underlying mechanisms, *Clin. Cancer Res.* 12 (15) (2006) 4738–4746.
- [66] D.E. Gerber, S.A. Grossman, M. Zeltzman, M.A. Parisi, L. Kleinberg, The impact of thrombocytopenia from temozolomide and radiation in newly diagnosed adults with high-grade gliomas, *Neurooncology* 9 (1) (2007) 47–52.
- [67] E. Le Rhun, P. Devos, C. Houillier, S. Cartalat, O. Chinot, A.L. Di Stefano, C. Lepage, N. Reyns, F. Dubois, M. Weller, Romipristin for temozolomide-induced thrombocytopenia in glioblastoma: the PLATUM trial, *Neurology* 93 (19) (2019) e1799–e1806.
- [68] S. Dixit, L. Baker, V. Walmsley, M. Hirngorani, Temozolomide-related idiosyncratic and other uncommon toxicities: a systematic review, *Anti Cancer Drugs* 23 (10) (2012) 1099–1106.
- [69] T.P. Brent, J.S. Remack, Formation of covalent complexes between human O6-alkylguanine-DNA alkyltransferase and BCNU-treated defined length synthetic oligodeoxynucleotides, *Nucleic Acids Res.* 16 (14B) (1988) 6779–6788.
- [70] S.A. Grossman, C. Reinhard, O.M. Colvin, M. Chasin, R. Brundrett, R.J. Tamargo, H. Brem, The intracerebral distribution of BCNU delivered by surgically implanted biodegradable polymers, *J. Neurosurg.* 76 (4) (1992) 640–647.
- [71] T.F. Gajewski, J. Sosman, S.L. Gerson, L. Liu, E. Dolan, S. Lin, E.E. Vokes, Phase II trial of the O6-alkylguanine DNA alkyltransferase inhibitor O6-benzylguanine and 1,3-bis(2-chloroethyl)-1-nitrosourea in advanced melanoma, *Clin. Cancer Res.* 11 (21) (2005) 7861–7865.
- [72] H.C. Bock, M.J.A. Puchner, F. Lohmann, M. Schütze, S. Koll, R. Ketter, R. Buchalla, N. Rainov, S.R. Kantelhardt, V. Rohde, A. Giese, First-line treatment of malignant glioma with carmustine implants followed by concomitant radiochemotherapy: a multicenter experience, *Neurosurg. Rev.* 33 (4) (2010) 441–449.
- [73] R. Bartzatt, Lomustine analogous drug structures for intervention of brain and spinal cord tumors: the benefit of in silico substructure search and analysis, *Chemother. Res. Pract.* 2013 (2013), 360624.
- [74] A.A. Brandes, G. Finocchiaro, V. Zagone, M. Reni, C. Caserta, A. Fabi, M. Clavarezz, E. Maiello, M. Eoli, G. Lombardi, M. Monteforte, E. Proietti, R. Agati, V. Eusebi, E. Franceschi, AVAREG: a phase II, randomized, noncomparative study of fotemustine or bevacizumab for patients with recurrent glioblastoma, *Neurooncology* 18 (9) (2016) 1304–1312.
- [75] M. Ameratunga, N. Pavlakis, H. Wheeler, R. Grant, J. Simes, M. Khasraw, Anti-angiogenic therapy for high-grade glioma, *Cochrane Database Syst. Rev.* 2018 (2018) 11.
- [76] H.S. Friedman, M.D. Prados, P.Y. Wen, T. Mikkelsen, D. Schiff, L.E. Abrey, W.K. A. Yung, N. Paleologos, M.K. Nicholas, R. Jensen, J. Vredenburgh, J. Huang, M. Zheng, T. Cloughesy, Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma, *J. Clin. Oncol.* 27 (28) (2009) 4733–4740.
- [77] O. Ozel, M. Kurt, O. Ozdemir, J. Bayram, H. Akdeniz, D. Koca, Complete response to bevacizumab plus irinotecan in patients with rapidly progressive GBM: cases report and literature review, *J. Oncol. Sci.* 2 (2) (2016) 87–94.
- [78] R.J. Diaz, S. Ali, M.G. Qadir, M.I. De La Fuente, M.E. Ivan, R.J. Komotor, The role of bevacizumab in the treatment of glioblastoma, *J. Neurooncol.* 133 (3) (2017) 455–467.
- [79] A.R. Cabrer, J.P. Kirkpatrick, J.B. Fiveash, H.A. Shih, E.J. Koay, S. Lutz, J. Petit, S.T. Chao, P.D. Brown, M. Vogelbaum, D.A. Reardon, A. Chakravarti, P.Y. Wen, E. Chang, Radiation therapy for glioblastoma: executive summary of an American Society for Radiation Oncology Evidence-Based Clinical Practice Guideline, *Pract. Radiat. Oncol.* 6 (4) (2016) 217–225.
- [80] H. Murshed, Chapter 3 – Radiation biology, in: H. Murshed (Ed.), *Fundamentals of Radiation Oncology*, third ed., Academic Press, 2019, pp. 57–87.
- [81] F.H. Hochberg, A. Pruitt, Assumptions in the radiotherapy of glioblastoma, *Neurology* 30 (9) (1980) 907–911.
- [82] P. Liu, G. Liu, G. Wang, W. Zhou, Y. Sun, W. Chen, Q. Zeng, J. Hong, Q. Xie, L. Ou, R. Wei, Comparison of dosimetric gains provided by intensity-modulated radiotherapy, volume-modulated arc therapy, and helical tomotherapy for high-grade glioma, *BioMed. Res. Int.* 2020 (2020), 4258989.
- [83] A. Narayana, J. Yamada, S. Berry, P. Shah, M. Hunt, P.H. Gutin, S.A. Leibel, Intensity-modulated radiotherapy in high-grade gliomas: clinical and dosimetric results, *Int. J. Radiat. Oncol. Biol. Phys.* 64 (3) (2006) 892–897.
- [84] J.C. Ganz, The journey from proton to gamma knife, *Prog. Brain Res.* 215 (2014) 67–75.
- [85] K.A. Leber, J. Berglöf, G. Pendleton, Dose-response tolerance of the visual pathways and cranial nerves of the cavernous sinus to stereotactic radiosurgery, *J. Neurosurg.* 88 (1) (1998) 43–50.
- [86] K.J. Redmond, M. Mehta, Stereotactic radiosurgery for glioblastoma, *Cureus* 7 (2015) 12.
- [87] E. Barbatte, J.T. Sick, E. Berchmans, A. Bregy, A.H. Shah, N. Elsayyad, R. J. Komotor, The role of brachytherapy in the treatment of glioblastoma multiforme, *Neurosurg. Rev.* 40 (2) (2017) 195–211.
- [88] N.J. Lapierre, P.M. Leung, S. McKenzie, M. Milosevic, S. Wong, J. Glen, M. Pintilie, M. Bernstein, Randomized study of brachytherapy in the initial management of patients with malignant astrocytoma, *Int. J. Radiat. Oncol. Biol. Phys.* 41 (5) (1998) 1005–1011.
- [89] R.G. Selker, W.R. Shapiro, P. Burger, M.S. Blackwood, V.C. Arena, J.C. Gilder, M. G. Malkin, J.J. Mealey, J.H. Neal, J. Olson, J.T. Robertson, G.H. Barnett, S. Bloomfield, R. Albright, F.H. Hochberg, E. Hiesiger, S. Green, Brain Tumor Cooperative Group, The Brain Tumor Cooperative Group NIH Trial 87-01: a randomized comparison of surgery, external radiotherapy, and carmustine versus surgery, interstitial radiotherapy boost, external radiation therapy, and carmustine, *Neurosurgery* 51 (2) (2002) 343–355, discussion 355–357.
- [90] A.M. Chen, S. Chang, J. Pouliot, P.K. Snead, M.D. Prados, K.R. Lamborn, M. K. Malec, M.W. McDermott, M.S. Berger, D.A. Larson, I. Phase, Trial of gross total resection, permanent iodine-125 brachytherapy, and hyperfractionated radiotherapy for newly diagnosed glioblastoma multiforme, *Int. J. Radiat. Oncol. Biol. Phys.* 69 (3) (2007) 825–830.
- [91] K. Parvez, A. Parvez, G. Zadeh, The diagnosis and treatment of pseudoprogression, radiation necrosis and brain tumor recurrence, *Int. J. Mol. Sci.* 15 (7) (2014) 11832–11846.
- [92] A. Pompos, M. Durante, H. Choy, Heavy ions in cancer therapy, *JAMA Oncol.* 2 (12) (2016) 1539–1540.
- [93] S. Chiblak, Z. Tang, D. Lemke, M. Knoll, I. Dokic, R. Warta, M. Moustafa, W. Mier, S. Brons, C. Rapp, S. Muschal, P. Seidel, M. Bendszus, S. Adeberg, O.D. Wiestler, U. Haberkorn, J. Debus, C. Herold-Mende, W. Wick, A. Abdollahi, Carbon irradiation overcomes glioma radioresistance by eradicating stem cells and forming an antiangiogenic and immunopermissive niche, *JCI Insight* 4 (2019) 2.
- [94] A. Tomiyama, K. Tachibana, K. Suzuki, S. Seino, J. Sunayama, K.I. Matsuda, A. Sato, Y. Matsumoto, T. Nomiya, K. Nemoto, H. Yamashita, T. Kayama, K. Ando, C. Kitanaka, MEK-ERK-dependent multiple caspase activation by mitochondrial proapoptotic Bcl-2 family proteins is essential for heavy ion irradiation-induced glioma cell death, *Cell Death Dis.* 1 (2010), e60.
- [95] L. Kong, J. Wu, J. Gao, X. Qiu, J. Yang, J. Hu, W. Hu, Y. Mao, J.J. Lu, Particle radiation therapy in the management of malignant glioma: early experience at the Shanghai Proton and Heavy Ion Center, *Cancer* 126 (12) (2020) 2802–2810.
- [96] S. Rockwell, I.T. Dobrucki, E.Y. Kim, S.T. Morrison, V.T. Vu, Hypoxia and radiation therapy: past history, ongoing research, and future promise, *Curr. Mol. Med.* 9 (4) (2009) 442–458.
- [97] Z. Yang, D. Wei, X. Dai, M.F.G. Stevens, T.D. Bradshaw, Y. Luo, J. Zhang, C8-substituted imidazotetrazine analogs overcome temozolomide resistance by inducing DNA adducts and DNA damage, *Front. Oncol.* 9 (2019) 485.
- [98] B. Verbeek, T.D. Southgate, D.E. Gilham, G.P. Margison, O6-methylguanine-DNA methyltransferase inactivation and chemotherapy, *Br. Med Bull.* 85 (2008) 17–33.
- [99] M. Weller, Assessing the MGMT status in glioblastoma: one step forward, two steps back? *Neurooncology* 15 (3) (2013) 253–254.
- [100] N. Thon, S. Kreth, F.W. Kreth, Personalized treatment strategies in glioblastoma: MGMT promoter methylation status, *Onco Targets Ther.* 6 (2013) 1363–1372.
- [101] W. Szopa, T.A. Burley, G. Kramer-Marek, W. Kasper, Diagnostic and therapeutic biomarkers in glioblastoma: current status and future perspectives, *Biomed. Res. Int.* 2017 (2017), 8013575.
- [102] G. Cabrini, E. Fabbri, C. Lo Nigro, M.C. Dechechchi, R. Gambari, Regulation of expression of O6-methylguanine-DNA methyltransferase and the treatment of glioblastoma (Review), *Int. J. Oncol.* 47 (2) (2015) 417–428.
- [103] A.A. Pandith, I. Qasim, W. Zahoor, P. Shah, A.R. Bhat, D. Sanadhya, Z.A. Shah, N. A. Naikoo, Concordant association validates MGMT methylation and protein expression as favorable prognostic factors in glioma patients on alkylating chemotherapy (Temozolomide), *Sci. Rep.* 8 (1) (2018) 6704.
- [104] M.M. Binabaj, A. Bahrami, S. ShahidSales, M. Joodi, M. Joudi Mashhad, S. M. Hassanian, K. Anvari, A. Avan, The prognostic value of MGMT promoter methylation in glioblastoma: a meta-analysis of clinical trials, *J. Cell Physiol.* 233 (1) (2018) 378–386.
- [105] W. Meng, Y. Jiang, J. Ma, Is the prognostic significance of O6-methylguanine-DNA methyltransferase promoter methylation equally important in glioblastomas of patients from different continents? A systematic review with meta-analysis, *Cancer Manag. Res.* 9 (2017) 411–425.
- [106] A. Christians, C. Hartmann, A. Benner, J. Meyer, A. von Deimling, M. Weller, W. Wick, M. Weiler, Prognostic value of three different methods of MGMT

- promoter methylation analysis in a prospective trial on newly diagnosed glioblastoma, *PLoS One* 7 (3) (2012), e33449.
- [107] I.M. Forte, P. Indovina, C.A. Iannuzzi, D. Cirillo, D. Di Marzo, D. Barone, F. Capone, F. Pentimalli, A. Giordano, Targeted therapy based on p53 reactivation reduces both glioblastoma cell growth and resistance to temozolomide, *Int. J. Oncol.* 54 (6) (2019) 2189–2199.
- [108] E. Nie, X. Jin, W. Wu, T. Yu, X. Zhou, T. Zhi, Z. Shi, J. Zhang, N. Liu, Y. You, BACH1 promotes temozolomide resistance in glioblastoma through antagonizing the function of p53, *Sci. Rep.* 6 (39743) (2016) p53.
- [109] M. Lotfi, S. Afsharnezhad, H.R. Raziee, K. Ghaffarzadegan, S. Sharif, J. Shamsara, S. Lary, J. Behravan, Immunohistochemical assessment of MGMT expression and p53 mutation in glioblastoma multiforme, *Tumori* 97 (1) (2011) 104–108.
- [110] Z.C. He, Y.F. Ping, S.L. Xu, Y. Lin, S.C. Yu, H.F. Kung, X.W. Bian, Lower MGMT expression predicts better prognosis in proneural-like glioblastoma, *Int. J. Clin. Exp. Med.* 8 (11) (2015) 20287–20294.
- [111] K. Baran, M. Yang, C.P. Dillon, L.L. Samson, D.R. Green, The proline rich domain of p53 is dispensable for MGMT-dependent DNA repair and cell survival following alkylation damage, *Cell Death Differ.* 24 (11) (2017) 1925–1936.
- [112] D. Bocangel, S. Sengupta, S. Mitra, K.K. Bhakat, p53-Mediated down-regulation of the human DNA repair gene O6-methylguanine-DNA methyltransferase (MGMT) via interaction with Sp1 transcription factor, *Cancer Res.* 29 (10) (2009) 3741–3750.
- [113] K.Y. Chang, T.I. Hsu, C.C. Hsu, S.Y. Tsai, J.J. Liu, S.W. Chou, M.S. Liu, J.P. Liou, C.Y. Ko, K.Y. Chen, J.J. Hung, W.C. Chang, C.K. Chuang, T.J. Kao, J.Y. Chuang, Specificity protein 1-modulated superoxide dismutase 2 enhances temozolomide resistance in glioblastoma, which is independent of O(6)-methylguanine-DNA methyltransferase, *Redox Biol.* 13 (2017) 655–664.
- [114] D. Aasland, T.R. Reich, M.T. Tomicic, O.J. Switzeny, B. Kaina, M. Christmann, Repair gene O(6)-methylguanine-DNA methyltransferase is controlled by SP1 and up-regulated by glucocorticoids, but not by temozolomide and radiation, *J. Neurochem.* 144 (2) (2018) 139–151.
- [115] M. Christmann, B. Kaina, Transcriptional regulation of human DNA repair genes following genotoxic stress: trigger mechanisms, inducible responses and genotoxic adaptation, *Nucleic Acids Res.* 41 (18) (2013) 8403–8420.
- [116] N.G. Avci, S. Ebrahimzadeh-Pustchi, Y.M. Akay, Y. Esquenazi, N. Tandon, J. Zhu, M. Akay, NF-kappaB inhibitor with Temozolomide results in significant apoptosis in glioblastoma via the NF-kappaB(p65) and actin cytoskeleton regulatory pathways, *Sci. Rep.* 10 (1) (2020) 13352.
- [117] Z. Yu, Y. Chen, S. Wang, P. Li, G. Zhou, Y. Yuan, Inhibition of NF-kappaB results in anti-glioma activity and reduces temozolomide-induced chemoresistance by down-regulating MGMT gene expression, *Cancer Lett.* 428 (2018) 77–89.
- [118] W. Yu, L. Zhang, Q. Wei, A.O. Shao, O(6)-Methylguanine-DNA methyltransferase (MGMT): challenges and new opportunities in glioma chemotherapy, *Front. Oncol.* 9 (2019) 1547.
- [119] Y.A. Medvedeva, A.M. Khamis, I.V. Kulakovskiy, W. Ba-Alawi, M.S. Bhuyan, H. Kawaji, T. Lassmann, M. Harbers, A.R. Forrest, V.B. Bajic, The FANTOM Consortium, Effects of cytosine methylation on transcription factor binding sites, *BMC Genom.* 15 (2014) 119.
- [120] A. Lo Dico, C. Martelli, C. Diceglie, G. Lucignani, L. Ottobrini, Hypoxia-inducible factor-1alpha activity as a switch for glioblastoma responsiveness to temozolomide, *Front. Oncol.* 8 (2018) 249.
- [121] A. Fidoamore, L. Cristiano, A. Antonosante, M. d'Angelo, E. Di Giacomo, C. Astarita, A. Giordano, R. Ippoliti, E. Benedetti, A. Cimini, Glioblastoma stem cells microenvironment: the paracrine roles of the niche in drug and radiosensitivity, *Stem Cells Int.* 2016 (2016), 6809105.
- [122] E. Codrici, A.M. Enciu, I.D. Popescu, S. Mihai, C. Tanase, Glioma stem cells and their microenvironments: providers of challenging therapeutic targets, *Stem Cells Int.* 2016 (2016), 5728438.
- [123] M. Romani, M.P. Pistillo, B. Banelli, Epigenetic targeting of glioblastoma, *Front. Oncol.* 8 (2018) 448.
- [124] J. Yang, X.B. Zhu, L.X. He, Z.W. Gu, M.Z. Jin, W.Y. Ji, Clinical significance of epigenetic silencing and re-expression of O6-methylguanine-DNA methyltransferase using epigenetic agents in laryngeal carcinoma, *Oncol. Lett.* 9 (1) (2015) 35–42.
- [125] M. Nowacka-Zawisza, E. Wisnik, DNA methylation and histone modifications as epigenetic regulation in prostate cancer (Review), *Oncol. Rep.* 38 (5) (2017) 2587–2596.
- [126] H. Erasmus, M. Gobin, S. Niclou, E. Van Dyck, DNA repair mechanisms and their clinical impact in glioblastoma, *Mutat. Res. Rev. Mutat. Res.* 769 (2016) 19–35.
- [127] G.X. Reyes, T.T. Schmidt, R.D. Kolodner, H. Hombauer, New insights into the mechanism of DNA mismatch repair, *Chromosoma* 124 (4) (2015) 443–462.
- [128] D. Gao, J.G. Herman, M. Guo, The clinical value of aberrant epigenetic changes of DNA damage repair genes in human cancer, *Oncotarget* 7 (24) (2016) 37331–37346.
- [129] P. Modrich, R. Lahue, Mismatch repair in replication fidelity, genetic recombination, and cancer biology, *Annu Rev. Biochem.* 65 (1996) 101–133.
- [130] E.M. Noonan, D. Shah, M.B. Yaffe, D.A. Lauffenburger, L.D. Samson, D.N.A. O6-Methylguanine, lesions induce an intra-S-phase arrest from which cells exit into apoptosis governed by early and late multi-pathway signaling network activation, *Integr. Biol.* 4 (10) (2012) 1237–1255.
- [131] G. Perazzoli, J. Prados, R. Ortiz, O. Caba, L. Cabeza, M. Berdasco, B. Gonzalez, C. Melguzo, Temozolomide resistance in glioblastoma cell lines: implication of MGMT, MMR, P-glycoprotein and CD133 expression, *PLoS One* 10 (10) (2015), e0140131.
- [132] J. Stritzelberger, L. Distel, R. Buslei, R. Fietkau, F. Putz, Acquired temozolomide resistance in human glioblastoma cell line U251 is caused by mismatch repair deficiency and can be overcome by lomustine, *Clin. Transl. Oncol.* 20 (4) (2018) 508–516.
- [133] T.C. Network, Corrigendum: comprehensive genomic characterization defines human glioblastoma genes and core pathways, *Nature* 494 (7438) (2013) 506.
- [134] J.L. McFalone-Figueroa, C.J. Braun, M. Stanciu, Z.D. Nagel, P. Mazzucato, D. Sangaraju, E. Cerniauskas, K. Barford, A. Vargas, Y. Chen, N. Tretyakova, J. A. Lees, M.T. Hermann, F.M. White, L.D. Samson, Minor changes in expression of the mismatch repair protein MSH2 exert a major impact on glioblastoma response to temozolomide, *Cancer Res.* 75 (15) (2015) 3127–3138.
- [135] Q. Sun, C. Pei, Q. Li, T. Dong, Y. Dong, W. Xing, P. Zhou, Y. Gong, Z. Zhen, Y. Gao, Y. Xiao, J. Su, H. Ren, Up-regulation of MSH6 is associated with temozolomide resistance in human glioblastoma, *Biochem Biophys. Res Commun.* 496 (4) (2018) 1040–1046.
- [136] J. Felsberg, N. Thon, S. Eigenbrod, B. Hentschel, M.C. Sabel, M. Westphal, G. Schackert, F.W. Kreth, T. Pietsch, M. Löffler, M. Weller, G. Reifenberger, J. C. Tonn, German, N. Glioma, Promoter methylation and expression of MGMT and the DNA mismatch repair genes MLH1, MSH2, MSH6 and PMS2 in paired primary and recurrent glioblastomas, *Int. J. Cancer* 129 (3) (2011) 659–670.
- [137] A.M. Stark, A. Doukas, H.H. Hugo, J. Hedderich, K. Hattermann, H. Maximilian Mehndorn, H. Held-Feindt, Expression of DNA mismatch repair proteins MLH1, MSH2, and MSH6 in recurrent glioblastoma, *Neuro. Res.* 37 (2) (2015) 95–105.
- [138] S. Yip, J. Miao, D.P. Cahill, A.J. Iafrate, K. Aldape, C.L. Nutt, D.N. Louis, MSH6 mutations arise in glioblastomas during temozolomide therapy and mediate temozolomide resistance, *Clin. Cancer Res.* 15 (14) (2009) 4622–4629.
- [139] R.C. Gimple, S. Bhargava, D. Dixit, J.N. Rich, Glioblastoma stem cells: lessons from the tumor hierarchy in a lethal cancer, *Genes Dev.* 33 (11–12) (2019) 591–609.
- [140] A. Dirkse, A. Golebiewska, T. Budor, P.V. Nazarov, A. Muller, S. Poovathingal, N. H.C. Brons, S. Leite, N. Sauvageot, D. Sarkisjan, M. Seyfrid, S. Fritah, D. Stieber, A. Michelucci, F. Hertel, C. Herold-Mende, F. Azuaje, A. Skupin, R. Bjerkvig, A. Deutsch, A. Voss-Bohme, S.P. Niclou, Stem cell-associated heterogeneity in glioblastoma results from intrinsic tumor plasticity shaped by the microenvironment, *Nat. Commun.* 10 (1) (2019) 1787.
- [141] S.K. Singh, C. Hawkins, I.D. Clarke, J.A. Squire, J. Bayani, T. Hide, R. M. Henkelman, M.D. Cusimano, P.B. Dirks, Identification of human brain tumour initiating cells, *Nature* 432 (7015) (2004) 396–401.
- [142] P.M. Glumac, A.M. LeBeau, The role of CD133 in cancer: a concise review, *Clin. Transl. Med.* 7 (1) (2018) 18.
- [143] Y. Yan, X. Zuo, D. Wei, Concise review: emerging role of CD44 in cancer stem cells: a promising biomarker and therapeutic target, *Stem Cells Transl. Med.* 4 (9) (2015) 1033–1043.
- [144] L. Zinzi, M. Contino, M. Cantore, E. Capparelli, M. Leopoldo, N.A. Colabufo, ABC transporters in CSCs membranes as a novel target for treating tumor relapse, *Front. Pharm.* 5 (2014) 163.
- [145] D. Si, F. Yin, J. Peng, G. Zhang, High expression of CD44 predicts a poor prognosis in glioblastomas, *Cancer Manag. Res.* 12 (2020) 769–775.
- [146] A.M. McCord, M. Jamal, E.S. Williams, K. Camphausen, P.J. Tofilon, CD133+ glioblastoma stem-like cells are radiosensitive with a defective DNA damage response compared with established cell lines, *Clin. Cancer Res.* 15 (16) (2009) 5145–5153.
- [147] S. Bao, Q. Wu, R.E. McLendon, Y. Hao, Q. Shi, A.B. Hjelmeland, M.W. Dewhirst, D.D. Bigner, J.N. Rich, Glioma stem cells promote radioresistance by preferential activation of the DNA damage response, *Nature* 444 (7120) (2006) 756–760.
- [148] S.U. Ahmed, R. Carruthers, L. Gilmour, S. Yildirim, C. Watts, A.J. Chalmers, Selective inhibition of parallel DNA damage response pathways optimizes radiosensitization of glioblastoma stem-like cells, *Cancer Res.* 75 (20) (2015) 4416–4428.
- [149] S. Facchino, M. Abdouh, W. Chatoo, G. Bernier, BMI1 confers radioresistance to normal and cancerous neural stem cells through recruitment of the DNA damage response machinery, *J. Neurosci.* 30 (30) (2010) 10096–10111.
- [150] G. Tachon, U. Cortes, P.O. Guichet, P. Rivet, A. Balbous, K. Maslantsev, A. Berger, O. Boissonnade, M. Wager, L. Karayan-Tapon, Cell cycle changes after glioblastoma stem cell irradiation: the major role of RAD51, *Int. J. Mol. Sci.* 19 (2018) 10.
- [151] J. Wijaya, Y. Fukuda, J.D. Schuetz, Obstacles to brain tumor therapy: key ABC transporters, *Int. J. Mol. Sci.* 18 (2017) 12.
- [152] D. Uribe, A. Torres, J.D. Rocha, I. Niechi, C. Oyarzun, L. Sobrevia, R. San Martin, C. Quezada, Multidrug resistance in glioblastoma stem-like cells: role of the hypoxic microenvironment and adenosine signaling, *Mol. Asp. Med.* 55 (2017) 140–151.
- [153] D. Westover, F. Li, New trends for overcoming ABCG2/BCRP-mediated resistance to cancer therapies, *J. Exp. Clin. Cancer Res.* 34 (2015) 159.
- [154] L. Peignan, W. Garrido, R. Segura, R. Melo, D. Rojas, J.G. Carcamo, R. San Martin, C. Quezada, Combined use of anticancer drugs and an inhibitor of multiple drug resistance-associated protein-1 increases sensitivity and decreases survival of glioblastoma multiforme cells in vitro, *Neurochem. Res.* 36 (8) (2011) 1397–1406.
- [155] A. Tiñan, Z. Zakaria, C. O'Leary, D. Kogel, J.L. Pokorny, J.N. Sarkaria, J. H. Prehn, Inhibition of multidrug resistance protein 1 (MRP1) improves chemotherapy drug response in primary and recurrent glioblastoma multiforme, *Front. Neurosci.* 9 (2015) 218.
- [156] W.J. Huang, W.W. Chen, X. Zhang, Glioblastoma multiforme: effect of hypoxia and hypoxia inducible factors on therapeutic approaches, *Oncol. Lett.* 12 (4) (2016) 2283–2288.
- [157] J. Kolenda, S.S. Jensen, C. Aaberg-Jessen, K. Christensen, C. Andersen, N. Brunner, B.W. Kristensen, Effects of hypoxia on expression of a panel of stem

- cell and chemoresistance markers in glioblastoma-derived spheroids, *J. Neurocol.* 103 (1) (2011) 43–58.
- [158] C.A.A. Lee, P. Banerjee, B.J. Wilson, S. Wu, Q. Guo, G. Berg, S. Karpova, A. Mishra, J.W. Lian, J. Tran, M. Emmerich, G.F. Murphy, M.H. Frank, N.Y. Frank, Targeting the ABC transporter ABCB5 sensitizes glioblastoma to temozolomide-induced apoptosis through a cell-cycle checkpoint regulation mechanism, *J. Biol. Chem.* 295 (22) (2020) 7774–7788.
- [159] X. Jing, F. Yang, C. Shao, K. Wei, M. Xie, H. Shen, Y. Shu, Role of hypoxia in cancer therapy by regulating the tumor microenvironment, *Mol. Cancer* 18 (1) (2019) 157.
- [160] C.R. Gomez, Editorial: tumor hypoxia: impact in tumorigenesis, diagnosis, prognosis, and therapeutics, *Front. Oncol.* 6 (2016) 229.
- [161] J.C. Walsh, A. Lebedev, E. Aten, K. Madsen, L. Marciano, H.C. Kolb, The clinical importance of assessing tumor hypoxia: relationship of tumor hypoxia to prognosis and therapeutic opportunities, *Antioxid. Redox Signal.* 21 (10) (2014) 1516–1554.
- [162] A.R. Monteiro, R. Hill, G.J. Pilkington, P.A. Madureira, The role of hypoxia in glioblastoma invasion, *Cells* 6 (2017) 4.
- [163] B. Kaur, F.W. Khwaja, E.A. Severson, S.L. Matheny, D.J. Brat, Van, E.G. Meir, Hypoxia and the hypoxia-inducible-factor pathway in glioma growth and angiogenesis, *Neurooncology* 7 (2) (2005) 134–153.
- [164] N.M. Kocaturk, D. Gozcuacik, Crosstalk between mammalian autophagy and the ubiquitin-proteasome system, *Front. Cell Dev. Biol.* 6 (2018) 128.
- [165] M. Logun, W. Zhao, L. Mao, L. Karumbaiah, Microfluidics in malignant glioma research and precision medicine, *Adv. Biosyst.* 2 (2018) 5.
- [166] I. Daskalaki, I. Gkikas, N. Tavernarakis, Hypoxia and selective autophagy in cancer development and therapy, *Front. Cell Dev. Biol.* 6 (2018) 104.
- [167] D. Glick, S. Barth, K.F. Macleod, Autophagy: cellular and molecular mechanisms, *J. Pathol.* 221 (1) (2010) 3–12.
- [168] G. Hewitt, V.I. Korolchuk, Repair, reuse, recycle: the expanding role of autophagy in genome maintenance, *Trends Cell Biol.* 27 (5) (2017) 340–351.
- [169] S. Jawhari, M.H. Ratinaud, M. Verdier, Glioblastoma, hypoxia and autophagy: a survival-prone "menage-a-trois", *Cell Death Dis.* 7 (10) (2016), e2434.
- [170] S. Talukdar, A.K. Pradhan, P. Bhoopathi, X.N. Shen, L.A. August, J.J. Windle, D. Sarkar, F.B. Furnari, W.K. Cavenee, S.K. Das, L. Emdad, P.B. Fisher, MDA-9/Syntenin regulates protective autophagy in anoikis-resistant glioma stem cells, *Proc. Natl. Acad. Sci. U. S. A.* 115 (22) (2018) 5768–5773.
- [171] T. Huang, C.K. Kim, A.A. Alvarez, R.P. Pangeni, X. Wan, X. Song, T. Shi, Y. Yang, N. Sastry, C.M. Horbinski, S. Lu, R. Stupp, J.A. Kessler, R. Nishikawa, I. Nakano, E.P. Sulman, X. Lu, C.D. James, X.M. Yin, B. Hu, S.Y. Cheng, MST4 phosphorylation of ATG4B regulates autophagic activity, tumorigenicity, and radiosensitivity in glioblastoma, *Cancer Cell* 32 (6) (2017) 840–855, e848.
- [172] M. Buccarelli, M. Marconi, S. Pacioni, I. De Pascalis, Q.G. D'Alessandris, M. Martini, B. Ascione, W. Malorni, L.M. Larocca, R. Pallini, L. Ricci-Vitiani, P. Matarrese, Inhibition of autophagy increases susceptibility of glioblastoma stem cells to temozolamide by igniting ferroptosis, *Cell Death Dis.* 9 (8) (2018) 841.
- [173] W. Wu, J. Schecker, S. Wurstle, F. Schneider, M. Schonfelder, J. Schlegel, Aldehyde dehydrogenase 1A3 (ALDH1A3) is regulated by autophagy in human glioblastoma cells, *Cancer Lett.* 417 (2018) 112–123.
- [174] W. Wu, Y. Wu, K. Mayer, C. von Rosenstiel, J. Schecker, S. Baur, S. Wurstle, F. Liesche-Starnecker, J. Gempt, J. Schlegel, Lipid peroxidation plays an important role in chemotherapeutic effects of temozolomide and the development of therapy resistance in human glioblastoma, *Transl. Oncol.* 13 (3) (2020), 100748.
- [175] Y.L. Hu, M. DeLay, A. Jahangiri, A.M. Molinaro, S.D. Rose, W.S. Carbonell, M. K. Aghi, Hypoxia-induced autophagy promotes tumor cell survival and adaptation to antiangiogenic treatment in glioblastoma, *Cancer Res* 72 (7) (2012) 1773–1783.
- [176] J. Sotelo, E. Briceno, M.A. Lopez-Gonzalez, Adding chloroquine to conventional treatment for glioblastoma multiforme: a randomized, double-blind, placebo-controlled trial, *Ann. Intern. Med.* 144 (5) (2006) 337–343.
- [177] E.N. Wainwright, P. Scaffidi, Epigenetics and cancer stem cells: unleashing, hijacking, and restricting cellular plasticity, *Trends Cancer* 3 (5) (2017) 372–386.
- [178] A. Mishra, M. Verma, Epigenetics of solid cancer stem cells, *Methods Mol. Biol.* 863 (2012) 15–31.
- [179] T.B. Toh, J.J. Lim, E.K. Chow, Epigenetics in cancer stem cells, *Mol. Cancer* 16 (1) (2017) 29.
- [180] K. Lapinska, G. Faria, S. McGonagle, K.M. Macumber, S. Heerboth, S. Sarkar, Cancer progenitor cells: the result of an epigenetic event? *Anticancer Res* 38 (1) (2018) 1–6.
- [181] J.W. Wei, K. Huang, C. Yang, C.S. Kang, Non-coding RNAs as regulators in epigenetics (Review), *Oncol. Rep.* 37 (1) (2017) 3–9.
- [182] R.I. Joh, C.M. Palmieri, I.T. Hill, M. Motamedi, Regulation of histone methylation by noncoding RNAs, *Biochim Biophys. Acta* 1839 (12) (2014) 1385–1394.
- [183] H. Tao, H. Li, Y. Su, D. Feng, X. Wang, C. Zhang, H. Ma, Q. Hu, Histone methyltransferase G9a and H3K9 dimethylation inhibit the self-renewal of glioma cancer stem cells, *Mol. Cell Biochem* 394 (1–2) (2014) 23–30.
- [184] B.L. Liu, J.X. Cheng, X. Zhang, R. Wang, W. Zhang, H. Lin, X. Xiao, S. Cai, X. Y. Chen, H. Cheng, Global histone modification patterns as prognostic markers to classify glioma patients, *Cancer Epidemiol. Biomark. Prev.* 19 (11) (2010) 2888–2896.
- [185] M. Hussain, M. Rao, A.E. Humphries, J.A. Hong, F. Liu, M. Yang, D. Caragacianu, D.S. Schrump, Tobacco smoke induces polycomb-mediated repression of Dickkopf-1 in lung cancer cells, *Cancer Res* 69 (8) (2009) 3570–3578.
- [186] Y. Chen, R. Fang, C. Yue, G. Chang, P. Li, Q. Guo, J. Wang, A. Zhou, S. Zhang, G. N. Fuller, X. Shi, S. Huang, Wnt-induced stabilization of KDM4C is required for Wnt/beta-Catenin target gene expression and glioblastoma tumorigenesis, *Cancer Res.* 80 (5) (2020) 1049–1063.
- [187] Y.C. Huang, S.J. Lin, H.Y. Shih, C.H. Chou, H.H. Chu, C.C. Chiu, C.H. Yuh, T. H. Yeh, Y.C. Cheng, Epigenetic regulation of NOTCH1 and NOTCH3 by KMT2A inhibits glioma proliferation, *Oncotarget* 8 (38) (2017) 63110–63120.
- [188] A.J. Tsung, M.R. Guda, S. Asuthkar, C.M. Labak, I.J. Purvis, Y. Lu, N. Jain, S. E. Bach, D.V.R. Prasad, K.K. Velpula, Methylation regulates HEY1 expression in glioblastoma, *Oncotarget* 8 (27) (2017) 44398–44409.
- [189] B.K. Allen, V. Stathias, M.E. Maloof, D. Vidovic, E.F. Winterbottom, A. J. Capobianco, J. Clarke, S. Schurer, D.J. Robbins, N.G. Ayad, Epigenetic pathways and glioblastoma treatment: insights from signaling cascades, *J. Cell Biochem* 116 (3) (2015) 351–363.
- [190] M. Malatesta, C. Steinbauer, F. Mohammad, D.P. Pandey, M. Squatrito, K. Helin, Histone acetyltransferase PCAF is required for Hedgehog-Gli-dependent transcription and cancer cell proliferation, *Cancer Res.* 73 (20) (2013) 6323–6333.
- [191] R. Bazzoni, A. Bentivegna, Role of notch signaling pathway in glioblastoma pathogenesis, *Cancers* (2019) 3.
- [192] Y. Lee, J.K. Lee, S.H. Ahn, J. Lee, D.H. Nam, WNT signaling in glioblastoma and therapeutic opportunities, *Lab Investig.* 96 (2) (2016) 137–150.
- [193] M. Touat, A. Idbaih, M. Sanson, K.L. Ligon, Glioblastoma targeted therapy: updated approaches from recent biological insights, *Ann. Oncol.* 28 (7) (2017) 1457–1472.
- [194] F. Rojo, J. García-Parra, S. Zazo, I. Tusquets, J. Ferrer-Lozano, S. Menendez, P. Eroles, C. Chamizo, S. Servitja, N. Ramírez-Merino, F. Lobo, B. Bellosillo, J. M. Corominas, J. Yelamos, S. Serrano, A. LLuch, A. Rovira, J. Albanell, Nuclear PARP-1 protein overexpression is associated with poor overall survival in early breast cancer, *Ann. Oncol.* 23 (5) (2012) 1156–1164.
- [195] V. Schreiber, F. Dantzer, J.-C. Ame, G. de Murcia, Poly(ADP-ribose): novel functions for an old molecule, *Nat. Rev. Mol. Cell Biol.* 7 (7) (2006) 517–528.
- [196] S.K. Gupta, E.J. Smith, A.C. Mladek, S. Tian, P.A. Decker, S.H. Kizilbash, G. J. Kitange, J.N. Sarkaria, PARP inhibitors for sensitization of alkylating chemotherapy in glioblastoma: impact of blood-brain barrier and molecular heterogeneity, *Front. Oncol.* (2019) 8.
- [197] M.J. Clarke, E.A. Mulligan, P.T. Grogan, A.C. Mladek, B.L. Carlson, M. A. Schroeder, N.J. Curtin, Z. Lou, P.A. Decker, W. Wu, E.R. Plummer, J. N. Sarkaria, Effective sensitization of temozolomide by ABT-888 is lost with development of temozolomide resistance in glioblastoma xenograft lines, *Mol. Cancer Ther.* 8 (2) (2009) 407–414.
- [198] N.V. Malyuchenko, E.Y. Kotova, O.I. Kulueva, M.P. Kirpichnikov, V.M. Studitskiy, PARP1 inhibitors: antitumor drug design, *Acta Nat.* 7 (3) (2015) 27–37.
- [199] P. Lesueur, F. Chevalier, E.A. El-Habri, M.-P. Junier, H. Chneiweiss, L. Castera, E. Müller, D. Stefan, Y. Saintigny, Radiosensitization effect of Talazoparib, a PARP inhibitor, on glioblastoma stem cells exposed to low and high linear energy transfer radiation, *Sci. Rep.* 8 (1) (2018) 3664.
- [200] H.I. Robins, P. Zhang, M.R. Gilbert, A. Chakravarti, J.F. de Groot, S.A. Grimm, F. Wang, F.S. Lieberman, A. Krauze, A.M. Trott, N. Mohile, A.Y.J. Kee, H. Colman, R. Cavaliere, S. Kesari, S.J. Chmura, M. Mehta, A randomized phase I/II study of ABT-888 in combination with temozolomide in recurrent glioblastoma resistant glioblastoma: an NRG oncology RTOG group study, *J. Neuro Oncol.* 126 (2) (2016) 309–316.
- [201] P.A. Baxter, J.M. Su, A. Onar-Thomas, C.A. Billups, X.-N. Li, T.Y. Poussaint, E. R. Smith, P. Thompson, A. Adesina, P. Ansell, V. Giranda, A. Paulino, L. Kilburn, I. Quaddoumi, A. Broniscer, S.M. Blaney, I.J. Dunkel, M. Fouladi, A phase I/II study of veliparib (ABT-888) with radiation and temozolomide in newly diagnosed diffuse pontine glioma: a Pediatric Brain Tumor Consortium study, *Neurooncology* 22 (6) (2020) 875–885.
- [202] C. Hanna, K.M. Kurian, K. Williams, C. Watts, A. Jackson, R. Carruthers, K. Strathee, G. Cruickshank, L. Dunn, S. Erridge, L. Godfrey, S. Jefferies, C. McBain, R. Sleight, A. McCormick, M. Pittman, S. Halford, A.J. Chalmers, Pharmacokinetics safety and tolerability of olaparib and temozolomide for recurrent glioblastoma: results of the phase I OPARATIC trial, *Neurooncology* (2020).
- [203] P.J. Choi, E. Cooper, P. Schweder, E. Mee, C. Turner, R. Faull, W.A. Denny, M. Dragunow, T.I.H. Park, J. Jose, PARP inhibitor cyanine dye conjugate with enhanced cytotoxic and antiproliferative activity in patient derived glioblastoma cell lines, *Bioorg. Med. Chem. Lett.* 30 (14) (2020), 127252.
- [204] K.E. Parrish, L. Cen, J. Murray, D. Calligaris, S. Kizilbash, R.K. Mittapalli, B. L. Carlson, M.A. Schroeder, J. Sludden, A.V. Boddy, N.Y.R. Agar, N.J. Curtin, W. F. Elmquist, J.N. Sarkaria, Efficacy of PARP inhibitor rucaparib in orthotopic glioblastoma xenografts is limited by ineffective drug penetration into the central nervous system, *Mol. Cancer Ther.* 14 (12) (2015) 2735–2743.
- [205] S. Wu, F. Gao, S. Zheng, C. Zhang, E. Martinez-Ledesma, R. Ezhilarasan, J. Ding, X. Li, N. Feng, A. Multani, E.P. Sulman, R.G. Verhaak, J.F. de Groot, T. P. Heffernan, W.K.A. Yung, D. Koul, EGFR amplification induces increased DNA damage response and renders selective sensitivity to talazoparib (PARP Inhibitor) in glioblastoma, *Clin. Cancer Res.* 26 (6) (2020) 1395–1407.
- [206] S.H. Kizilbash, S.K. Gupta, K. Chang, R. Kawashima, K.E. Parrish, B.L. Carlson, K. K. Bakken, A.C. Mladek, M.A. Schroeder, P.A. Decker, G.J. Kitange, Y. Shen, Y. Feng, A.A. Protter, W.F. Elmquist, J.N. Sarkaria, Restricted delivery of talazoparib across the blood-brain barrier limits the sensitizing effects of PARP inhibition on temozolomide therapy in glioblastoma, *Mol. Cancer Ther.* 16 (12) (2017) 2735–2746.

- [207] D.R. Robinson, Y.M. Wu, S.F. Lin, The protein tyrosine kinase family of the human genome, *Oncogene* 19 (49) (2000) 5548–5557.
- [208] N. Jin, A. Bi, X. Lan, J. Xu, X. Wang, Y. Liu, T. Wang, S. Tang, H. Zeng, Z. Chen, M. Tan, J. Ai, H. Xie, T. Zhang, D. Liu, R. Huang, Y. Song, E.L.-H. Leung, X. Yao, J. Ding, M. Geng, S.-H. Lin, M. Huang, Identification of metabolic vulnerabilities of receptor tyrosine kinases-driven cancer, *Nat. Commun.* (2019) 10.
- [209] H. Yamazaki, Y. Fukui, Y. Ueyama, N. Tamaoki, T. Kawamoto, S. Taniguchi, M. Shibuya, Amplification of the structurally and functionally altered epidermal growth factor receptor gene (c-erbB) in human brain tumors, *Mol. Cell. Biol.* 8 (4) (1988) 1816–1820.
- [210] D. Singh, J.M. Chan, P. Zoppoli, F. Niola, R. Sullivan, A. Castano, E.M. Liu, J. Reichel, P. Porrti, S. Pellegatta, K. Qiu, Z. Gao, M. Ceccarelli, R. Riccardi, D. J. Brat, A. Guha, K. Aldape, J.G. Golfinos, D. Zagzag, T. Mikkelsen, G. Finocchiaro, A. Lasorella, R. Rabadian, A. Iavarone, Transforming fusions of FGFR and TACC genes in human glioblastoma, *Science* 337 (6099) (2012) 1231–1235.
- [211] S.P. Weathers, J. de Groot, VEGF manipulation in glioblastoma, *Oncology* 29 (10) (2015) 720–727.
- [212] T.D. Barber, B. Vogelstein, K.W. Kinzler, V.E. Velculescu, Somatic mutations of EGFR in colorectal cancers and glioblastomas, *New Engl. J. Med.* 351 (27) (2004) 2883.
- [213] T.P. Fleming, A. Saxena, W.C. Clark, J.T. Robertson, E.H. Oldfield, S.A. Aaronson, I.U. Ali, Amplification and/or overexpression of platelet-derived growth factor receptors and epidermal growth factor receptor in human glial tumors, *Cancer Res.* 52 (16) (1992) 4550–4553.
- [214] P. Guo, B. Hu, W. Gu, L. Xu, D. Wang, H.-J.S. Huang, W.K. Cavenee, S.-Y. Cheng, Platelet-derived growth factor-B enhances glioma angiogenesis by stimulating vascular endothelial growth factor expression in tumor endothelia and by promoting pericyte recruitment, *Am. J. Pathol.* 162 (4) (2003) 1083–1093.
- [215] T.T. Batchelor, D.G. Duda, E. di Tomaso, M. Ancukiewicz, S.R. Plotkin, E. Gerstner, A.F. Eichler, J. Drappatz, F.H. Hochberg, T. Benner, D.N. Louis, K. S. Cohen, H. Chea, A. Exarhopoulos, J.S. Loeffler, M.A. Moses, P. Ivy, A. G. Sorenson, P.Y. Wen, R.K. Jain, Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma, *J. Clin. Oncol.* 28 (17) (2010) 2817–2823.
- [216] E.R. Gerstner, X. Ye, D.G. Duda, M.A. Levine, T. Mikkelsen, T.J. Kaley, J.J. Olson, B.L. Nabors, M.S. Ahluwalia, P.Y. Wen, R.K. Jain, T.T. Batchelor, S. Grossman, A phase I study of cediranib in combination with cilengitide in patients with recurrent glioblastoma, *Neurooncology* 17 (10) (2015) 1386–1392.
- [217] T.T. Batchelor, P. Mulholland, B. Neys, L.B. Nabors, M. Campone, A. Wick, W. Mason, T. Mikkelsen, S. Phuphanich, L.S. Ashby, J. DeGroot, R. Gattamaneni, L. Cher, M. Rosenthal, F. Payer, J.M. Jürgensmeier, R.K. Jain, A.G. Sorenson, J. Xu, Q. Liu, M. van den Bent, Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma, *J. Clin. Oncol.* 31 (26) (2013) 3212–3218.
- [218] N. Brown, C. McBain, S. Nash, K. Hopkins, P. Sanghera, F. Saran, M. Phillips, F. Dunney, L. Clifton-Hadley, K. Wanek, D. Krell, S. Jeffries, I. Khan, P. Smith, P. Mulholland, Multi-center randomized phase II study comparing cediranib plus gefitinib with cediranib plus placebo in subjects with recurrent/progressive glioblastoma, *PloS One* 11 (5) (2016), e0156369.
- [219] T.T. Batchelor, E.R. Gerstner, K.E. Emblem, D.G. Duda, J. Kalpathy-Cramer, M. Snuderl, M. Ancukiewicz, P. Polaskova, M.C. Pinho, D. Jennings, S.R. Plotkin, A.S. Chi, A.F. Eichler, J. Dietrich, F.H. Hochberg, C. Lu-Emerson, A.J. Iafrate, S. P. Ivy, B.R. Rosen, J.S. Loefller, P.Y. Wen, A.G. Sorenson, R.K. Jain, Improved tumor oxygenation and survival in glioblastoma patients who show increased blood perfusion after cediranib and chemoradiation, *Proc. Natl. Acad. Sci. U. S. A.* 110 (47) (2013) 19059–19064.
- [220] A.R. Kaplan, S.E. Gueble, Y. Liu, S. Oeck, H. Kim, Z. Yun, P.M. Glazer, Cediranib suppresses homology-directed DNA repair through down-regulation of BRCA1/2 and RAD51, *Sci. Transl. Med* 11 (2019) 492.
- [221] T. Hundberger, D.A. Reardon, P.Y. Wen, Angiogenesis inhibitors in tackling recurrent glioblastoma, *Expert Rev. Anticancer Ther.* 17 (6) (2017) 507–515.
- [222] C. Lu-Emerson, D.G. Duda, K.E. Emblem, J.W. Taylor, E.R. Gerstner, J.S. Loefller, T.T. Batchelor, R.K. Jain, Lessons from anti-vascular endothelial growth factor and anti-vascular endothelial growth factor receptor trials in patients with glioblastoma, *J. Clin. Oncol.* 33 (10) (2015) 1197–1213.
- [223] G. Karpel-Massler, M.A. Westhoff, R.E. Kast, C.R. Wirtz, M.-E. Halatsch, Erlotinib in glioblastoma: lost in translation? *Anticancer Agents Med. Chem.* 11 (8) (2011) 748–755.
- [224] J.J. Raizer, P. Giglio, J. Hu, M. Groves, R. Merrell, C. Conrad, S. Phuphanich, V. K. Puduvalli, M. Loghin, N. Paleologos, Y. Yuan, D. Liu, A. Rademaker, W. K. Yung, B. Vaillant, J. Rudnick, M. Chamberlain, N. Vick, S. Grimm, I. W. Tremont-Lukats, J. De Groot, K. Aldape, M.R. Gilbert, Brain Tumor Trials Collaborative, A phase II study of bevacizumab and erlotinib after radiation and temozolamide in MGMT unmethylated GBM patients, *J. Neurooncol.* 126 (1) (2016) 185–192.
- [225] D.M. Peereboom, M.S. Ahluwalia, X. Ye, J.G. Supko, S.L. Hilderbrand, S. Phuphanich, L.B. Nabors, M.R. Rosenfeld, T. Mikkelsen, S.A. Grossman, New Approaches to Brain Tumor Therapy (NABTT) Consortium, NABTT 0502: a phase II and pharmacokinetic study of erlotinib and sorafenib for patients with progressive or recurrent glioblastoma multiforme, *Neurooncology* 15 (4) (2013) 490–496.
- [226] D.A. Reardon, A. Desjardins, J.J. Vredenburgh, S. Gururangan, A.H. Friedman, J. E. Herndon, J. Marcello, J.A. Norfleet, R.E. McLendon, J.H. Sampson, H. S. Friedman, Phase 2 trial of erlotinib plus sirolimus in adults with recurrent glioblastoma, *J. Neurooncol.* 96 (2) (2010) 219–230.
- [227] R. Addeo, S. Zappavigna, C. Parlati, M. Caraglia, Erlotinib: early clinical development in brain cancer, *Expert Opin. Investig. Drugs* 23 (7) (2014) 1027–1037.
- [228] J.N. Rich, D.A. Reardon, T. Peery, J.M. Dowell, J.A. Quinn, K.L. Penne, C. J. Wikstrand, L.B. Van Duyn, J.E. Dancey, R.E. McLendon, J.C. Kao, T.T. Stenzel, B.K. Ahmed Rasheed, S.E. Tourt-Uhlig, J.E. Herndon, J.J. Vredenburgh, J. H. Sampson, A.H. Friedman, D.D. Bigner, H.S. Friedman, Phase II trial of gefitinib in recurrent glioblastoma, *J. Clin. Oncol.* 22 (1) (2004) 133–142.
- [229] A. Chakravarti, M. Wang, H.I. Robins, T. Lautenschlaeger, W.J. Curran, D. G. Brachman, C.J. Schultz, A. Chouair, M. Dolled-Filhart, J. Christiansen, M. Gustavson, A. Molinaro, P. Mischel, A.P. Dicker, M. Bredel, M. Mehta, RTOG 0211: a phase 1/2 study of radiation therapy with concurrent gefitinib for newly diagnosed glioblastoma patients, *Int. J. Radiat. Oncol., Biol., Phys.* 85 (5) (2013) 1206–1211.
- [230] T.N. Kreisl, A.B. Lassman, P.S. Mischel, N. Rosen, H.I. Scher, J. Teruya-Feldstein, D. Shaffer, E. Lis, L.E. Abrey, A pilot study of everolimus and gefitinib in the treatment of recurrent glioblastoma (GBM), *J. Neurooncol.* 92 (1) (2009) 99–105.
- [231] J.H. Uhm, K.V. Ballman, W. Wu, C. Giannini, J.C. Krauss, J.C. Buckner, C. D. James, B.W. Scheithauer, R.J. Behrens, P.J. Flynn, P.L. Schaefer, S.R. Dakhill, K.A. Jaeckle, Phase II evaluation of gefitinib in patients with newly diagnosed Grade 4 astrocytoma: Mayo/North Central Cancer Treatment Group Study N0074, *Int. J. Radiat. Oncol. Biol. Phys.* 80 (2) (2011) 347–N0353.
- [232] L. Sautter, R. Hofheinz, J. Tuettnerberg, M. Grimm, P. Vajkoczy, C. Groden, K. Schmieder, A. Hochhaus, F. Wenz, F.A. Giordano, Open-label phase II evaluation of imatinib in primary inoperable or incompletely resected and recurrent glioblastoma, *Oncology* 98 (1) (2020) 16–22.
- [233] E. Raymond, A.B. Brandes, C. Dittrich, P. Fumoleau, B. Couder, P.M.J. Clement, M. Frenay, R. Rampling, R. Stupp, J.M. Kros, M.C. Heinrich, T. Gorlia, D. Lacome, M.J. van den Bent, European Organisation for Research and Treatment of Cancer Brain Tumor Group Study, Phase II study of imatinib in patients with recurrent gliomas of various histologies: a European Organisation for Research and Treatment of Cancer Brain Tumor Group Study, *J. Clin. Oncol.* 26 (28) (2008) 4659–4665.
- [234] E. Razis, P. Selvaiaridis, S. Labropoulos, J.L. Norris, M.-J. Zhu, D.D. Song, T. Kalebic, M. Torrens, A. Kalogerofountzila, G. Karkavelas, S. Karanastasi, J. A. Fletcher, G. Fountzilas, Phase II study of neoadjuvant imatinib in glioblastoma: evaluation of clinical and molecular effects of the treatment, *Clin. Cancer Res.* 15 (19) (2009) 6258–6266.
- [235] D.A. Reardon, M.J. Egorin, J.A. Quinn, J.N. Rich, I. Gururangan, J. J. Vredenburgh, A. Desjardins, S. Sathornsumetee, J.M. Provenzale, J.E. Herndon, J.M. Dowell, M.A. Badruddoja, R.E. McLendon, T.F. Lagattuta, K.P. Kicielinski, G. Dresemann, J.H. Sampson, A.H. Friedman, A.J. Salvado, H.S. Friedman, Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastoma multiforme, *J. Clin. Oncol.* 23 (36) (2005) 9359–9368.
- [236] D.A. Reardon, G. Dresemann, S. Taillibert, M. Campone, M. van den Bent, P. Clement, E. Blomquist, L. Gordower, H. Schultz, J. Raizer, P. Hau, J. Easaw, M. Gil, J. Tonn, A. Gijtenbeek, U. Schlegel, P. Bergstrom, S. Green, A. Weir, Z. Nikolova, Multicentre phase II studies evaluating imatinib plus hydroxyurea in patients with progressive glioblastoma, *Br. J. Cancer* 101 (12) (2009) 1995–2004.
- [237] G. Dresemann, Imatinib and hydroxyurea in pretreated progressive glioblastoma multiforme: a patient series, *Ann. Oncol.* 16 (10) (2005) 1702–1708.
- [238] A.B. Lassman, S.L. Pugh, M.R. Gilbert, K.D. Aldape, S. Geinoz, J.H. Beumer, S. M. Christner, R. Komaki, L.M. DeAngelis, R. Gaur, E. Youssef, H. Wagner, M. Won, M.P. Mehta, Phase 2 trial of dasatinib in target-selected patients with recurrent glioblastoma (RTOG 0627), *Neurooncology* 17 (7) (2015) 992–998.
- [239] E. Galanis, S.K. Anderson, E.L. Twohy, X.W. Carrero, J.G. Dixon, D.D. Tran, S. A. Jeyapalan, D.M. Anderson, T.J. Kaufmann, R.W. Feathers, C. Giannini, J. C. Buckner, P.Z. Anastasiadis, D. Schiff, A phase 1 and randomized, placebo-controlled phase 2 trial of bevacizumab plus dasatinib in patients with recurrent glioblastoma: Alliance/North Central Cancer Treatment Group N0872, *Cancer* 125 (21) (2019) 3790–N3800.
- [240] A. Broniscer, S. Jia, B. Mandrell, D. Hamideh, J. Huang, A. Onar-Thomas, A. Gajjar, S.C. Raimondi, R.G. Tatevosian, C.F. Stewart, Phase 1 trial, pharmacokinetics, and pharmacodynamics of dasatinib combined with crizotinib in children with recurrent or progressive high-grade and diffuse intrinsic pontine glioma, *Pediatr. Blood Cancer* 65 (7) (2018), e27035.
- [241] E. Franceschi, R. Stupp, M.J. van den Bent, C. van Herpen, F. Laigle Donadey, T. Gorlia, M. Hegi, B. Lhermitte, L.C. Strauss, A. Allgeier, D. Lacome, A. A. Brandes, EORTC 26083 phase I/II trial of dasatinib in combination with CCNU in patients with recurrent glioblastoma, *Neurooncology* 14 (12) (2012) 1503–1510.
- [242] S. Wilhelm, C. Carter, M. Lynch, T. Lowinger, J. Dumas, R.A. Smith, B. Schwartz, R. Simantov, S. Kelley, Discovery and development of sorafenib: a multikinase inhibitor for treating cancer, *Nat. Rev. Drug Discov.* 5 (10) (2006) 835–844.
- [243] F. Zustovich, L. Landi, G. Lombardi, C. Porta, L. Galli, A. Fontana, D. Amoroso, C. Galli, M. Andreuccetti, A. Falcone, V. Zagonel, Sorafenib plus daily low-dose temozolamide for relapsed glioblastoma: a phase II study, *Anticancer Res.* 33 (8) (2013) 3487–3494.
- [244] D.A. Reardon, J.J. Vredenburgh, A. Desjardins, K. Peters, S. Gururangan, J. H. Sampson, J. Marcello, J.E. Herndon, R.E. McLendon, D. Janney, A. H. Friedman, D.D. Bigner, H.S. Friedman, Effect of CYP3A-inducing anti-epileptics on sorafenib exposure: results of a phase II study of sorafenib plus daily temozolamide in adults with recurrent glioblastoma, *J. Neurooncol.* 101 (1) (2011) 57–66.

- [245] J.D. Hainsworth, T. Ervin, E. Friedman, V. Priego, P.B. Murphy, B.L. Clark, R.E. Lamar, Concurrent radiotherapy and temozolomide followed by temozolomide and sorafenib in the first-line treatment of patients with glioblastoma multiforme, *Cancer* 116 (15) (2010) 3663–3669.
- [246] E. Galanis, S.K. Anderson, J.M. Lasky, J.H. Uhm, C. Giannini, S.K. Kumar, T.K. Kimlinger, D.W. Northfelt, P.J. Flynn, K.A. Jaeckle, T.J. Kaufmann, J.C. Buckner, Phase II study of bevacizumab in combination with sorafenib in recurrent glioblastoma (N0776): a north central cancer treatment group trial, *Clin. Cancer Res.* 19 (17) (2013) 4816–4823.
- [247] D. Schiff, K.A. Jaeckle, S.K. Anderson, E. Galanis, C. Giannini, J.C. Buckner, P. Stella, P.J. Flynn, B.J. Erickson, J.F. Schwerkoske, V. Kaluza, E. Twohy, J. Dancey, J. Wright, J.N. Sarkaria, Phase 1/2 trial of temsirolimus and sorafenib in the treatment of patients with recurrent glioblastoma: North Central Cancer Treatment Group Study/Alliance N0572, *Cancer* 124 (7) (2018) 1455–N1463.
- [248] P.L. Nghiempou, V.A. Ebiana, P. Wen, M. Gilbert, L.E. Abrey, F. Lieberman, L.M. DeAngelis, H.I. Robins, W.K.A. Yung, S. Chang, J. Drappatz, M.P. Mehta, V.A. Levin, K. Aldape, J.E. Dancey, J.J. Wright, M. Prados, J. Kuhn, T.F. Cloughesy, Phase I study of sorafenib and tipifarnib for recurrent glioblastoma: NABTC 05-02, *J. Neurooncol.* 136 (1) (2018) 79–86.
- [249] Y. Jo, E.H. Kim, S. Sai, J.S. Kim, J.-M. Cho, H. Kim, J.-H. Baek, J.-Y. Kim, S.-G. Hwang, M. Yoon, Functional biological activity of sorafenib as a tumor-treating field sensitizer for glioblastoma therapy, *Int. J. Mol. Sci.* 19 (2018) 11.
- [250] E. Pan, D. Yu, B. Yue, L. Pothast, S. Chowdhary, P. Smith, M. Chamberlain, A prospective phase II single-institution trial of sunitinib for recurrent malignant glioma, *J. Neurooncol.* 110 (1) (2012) 111–118.
- [251] C. Balana, M.J. Gil, P. Perez, G. Reynes, O. Gallego, T. Ribalta, J. Capellades, S. Gonzalez, E. Verger, Sunitinib administered prior to radiotherapy in patients with non-resectable glioblastoma: results of a phase II study, *Target. Oncol.* 9 (4) (2014) 321–329.
- [252] T.N. Kreisl, P. Smith, J. Sul, C. Salgado, F.M. Iwamoto, J.H. Shih, H.A. Fine, Continuous daily sunitinib for recurrent glioblastoma, *J. Neurooncol.* 111 (1) (2013) 41–48.
- [253] P.Y. Wen, J. Drappatz, J. de Groot, M.D. Prados, D.A. Reardon, D. Schiff, M. Chamberlain, T. Mikkelsen, A. Desjardins, J. Holland, J. Ping, R. Weitzman, T.F. Cloughesy, Phase II study of cabozantinib in patients with progressive glioblastoma: subset analysis of patients naïve to antiangiogenic therapy, *Neurooncology* 20 (2) (2018) 249–258.
- [254] T.F. Cloughesy, J. Drappatz, J. de Groot, M.D. Prados, D.A. Reardon, D. Schiff, M. Chamberlain, T. Mikkelsen, A. Desjardins, J. Holland, R. Weitzman, P.Y. Wen, Phase II study of cabozantinib in patients with progressive glioblastoma: subset analysis of patients with prior antiangiogenic therapy, *Neurooncology* 20 (2) (2018) 259–267.
- [255] C. Chen, S. Zhu, X. Zhang, T. Zhou, J. Gu, Y. Xu, Q. Wan, X. Qi, Y. Chai, X. Liu, L. Chen, J. Yan, Y. Hua, F. Lin, Targeting the synthetic vulnerability of PTEN-deficient glioblastoma cells with MCL1 inhibitors, *Mol. Cancer Ther.* (2020).
- [256] A.H. Wei, A.W. Roberts, A. Spencer, A.S. Rosenberg, D. Siegel, R.B. Walter, S. Caenepeel, P. Hughes, Z. McIver, K. Mezzi, P.K. Morrow, A. Stein, Targeting MCL-1 in hematologic malignancies: rationale and progress, *Blood Rev.* (2020), 100672.
- [257] X. Zhang, X. Liu, D. Zhou, G. Zheng, Targeting anti-apoptotic BCL-2 family proteins for cancer treatment, *Future Med. Chem.* 12 (7) (2020) 563–565.
- [258] M. Mehner, C. Kubelt, V. Adamski, C. Schmitt, M. Synowitz, J. Held-Feindt, Combined treatment of AT101 and demethoxycurcumin yields an enhanced anti-proliferative effect in human primary glioblastoma cells, *J. Cancer Res. Clin. Oncol.* 146 (1) (2020) 117–126.
- [259] C. Mecca, I. Giambanco, R. Donato, C. Arcuri, Targeting mTOR in glioblastoma: rationale and preclinical/clinical evidence, *Dis. Markers* 2018 (2018), 9230479.
- [260] E. Galanis, J.C. Buckner, M.J. Maurer, J.I. Kriesberg, K. Ballman, J. Boni, J.M. Peralba, R.B. Jenkins, S.R. Dakhil, R.F. Morton, K.A. Jaeckle, B. W. Scheithauer, J. Dancey, M. Hidalgo, D.J. Walsh, North Central Cancer Treatment Group, Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study, *J. Clin. Oncol.* 23 (23) (2005) 5294–5304.
- [261] U. Lassen, M. Sorensen, T.B. Gazi, B. Hasselbalch, H.S. Poulsen, Phase II study of bevacizumab and temsirolimus combination therapy for recurrent glioblastoma multiforme, *Anticancer Res.* 33 (4) (2013) 1657–1660.
- [262] W. Wick, T. Gorlia, P. Bady, M. Platten, M.J. van den Bent, M.J.B. Taphorn, J. Steuve, A.A. Brandes, M.-F. Hamou, A. Wick, M. Kosch, M. Weller, R. Stupp, P. Roth, V. Golfinopoulos, J.-S. Frenel, M. Campone, D. Ricard, C. Marosi, S. Villa, A. Weyerbrock, K. Hopkins, K. Homischko, B. Lhermitte, G. Pesce, M.E. Hegi, Phase II study of radiotherapy and temsirolimus versus radiochemotherapy with temozolamide in patients with newly diagnosed glioblastoma without MGMT promoter hypermethylation (EORTC 26082), *Clin. Cancer Res.* 22 (19) (2016) 4797–4806.
- [263] B. Geoerger, M.W. Kieran, S. Grupp, D. Perek, J. Clancy, M. Krygowski, R. Ananthakrishnan, J.P. Boni, A. Berkennblit, S.L. Spunt, Phase II trial of temsirolimus in children with high-grade glioma, neuroblastoma and rhabdomyosarcoma, *Eur. J. Cancer* 48 (2) (2012) 253–262.
- [264] P. Chinnaiyan, M. Won, P.Y. Wen, A.M. Rojiani, M. Werner-Wasik, H.A. Shih, L.S. Ashby, H.-H. Michael Yu, V.W. Stieber, S.C. Malone, J.B. Fiveash, N.A. Mohile, M.S. Ahluwalia, M.M. Wendland, P.J. Stella, A.Y. Kee, M.P. Mehta, A randomized phase II study of everolimus in combination with chemoradiation in newly diagnosed glioblastoma: results of NRG Oncology RTOG 0913, *Neurooncology* 20 (5) (2018) 666–673.
- [265] D.J. Ma, E. Galanis, S.K. Anderson, D. Schiff, T.J. Kaufmann, P.J. Peller, C. Giannini, P.D. Brown, J.H. Uhm, S. McGraw, K.A. Jaeckle, P.J. Flynn, K. Ligon, J.C. Buckner, J.N. Sarkaria, A phase II trial of everolimus, temozolomide, and radiotherapy in patients with newly diagnosed glioblastoma: NCCTG N057K, *Neurooncology* 17 (9) (2015) 1261–1269.
- [266] J.D. Hainsworth, K.C. Shih, G.C. Shepard, G.W. Tillinghast, B.T. Brinker, D.R. Spigel, Phase II study of concurrent radiation therapy, temozolomide, and bevacizumab followed by bevacizumab/everolimus as first-line treatment for patients with glioblastoma, *Clin. Adv. Hematol. Oncol.* 10 (4) (2012) 240–246.
- [267] P. Munster, M. Mita, A. Mahipal, J. Nemunaitis, C. Massard, T. Mikkelsen, C. Cruz, L. Paz-Ares, M. Hidalgo, D. Rathkopf, G. Blumenschein, D.C. Smith, B. Eichhorst, T. Cloughesy, E.H. Filvaroff, S. Li, H. Raymon, H. de Haan, K. Hege, J.C. Bendell, First-In-Human, I. Phase, Study of a dual mTOR kinase and DNA-PK inhibitor (CC-115) in advanced malignancy, *Cancer Manag. Res.* 11 (2019) 10463–10476.
- [268] M.D. Prados, K. Lamborn, W.K. Yung, K. Jaeckle, H.I. Robins, M. Mehta, H.A. Fine, P.Y. Wen, T. Cloughesy, S. Chang, M.K. Nicholas, D. Schiff, H. Greenberg, L. Junck, K. Fink, K. Hess, J. Kuhn, North American Brain Tumor Consortium, A phase 2 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: a North American Brain Tumor Consortium study, *Neurooncology* 8 (2) (2006) 189–193.
- [269] J.J. Vredenburgh, A. Desjardins, J.E. Herndon, J. Marcello, D.A. Reardon, J.A. Quinn, J.N. Rich, S. Sathornsumetee, S. Gururangan, J. Sampson, M. Wagner, L. Bailey, D.D. Bigner, A.H. Friedman, H.S. Friedman, Bevacizumab plus irinotecan in recurrent glioblastoma multiforme, *J. Clin. Oncol.* 25 (30) (2007) 4722–4729.
- [270] J.J. Vredenburgh, A. Desjardins, D.A. Reardon, H.S. Friedman, Experience with irinotecan for the treatment of malignant glioma, *Neurooncology* 11 (1) (2009) 80–91.
- [271] T. Mesti, M.E. Moltara, M. Boc, M. Rebersek, J. Ocvirk, Bevacizumab and irinotecan in recurrent malignant glioma, a single institution experience, *Radiol. Oncol.* 49 (1) (2015) 80–85.
- [272] F.S. Lieberman, M. Wang, H.I. Robins, C.I. Tsien, W.J. Curran Jr., M. Werner-Wasik, R.P. Smith, C. Schultz, A.C. Hartford, P. Zhang, M.P. Mehta, Phase 2 study of radiation therapy plus low-dose temozolomide followed by temozolomide and irinotecan for glioblastoma: NRG oncology RTOG trial 0420, *Int. J. Radiat. Oncol. Biol. Phys.* 103 (4) (2019) 878–886.
- [273] W. Wick, S. Dettmer, A. Berberich, T. Kessler, I. Karapanagiotou-Schenkel, A. Wick, F. Winkler, E. Pfaff, B. Brors, J. Debus, A. Unterberg, M. Bendszus, C. Herold-Mende, A. Eisenmenger, A. von Deimling, D.T.W. Jones, S.M. Pfister, F. Sahm, M. Platten, N2M2 (NOA-20) phase I/II trial of molecularly matched targeted therapies plus radiotherapy in patients with newly diagnosed non-MGMT hypermethylated glioblastoma, *Neurooncology* 21 (1) (2019) 95–105.
- [274] Q.G. D'Alessandris, M. Martini, T. Cenci, R. Di Bonaventura, L. Lauretti, V. Stumpo, A. Olivi, L.M. Larocca, R. Pallini, N. Montano, Tailored therapy for recurrent glioblastoma, *Rep. Pers. Mol. Approach J. Neurosurg. Sci.* (2020).
- [275] A.H. Sharpe, K.E. Pauken, The diverse functions of the PD1 inhibitory pathway, *Nat. Rev. Immunol.* 18 (3) (2018) 153–167.
- [276] K. Woroniecka, P.E. Fecchi, T-cell exhaustion in glioblastoma, *Oncotarget* 9 (82) (2018) 35287–35288.
- [277] A. Ribas, Tumor immunotherapy directed at PD-1, *New Engl. J. Med.* 366 (26) (2012) 2517–2519.
- [278] L. Sevenich, Turning “cold” into “hot” tumors—opportunities and challenges for radio-immunotherapy against primary and metastatic brain cancers, *Front. Oncol.* 9 (2019) 163.
- [279] W.J. Kelly, A.J. Giles, M. Gilbert, T lymphocyte-targeted immune checkpoint modulation in glioma, *J. Immunother. Cancer* 8 (2020) 1.
- [280] J.A. Seidel, A. Otsuka, K. Kabashima, Anti-PD-1 and Anti-CTLA-4 therapies in cancer: mechanisms of action, efficacy, and limitations, *Front. Oncol.* 8 (2018) 86.
- [281] T.F. Cloughesy, A.Y. Mochizuki, J.R. Orpilla, W. Hugo, A.H. Lee, T.B. Davidson, A.C. Wang, B.M. Ellingson, J.A. Rytlewski, C.M. Sanders, E.S. Kawaguchi, L. Du, G. Li, W.H. Yong, S.C. Gaffey, A.L. Cohen, I.K. Mellinghoff, E.Q. Lee, D. A. Reardon, B.J. O'Brien, N.A. Butowski, P.L. Nghiempou, J.L. Clarke, I. C. Arrillaga-Romany, H. Colman, T.J. Kaley, J.F. de Groot, L.M. Liau, P.Y. Wen, R. M. Prins, Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma, *Nat. Med.* 25 (3) (2019) 477–486.
- [282] D.A. Reardon, A.A. Brandes, A. Omuro, P. Mulholland, M. Lim, A. Wick, J. Baehring, M.S. Ahluwalia, P. Roth, O. Bahr, S. Phuphanich, J.M. Sepulveda, P. De Souza, S. Sahebjam, M. Carleton, K. Tatsuoka, C. Taitt, R. Zwirles, J. Sampson, M. Weller, Effect of nivolumab vs bevacizumab in patients with recurrent glioblastoma: the CheckMate 143 Phase 3 randomized clinical trial, *JAMA Oncol.* 6 (7) (2020) 1003–1010.
- [283] Bristol-Myers Squibb Provides Update on Phase 3 Opdivo (nivolumab) CheckMate -548 Trial in Patients with Newly Diagnosed MGMT-Methylated Glioblastoma Multiforme. <https://news.bms.com/news/corporate-financial/2019/Bristol-Myer-Squibb-Provides-Update-on-Phase-3-Opdivo-nivolumab-CheckMate-548-Trial-in-Patients-with-Newly-Diagnosed-MGMT-Methylated-Glioblastoma-Multiforme/default.aspx>.
- [284] Company B-MS. Bristol-Myers Squibb Announces Phase 3 CheckMate -498 Study Did Not Meet Primary Endpoint of Overall Survival with Opdivo (nivolumab) Plus Radiation in Patients with Newly Diagnosed MGMT-Unmethylated Glioblastoma Multiforme. <https://news.bms.com/news/corporate-financial/2019/Bristol-Myers-Squibb-Announces-Phase-3-CheckMate-498-Study-Did-Not-Meet-Primary-Endpoint-of-Overall-Survival-with-Opdivo-nivolumab-Plus-Radiation-in-Patients-with-Newly-Diagnosed-MGMT-Unmethylated-Glioblastoma-Multiforme/default.aspx>.

- [285] W. Hugo, J.M. Zaretsky, L. Sun, C. Song, B.H. Moreno, S. Hu-Lieskovian, B. Berent-Maoz, J. Pang, B. Chmielowski, G. Cherry, E. Seja, S. Lomeli, X. Kong, M.C. Kelley, J.A. Sosman, D.B. Johnson, A. Ribas, R.S. Lo, Genomic and transcriptomic features of response to anti-PD-1 therapy in metastatic melanoma, *Cell* 168 (3) (2017) 542.
- [286] S.P. Arlauckas, C.S. Garris, R.H. Kohler, M. Kitaoka, M.F. Cuccarese, K.S. Yang, M.A. Miller, J.C. Carlson, G.J. Freeman, R.M. Anthony, R. Weissleder, M.J. Pittet, In vivo imaging reveals a tumor-associated macrophage-mediated resistance pathway in anti-PD-1 therapy, *Sci. Transl. Med* 9 (2017) 389.
- [287] T. Maj, W. Wang, J. Crespo, H. Zhang, W. Wang, S. Wei, L. Zhao, L. Vatan, I. Shao, W. Szeliga, C. Lyssiotis, J.R. Liu, I. Kryczek, W. Zou, Oxidative stress controls regulatory T cell apoptosis and suppressor activity and PD-L1-blockade resistance in tumor, *Nat. Immunol.* 18 (12) (2017) 1332–1341.
- [288] D.R. Sen, J. Kaminski, R.A. Barnitz, M. Kurachi, U. Gerdemann, K.B. Yates, H.W. Tsao, J. Godec, M.W. LaFleur, F.D. Brown, P. Tonnerre, R.T. Chung, D.C. Tully, T.M. Allen, N. Frahm, G.M. Lauer, E.J. Wherry, N. Yosef, W.N. Haining, The epigenetic landscape of T cell exhaustion, *Science* 354 (6316) (2016) 1165–1169.
- [289] K.E. Pauken, M.A. Sammons, P.M. Odorizzi, S. Manne, J. Godec, O. Khan, A. M. Drake, Z. Chen, D.R. Sen, M. Kurachi, R.A. Barnitz, C. Bartman, B. Bengsch, A. C. Huang, J.M. Schenkel, G. Vahedi, W.N. Haining, S.L. Berger, E.J. Wherry, Epigenetic stability of exhausted T cells limits durability of reinvigoration by PD-1 blockade, *Science* 354 (6316) (2016) 1160–1165.
- [290] D.S. Thommen, J. Schreiner, P. Muller, P. Herzig, A. Roller, A. Belousov, P. Umana, P. Pisa, C. Klein, M. Bacac, O.S. Fischer, W. Moersig, S. Savic Prince, V. Levitsky, V. Karanikas, D. Lardinois, A. Zippelius, Progression of lung cancer is associated with increased dysfunction of T cells defined by coexpression of multiple inhibitory receptors, *Cancer Immunol. Res* 3 (12) (2015) 1344–1355.
- [291] L. Long, X. Zhang, F. Chen, Q. Pan, P. Phiphatwatchara, Y. Zeng, H. Chen, The promising immune checkpoint LAG-3; from tumor microenvironment to cancer immunotherapy, *Genes Cancer* 9 (5–6) (2018) 176–189.
- [292] J.E. Kim, M.A. Patel, A. Mangraviti, E.S. Kim, D. Theodos, E. Velarde, A. Liu, E. W. Sankey, A. Tam, H. Xu, D. Mathios, C.M. Jackson, S. Harris-Bookman, T. Garzon-Muvdi, M. Sheu, A.M. Martin, B.M. Tyler, P.T. Tran, X. Ye, A. Olivi, J. M. Taube, P.C. Burger, C.G. Drake, H. Brem, D.M. Pardoll, M. Lim, Combination therapy with Anti-PD-1, anti-TIM-3, and focal radiation results in regression of murine gliomas, *Clin. Cancer Res* 23 (1) (2017) 124–136.
- [293] A.B. Singh, R.C. Harris, Autocrine paracrine and juxtacrine signaling by EGFR ligands, *Cell Signal* 17 (10) (2005) 1183–1193.
- [294] B.D. Choi, G.E. Archer, D.A. Mitchell, A.B. Heimberger, R.E. McLendon, D. Bigner, J.H. Sampson, EGFRvIII-targeted vaccination therapy of malignant glioma, *Brain Pathol.* 19 (4) (2009) 713–723.
- [295] M. Weller, N. Butowski, D.D. Tran, L.D. Recht, M. Lim, H. Hirte, L. Ashby, L. Mechta, S.A. Goldlust, F. Iwamoto, J. Drappatz, D.M. O'Rourke, M. Wong, M. G. Hamilton, G. Finocchiaro, J. Perry, W. Wick, J. Green, Y. He, C.D. Turner, M. J. Yellin, T. Keler, T.A. Davis, R. Stupp, J.H. Sampson, investigators Alt. Rindopeimut with temozolamide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial, *Lancet Oncol.* 18 (10) (2017) 1373–1385.
- [296] A.H. Wu, J. Xiao, L. Anker, W.A. Hall, D.S. Gregerson, W.K. Cavenee, W. Chen, W. C. Low, Identification of EGFRvIII-derived CTL epitopes restricted by HLA A0201 for dendritic cell based immunotherapy of gliomas, *J. Neurooncol.* 76 (1) (2006) 23–30.
- [297] J.H. Sampson, A.B. Heimberger, G.E. Archer, K.D. Aldape, A.H. Friedman, H. S. Friedman, M.R. Gilbert, J.E. Herndon 2nd, R.E. McLendon, D.A. Mitchell, D. A. Reardon, R. Sawaya, R.J. Schmittling, W. Shi, J.J. Vredenburgh, Bigner DD. Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma, *J. Clin. Oncol.* 28 (31) (2010) 4722–4729.
- [298] D.A. Reardon, A. Desjardins, J.J. Vredenburgh, D.M. O'Rourke, D.D. Tran, K. L. Fink, L.B. Nabors, G. Li, D.A. Bota, R.V. Lukas, L.S. Ashby, J.P. Duic, M. M. Mrugala, S. Cruickshank, L. Vitale, Y. He, J.A. Green, M.J. Yellin, C.D. Turner, T. Keler, T.A. Davis, J.H. Sampson, REACT Trial Investigators, Rindopeimut with bevacizumab for patients with relapsed EGFRvIII-expressing glioblastoma (REACT): results of a double-blind randomized phase II trial, *Clin. Cancer Res* 26 (7) (2020) 1586–1594.
- [299] P.M. Santos, L.H. Butterfield, Dendritic cell-based cancer vaccines, *J. Immunol.* 200 (2) (2018) 443–449.
- [300] D.D. Bigner, O.M. Pitts, C.J. Wikstrand, Induction of lethal experimental allergic encephalomyelitis in nonhuman primates and guinea pigs with human glioblastoma multiforme tissue, *J. Neurosurg.* 55 (1) (1981) 32–42.
- [301] L.M. Liau, K. Ashkan, D.D. Tran, J.L. Campian, J.E. Trusheim, C.S. Cobbs, J. A. Heth, M. Salacz, S. Taylor, S.D. D'Andre, F.M. Iwamoto, E.J. Dropcho, Y. A. Moshel, K.A. Walter, C.P. Pillainayagam, R. Aiken, R. Chaudhary, S. A. Goldlust, D.A. Bota, P. Duic, J. Grewal, H. Elinzano, S.A. Toms, K.O. Lillehei, T. Mikkelsen, T. Walbert, S.R. Abram, A.J. Brenner, S. Brem, M.G. Ewend, S. Khagi, J. Portnow, L.J. Kim, W.G. Loudon, R.C. Thompson, D.E. Avigan, K. L. Fink, F.J. Geoffroy, S. Lindhorst, J. Lutzky, A.E. Sloan, G. Schackert, D. Krex, H. J. Meisel, J. Wu, R.P. Davis, C. Duma, A.B. Etame, D. Mathieu, S. Kesari, D. Piccioni, M. Westphal, D.S. Baskin, P.Z. New, M. Lacroix, S.A. May, T.J. Pluard, V. Tse, R.M. Green, J.L. Villano, M. Pearlman, K. Petrecca, M. Schulder, L. P. Taylor, A.E. Maida, R.M. Prins, T.F. Cloughesy, P. Mulholland, M.L. Bosch, First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma, *J. Transl. Med.* 16 (1) (2018) 142.
- [302] I.J. De Vries, D.J. Krooshoop, N.M. Scharenborg, W.J. Lesterhuis, J.H. Diepstra, G. N. Van Muijen, S.P. Strijk, T.J. Ruers, O.C. Boerman, W.J. Oyen, G.J. Adema, C. J. Punt, C.G. Figdor, Effective migration of antigen-pulsed dendritic cells to lymph nodes in melanoma patients is determined by their maturation state, *Cancer Res.* 63 (1) (2003) 12–17.
- [303] H. Liu, L. Chen, J. Liu, H. Meng, R. Zhang, L. Ma, L. Wu, S. Yu, F. Shi, Y. Li, L. Zhang, L. Wang, S. Feng, Q. Zhang, Y. Peng, Q. Wu, C. Liu, X. Chang, L. Yang, Y. Uemura, X. Yu, T. Liu, Co-delivery of tumor-derived exosomes with alpha-galactosylceramide on dendritic cell-based immunotherapy for glioblastoma, *Cancer Lett.* 411 (2017) 182–190.
- [304] K.M. Dhopakar, B. Cirignano, F. Chamian, D. Zagzag, D.C. Miller, J.L. Finlay, R. M. Steinman, Invariant natural killer T cells are preserved in patients with glioma and exhibit antitumor lytic activity following dendritic cell-mediated expansion, *Int. J. Cancer* 109 (6) (2004) 893–899.
- [305] T. Garzon-Muvdi, D. Theodos, A.S. Luksik, R. Maxwell, E. Kim, C.M. Jackson, Z. Belcaid, S. Ganguly, B. Tyler, H. Brem, D.M. Pardoll, M. Lim, Dendritic cell activation enhances anti-PD-1 mediated immunotherapy against glioblastoma, *Oncotarget* 9 (29) (2018) 20681–20697.
- [306] J.P. Antonios, H. Soto, R.G. Everson, J. Orpilla, D. Moughon, N. Shin, S. Sedighim, W.H. Yong, G. Li, T.F. Cloughesy, L.M. Liau, R.M. Prins, PD-1 blockade enhances the vaccination-induced immune response in glioma, *JCI Insight* 1 (2016) 10.
- [307] B.W. Bridle, K.B. Stephenson, J.E. Boudreau, S. Koshy, N. Kazhdan, E. Pullenayegum, J. Brunelliere, J.L. Bramson, B.D. Lichy, Y. Wan, Potentiating cancer immunotherapy using an oncolytic virus, *Mol. Ther.* 18 (8) (2010) 1430–1439.
- [308] Q. Zhang, F. Liu, Advances and potential pitfalls of oncolytic viruses expressing immunomodulatory transgene therapy for malignant gliomas, *Cell Death Dis.* 11 (6) (2020) 485.
- [309] C. Kurokawa, I.D. Iankov, S.K. Anderson, I. Aderca, A.A. Leontovich, M.J. Maurer, A.L. Oberg, M.A. Schroeder, C. Giannini, S.M. Greiner, M.A. Becker, E. A. Thompson, P. Haluska, M.E. Jenoft, I.F. Parney, S.J. Weroha, J. Jen, J. N. Sarkaria, E. Galanis, Constitutive interferon pathway activation in tumors as an efficacy determinant following oncolytic virotherapy, *J. Natl. Cancer Inst.* 110 (10) (2018) 1123–1132.
- [310] L. Menotti, E. Avitabile, Herpes simplex virus oncolytic immunotherapy: the blossoming branch of multimodal therapy, *Int. J. Mol. Sci.* 21 (2020) 21.
- [311] S. Rius-Rocabert, N. Garcia-Romero, A. Garcia, A. Ayuso-Sacido, E. Nistal-Villan, Oncolytic virotherapy in glioma tumors, *Int. J. Mol. Sci.* 21 (2020) 20.
- [312] R.H. Andtbacka, H.L. Kaufman, F. Collichio, T. Amatruda, N. Senzer, J. Chesney, K.A. Delman, L.E. Spitzer, I. Puzanov, S.S. Agarwala, M. Milhem, L. Cranmer, B. Curti, K. Lewis, M. Ross, T. Guthrie, G.P. Linette, G.A. Daniels, K. Harrington, M.R. Middleton, W.H. Miller Jr., J.S. Zager, Y. Ye, B. Yao, A. Li, S. Doleman, A. VanderWalde, J. Gansert, R.S. Coffin, Tafimumogene laherparepvec improves durable response rate in patients with advanced melanoma, *J. Clin. Oncol.* 33 (25) (2015) 2780–2788.
- [313] F.F. Lang, C. Conrad, C. Gomez-Manzano, W.K.A. Yung, R. Sawaya, J.S. Weinberg, S.S. Prabhu, G. Rao, G.N. Fuller, K.D. Aldape, J. Gumin, L.M. Vence, I. Wistuba, J. Rodriguez-Canales, P.A. Villalobos, C.M.F. Dirven, S. Tejada, R.D. Valle, M. M. Alonso, B. Ewald, J.J. Peterkin, F. Tufaro, J. Fueyo, I. Phase, Study of DNX-2401 (Delta-24-RGD) oncolytic adenovirus: replication and immunotherapeutic effects in recurrent malignant glioma, *J. Clin. Oncol.* 36 (14) (2018) 1419–1427.
- [314] D.A. Spencer, J.S. Young, D. Kanjoia, J.W. Kim, S.P. Polster, J.P. Murphy, M. S. Lesniak, Unlocking the promise of oncolytic virotherapy in glioma: combination with chemotherapy to enhance efficacy, *Ther. Deliv.* 6 (4) (2015) 453–468.
- [315] V. Cerullo, I. Diaconu, L. Kangasniemi, M. Rajecski, S. Escutenaire, A. Koski, V. Romano, N. Rouvinen, T. Tuuminen, L. Laasonen, K. Partanen, S. Kauppinen, T. Joensuu, M. Oksanen, S.L. Holm, E. Haavisto, A. Karioja-Kallio, A. Kanerva, S. Pesonen, P.T. Arstila, A. Hemminki, Immunological effects of low-dose cyclophosphamide in cancer patients treated with oncolytic adenovirus, *Mol. Ther.* 19 (9) (2011) 1737–1746.
- [316] P.W. Kantoff, C.S. Higano, N.D. Shore, E.R. Berger, E.J. Small, D.F. Penson, C. H. Redfern, A.C. Ferrari, R. Dreicer, R.B. Sims, Y. Xu, M.W. Frohlich, P. F. Schellhammer, I.S. Investigators, Sipuleucel-T immunotherapy for castration-resistant prostate cancer, *New Engl. J. Med.* 363 (5) (2010) 411–422.
- [317] O.D. Perez, C.R. Llogg, K. Hiraoka, O. Diago, R. Burnett, A. Inagaki, D. Jolson, K. Amundson, T. Buckley, D. Lohse, A. Lin, C. Burrascano, C. Ibanez, N. Kasahara, H.E. Gruber, D.J. Jolly, Design and selection of Toca 511 for clinical use: modified retroviral replicating vector with improved stability and gene expression, *Mol. Ther.* 20 (9) (2012) 1689–1698.
- [318] L.A. Wheeler, A.G. Manzanera, S.D. Bell, R. Cavaliere, J.M. McGregor, J. C. Grecula, H.B. Newton, S.S. Lo, B. Badie, J. Portnow, B.S. Teh, T.W. Trask, D. S. Baskin, P.Z. New, L.K. Aguilar, E. Aguilar-Cordova, E.A. Chiocca, Phase II multicenter study of gene-mediated cytotoxic immunotherapy as adjuvant to surgical resection for newly diagnosed malignant glioma, *Neurooncology* 18 (8) (2016) 1137–1145.
- [319] A.A. Stepanenko, V.P. Chekhonin, Recent advances in oncolytic virotherapy and immunotherapy for glioblastoma: a glimmer of hope in the search for an effective therapy? *Cancers* 10 (12) (2018).
- [320] M. Westphal, S. Yla-Herttuala, J. Martin, P. Warnke, P. Menei, D. Eckland, J. Kinley, R. Kay, Z. Ram, A.S. Group, Adenovirus-mediated gene therapy with sitimagene ceradenovec followed by intravenous ganciclovir for patients with operable high-grade glioma (ASPECT): a randomised, open-label, phase 3 trial, *Lancet Oncol.* 14 (9) (2013) 823–833.
- [321] B. Jena, G. Dotti, L.J. Cooper, Redirecting T-cell specificity by introducing a tumor-specific chimeric antigen receptor, *Blood* 116 (7) (2010) 1035–1044.
- [322] D.M. O'Rourke, M.P. Nasrallah, A. Desai, J.J. Melenhorst, K. Mansfield, J.J. D. Morrisette, M. Martinez-Lage, S. Brem, E. Maloney, A. Shen, R. Isaacs, S. Mohan, G. Plesa, S.F. Lacey, J.M. Navenot, Z. Zheng, B.L. Levine, H. Okada, C.

- H. June, J.L. Brogdon, M.V. Maus, A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma, *Sci. Transl. Med.* 9 (2017) 399.
- [323] N. Ahmed, V. Brawley, M. Hegde, K. Bielamowicz, M. Kalra, D. Landi, C. Robertson, T.L. Gray, O. Diouf, A. Wakefield, A. Ghazi, C. Gerken, Z. Yi, A. Ashoori, M.F. Wu, H. Liu, C. Rooney, G. Dotti, A. Gee, J. Su, Y. Kew, D. Baskin, Y.J. Zhang, P. New, B. Grilley, M. Stojakovic, J. Hicks, S.Z. Powell, M.K. Brenner, H.E. Heslop, R. Grossman, W.S. Wels, S. Gottschalk, HER2-specific chimeric antigen receptor-modified virus-specific T Cells for progressive glioblastoma: a phase I dose-escalation trial, *JAMA Oncol.* 3 (8) (2017) 1094–1101.
- [324] K. Bielamowicz, K. Fousek, T.T. Byrd, H. Samaha, M. Mukherjee, N. Aware, M.F. Wu, J.S. Orange, P. Sumazin, T.K. Man, S.K. Joseph, M. Hegde, C.A. R. Trivalent, T cells overcome interpatient antigenic variability in glioblastoma, *Neurooncology* 20 (4) (2018) 506–518.
- [325] X. Tang, S. Zhao, Y. Zhang, Y. Wang, Z. Zhang, M. Yang, Y. Zhu, G. Zhang, G. Guo, A. Tong, L. Zhou, B7-H3 as a Novel CAR-T therapeutic target for glioblastoma, *Mol. Ther. Oncol.* 14 (2019) 279–287.
- [326] P.E. Fecci, J.H. Sampson, The current state of immunotherapy for gliomas: an eye toward the future, *J. Neurosurg.* 131 (3) (2019) 657–666.
- [327] E. Stillo, D.M. Barrett, K.L. Black, A. Bagashev, D. Oldridge, G. Wu, R. Sussman, C. Lanauze, M. Ruella, M.R. Gazzara, N.M. Martinez, C.T. Harrington, E.Y. Chung, J. Perazzelli, T.J. Hofmann, S.L. Maude, P. Raman, A. Barrera, S. Gill, S.F. Lacey, J.J. Melenhorst, D. Allman, E. Jacoby, T. Fry, C. Mackall, Y. Barash, K.W. Lynch, J.M. Maris, S.A. Grupp, A. Thomas-Tikhonenko, Convergence of acquired mutations and alternative splicing of CD19 enables resistance to CART-19 immunotherapy, *Cancer Discov.* 5 (12) (2015) 1282–1295.
- [328] B.D. Choi, X. Yu, A.P. Castano, A.A. Bouffard, A. Schimdt, R.C. Larson, S. R. Bailey, A.C. Boroughs, M.J. Frigault, M.B. Leick, I. Scarfo, C.L. Cetrulo, S. Demehri, B.V. Nahed, D.P. Cahill, H. Wakimoto, W.T. Curry, B.S. Carter, M. V. Maus, CAR-T cells secreting BiTEs circumvent antigen escape without detectable toxicity, *Nat. Biotechnol.* 37 (9) (2019) 1049–1058.
- [329] C.M. Jackson, J. Choi, M. Lim, Mechanisms of immunotherapy resistance: lessons from glioblastoma, *Nat. Immunol.* 20 (9) (2019) 1100–1109.
- [330] V. Anagnosou, K.N. Smith, P.M. Forde, N. Niknafs, R. Bhattacharya, J. White, T. Zhang, V. Adleff, J. Phallen, N. Wali, C. Hruban, V.B. Guthrie, K. Rodgers, J. Naidoo, H. Kang, W. Sharfman, C. Georgiades, F. Verde, P. Illei, Q.K. Li, E. Gabrielson, M.V. Brock, C.A. Zahnow, S.B. Baylin, R.B. Sharpf, J.R. Brahmer, R. Karchin, D.M. Pardoll, V.E. Velculescu, Evolution of neantigen landscape during immune checkpoint blockade in non-small cell lung, *Cancer Cancer Discov.* 7 (3) (2017) 264–276.
- [331] S. Kailayangiri, B. Altwater, M. Wiebel, S. Jamitzky, C. Rossig, Overcoming heterogeneity of antigen expression for effective CAR T cell targeting of cancers, *Cancer* 12 (5) (2020).
- [332] C. Lhuillier, N.P. Rudqvist, O. Elemento, S.C. Formenti, S. Demaria, Radiation therapy and anti-tumor immunity: exposing immunogenic mutations to the immune system, *Genome Med.* 11 (1) (2019) 40.
- [333] L. Jin, H. Tao, A. Karachi, Y. Long, A.Y. Hou, M. Na, K.A. Dyson, A.J. Grrippin, L. P. Deleyrolle, W. Zhang, D.A. Rajon, Q.J. Wang, J.C. Yang, J.L. Kresak, E. J. Sayour, M. Rahman, F.J. Bova, Z. Lin, D.A. Mitchell, J. Huang, CXCR1- or CXCR2-modified CAR T cells co-opt IL-8 for maximal antitumor efficacy in solid tumors, *Nat. Commun.* 10 (1) (2019) 4016.
- [334] S. Murty, S.T. Haile, C. Beinat, A. Aalipour, I.S. Alam, T. Murty, T.M. Shaffer, C. B. Patel, E.E. Graves, C.L. Mackall, S.S. Gambhir, Intravital imaging reveals synergistic effect of CAR T-cells and radiation therapy in a preclinical immunocompetent glioblastoma model, *Oncoimmunology* 9 (1) (2020), 1757360.
- [335] J.T. Oswald, H. Patel, D. Khan, N.N. Jeorje, H. Golzar, E.L. Oswald, S. Tang, Drug delivery systems using surface markers for targeting cancer stem cells, *Curr. Pharm. Des.* 26 (17) (2020) 2057–2071.
- [336] J.K. Patra, G. Das, L.F. Fraceto, E.V.R. Campos, M.D.P. Rodriguez-Torres, L. S. Acosta-Torres, L.A. Diaz-Torres, R. Grillo, M.K. Swamy, S. Sharma, S. Habtemariam, H.S. Shin, Nano based drug delivery systems: recent developments and future prospects, *J. Nanobiotechnol.* 16 (1) (2018) 71.
- [337] E. Alphandery, Nano-therapies for glioblastoma treatment, *Cancers* 12 (1) (2020).
- [338] Y. Shi, R. van der Meel, X. Chen, T. Lammers, The EPR effect and beyond: strategies to improve tumor targeting and cancer nanomedicine treatment efficacy, *Theranostics* 10 (17) (2020) 7921–7924.
- [339] S.K. Golombok, J.N. May, B. Theek, L. Appold, N. Drude, F. Kiessling, T. Lammers, Tumor targeting via EPR: Strategies to enhance patient responses, *Adv. Drug Deliv. Rev.* 130 (2018) 17–38.
- [340] D. Rosenblum, N. Joshi, W. Tao, J.M. Karp, D. Peer, Progress and challenges towards targeted delivery of cancer therapeutics, *Nat. Commun.* 9 (1) (2018) 1410.
- [341] Y. Xu, H. Wu, J. Huang, W. Qian, D.E. Martinson, B. Ji, Y. Li, Y.A. Wang, L. Yang, H. Mao, Probing and enhancing ligand-mediated active targeting of tumors using sub-5 nm ultrafine iron oxide nanoparticles, *Theranostics* 10 (6) (2020) 2479–2494.
- [342] G. Bort, F. Lux, S. Dufort, Y. Cremillieux, C. Verry, O. Tillement, EPR-mediated tumor targeting using ultrasmall-hybrid nanoparticles: From animal to human with theranostic AGuX nanoparticles, *Theranostics* 10 (3) (2020) 1319–1331.
- [343] E. Jang, E. Kim, H.Y. Son, E.K. Lim, H. Lee, Y. Choi, K. Park, S. Han, J.S. Suh, Y. M. Huh, S. Haam, Nanovesicle-mediated systemic delivery of microRNA-34a for CD44 overexpressing gastric cancer stem cell therapy, *Biomaterials* 105 (2016) 12–24.
- [344] C. Liu, G. Zhao, J. Liu, N. Ma, P. Chivukula, L. Perelman, K. Okada, Z. Chen, D. Gough, L. Yu, Novel biodegradable lipid nano complex for siRNA delivery significantly improving the chemosensitivity of human colon cancer stem cells to paclitaxel, *J. Control Release* 140 (3) (2009) 277–283.
- [345] H. Lopez-Bertoni, K.L. Kozielski, Y. Rui, B. Lal, H. Vaughan, D.R. Wilson, N. Mihelson, C.G. Eberhart, J. Laterra, J.J. Green, Bioreducible polymeric nanoparticles containing multiplexed cancer stem cell regulating miRNAs inhibit glioblastoma growth and prolong survival, *Nano Lett.* 18 (7) (2018) 4086–4094.
- [346] H. Ling, M. Fabbri, G.A. Calin, MicroRNAs and other non-coding RNAs as targets for anticancer drug development, *Nat. Rev. Drug Discov.* 12 (11) (2013) 847–865.
- [347] M. Nawaz, Extracellular vesicle-mediated transport of non-coding RNAs between stem cells and cancer cells: implications in tumor progression and therapeutic resistance, *Stem Cell Investig.* 4 (2017) 83.
- [348] T. Glaser, I. Han, L. Wu, X. Zeng, Targeted nanotechnology in glioblastoma multiforme, *Front. Pharm.* 8 (2017) 166.
- [349] G. Basati, M. Khaksarian, S. Abbaszadeh, H.E. Lashgarian, A. Marzban, Cancer stem cells and nanotechnological approaches for eradication, *Stem Cell Investig.* 6 (2019) 38.
- [350] V.P. Chekhonin, V.P. Baklaushev, G.M. Yusubalieva, A.E. Belorusova, M. V. Gulyaev, E.B. Tsitrin, N.F. Grinenko, O.I. Gurina, Y.A. Pirogov, Targeted delivery of liposomal nanocontainers to the peritumoral zone of glioma by means of monoclonal antibodies against GFAP and the extracellular loop of Cx43, *Nanomedicine* 8 (1) (2012) 63–70.
- [351] B. Wang, L. Lv, Z. Wang, Y. Jiang, W. Lv, X. Liu, Z. Wang, Y. Zhao, H. Xin, Q. Xu, Improved anti-glioblastoma efficacy by IL-13Ralpha2 mediated copolymer nanoparticles loaded with paclitaxel, *Sci. Rep.* 5 (2015) 16589.
- [352] N. Grafals-Ruiz, C.I. Rios-Vicil, E.L. Lozada-Delgado, B.I. Quinones-Diaz, R. A. Noriega-Rivera, G. Martinez-Zayas, Y. Santana-Rivera, G.S. Santiago-Sanchez, F. Valiyeva, P.E. Vivas-Mejia, Brain targeted gold liposomes improve RNAi delivery for glioblastoma, *Int. J. Nanomed.* 15 (2020) 2809–2828.
- [353] Z. Belhadji, C. Zhan, M. Ying, X. Wei, C. Xie, Z. Yan, W. Lu, Multifunctional targeted liposomal drug delivery for efficient glioblastoma treatment, *Oncotarget* 8 (40) (2017) 66889–66900.
- [354] H. Chen, W. Zhang, G. Zhu, J. Xie, X. Chen, Rethinking cancer nanotheranostics, *Nat. Rev. Mater.* (2017) 2.
- [355] P. Mi, Stimuli-responsive nanocarriers for drug delivery, tumor imaging, therapy and theranostics, *Theranostics* 10 (10) (2020) 4557–4588.
- [356] Y. Liu, Y. Jiang, M. Zhang, Z. Tang, M. He, W. Bu, Modulating hypoxia via nanomaterials chemistry for efficient treatment of solid tumors, *Acc. Chem. Res.* 51 (10) (2018) 2502–2511.
- [357] H.M. Liu, Y.F. Zhang, Y.D. Xie, Y.F. Cai, B.Y. Li, W. Li, L.Y. Zeng, Y.L. Li, R.T. Yu, Hypoxia-responsive ionizable liposome delivery siRNA for glioma therapy, *Int. J. Nanomed.* 12 (2017) 1065–1083.
- [358] L. Hua, Z. Wang, L. Zhao, H. Mao, G. Wang, K. Zhang, X. Liu, D. Wu, Y. Zheng, J. Lu, R. Yu, H. Liu, Hypoxia-responsive lipid-poly-(hypoxic radiosensitized prodrug) nanoparticles for glioma chemo- and radiotherapy, *Theranostics* 8 (18) (2018) 5088–5105.
- [359] S. Mohanty, Z. Chen, K. Li, G.R. Morais, J. Klockow, K. Yerneni, L. Pisani, F. T. Chin, S. Mitra, S. Cheshier, E. Chang, S.S. Gambhir, J. Rao, P.M. Loadman, R. A. Falconer, H.E. Daldrup-Link, A novel theranostic strategy for MMP-14-expressing glioblastomas impacts survival, *Mol. Cancer Ther.* 16 (9) (2017) 1909–1921.
- [360] W. Wu, J.L. Klockow, S. Mohanty, K.S. Ku, M. Aghighi, S. Melemenidis, Z. Chen, K. Li, G.R. Morais, N. Zhao, J. Schlegel, E.E. Graves, J. Rao, P.M. Loadman, R. A. Falconer, S. Mukherjee, F.T. Chin, H.E. Daldrup-Link, Theranostic nanoparticles enhance the response of glioblastomas to radiation, *Nanotheranostics* 3 (4) (2019) 299–310.
- [361] J.N. Sarkaria, L.S. Hu, I.F. Parney, D.H. Pafundi, D.H. Brinkmann, N.N. Laack, C. Giannini, T.C. Burns, S.H. Kizilbash, J.K. Laramy, K.R. Swanson, T. J. Kaufmann, P.D. Brown, N.Y.R. Agar, E. Galanis, J.C. Buckner, W.F. Elmquist, Is the blood-brain barrier really disrupted in all glioblastomas? A critical assessment of existing clinical data, *Neurooncology* 20 (2) (2018) 184–191.
- [362] Z. Deng, Z. Sheng, F. Yan, Ultrasound-induced blood-brain-barrier opening enhances anticancer efficacy in the treatment of glioblastoma: current status and future prospects, *J. Oncol.* 2019 (2019), 2345203.
- [363] D.G. Fisher, R.J. Price, Recent advances in the use of focused ultrasound for magnetic resonance image-guided therapeutic nanoparticle delivery to the central nervous system, *Front. Pharm.* 10 (2019) 1348.
- [364] C.T. Curley, B.P. Mead, K. Negron, N. Kim, W.J. Garrison, G.W. Miller, K. M. Kingsmore, E.A. Thim, J. Song, J.M. Munson, A.L. Klibanov, J.S. Suk, J. Hanes, R.J. Price, Augmentation of brain tumor interstitial flow via focused ultrasound promotes brain-penetrating nanoparticle dispersion and transfection, *Sci. Adv.* 6 (18) (2020) eaay1344.
- [365] C.H. Fan, T.W. Wang, Y.K. Hsieh, C.F. Wang, Z. Gao, A. Kim, Y. Nagasaki, C. K. Yeh, Enhancing boron uptake in brain glioma by a boron-polymer/microbubble complex with focused ultrasound, *ACS Appl. Mater. Interfaces* 11 (12) (2019) 11144–11156.
- [366] Y. Li, M. Wu, N. Zhang, C. Tang, P. Jiang, X. Liu, F. Yan, H. Zheng, Mechanisms of enhanced antglioma efficacy of polysorbate 80-modified paclitaxel-loaded PLGA nanoparticles by focused ultrasound, *J. Cell Mol. Med.* 22 (9) (2018) 4171–4182.
- [367] R. Gupta, D. Sharma, Evolution of magnetic hyperthermia for glioblastoma multiforme therapy, *ACS Chem. Neurosci.* 10 (3) (2019) 1157–1172.
- [368] K. Mahmoudi, A. Bouras, D. Bozec, R. Ivkovic, C. Hadjipanayis, Magnetic hyperthermia therapy for the treatment of glioblastoma: a review of the therapy's history, efficacy and application in humans, *Int. J. Hyperth.* 34 (8) (2018) 1316–1328.

- [369] R. Gupta, D. Sharma, Manganese-doped magnetic nanoclusters for hyperthermia and photothermal glioblastoma therapy, *ACS Appl. Nano Mater.* 3 (2) (2020) 2026–2037.
- [370] J.B. Mamani, B.S. Marinho, G.N.A. Rego, M.P. Nucci, F. Alvieri, R.S.D. Santos, J. V.M. Ferreira, F.A. Oliveira, L.F. Gamarra, Magnetic hyperthermia therapy in glioblastoma tumor on-a-Chip model, *Einstein* 18 (2020), eAO4954.
- [371] F. Sousa, H.K. Dhaliwal, F. Gattacceca, B. Sarmento, M.M. Amiji, Enhanced anti-angiogenic effects of bevacizumab in glioblastoma treatment upon intranasal administration in polymeric nanoparticles, *J. Control Release* 309 (2019) 37–47.
- [372] A. Khan, M. Aqil, S.S. Imam, A. Ahad, Y. Sultana, A. Ali, K. Khan, Temozolomide loaded nano lipid based chitosan hydrogel for nose to brain delivery: characterization, nasal absorption, histopathology and cell line study, *Int J. Biol. Macromol.* 116 (2018) 1260–1267.
- [373] M. Van Woensel, T. Mathivet, N. Wauthoz, R. Rosiere, A.D. Garg, P. Agostinis, V. Mathieu, R. Kiss, F. Lefranc, L. Boon, J. Belmans, S.W. Van Gool, H. Gerhardt, K. Amighi, S. De Vleeschouwer, Sensitization of glioblastoma tumor micro-environment to chemo- and immunotherapy by Galectin-1 intranasal knock-down strategy, *Sci. Rep.* 7 (1) (2017) 1217.
- [374] A. Arshad, B. Yang, A.S. Bienemann, N.U. Barua, M.J. Wyatt, M. Woolley, D. E. Johnson, K.J. Edler, S.S. Gill, Convection-enhanced delivery of carboplatin PLGA nanoparticles for the treatment of glioblastoma, *PLoS One* 10 (7) (2015), e0132266.
- [375] R.H. Bobo, D.W. Laske, A. Akbasak, P.F. Morrison, R.L. Dedrick, E.H. Oldfield, Convection-enhanced delivery of macromolecules in the brain, *Proc. Natl. Acad. Sci. U. S. A.* 91 (6) (1994) 2076–2080.
- [376] S. Kunwar, S. Chang, M. Westphal, M. Vogelbaum, J. Sampson, G. Barnett, M. Shaffrey, Z. Ram, J. Piepmeier, M. Prados, D. Croteau, C. Pedain, P. Leland, S. R. Husain, B.H. Joshi, R.K. Puri, P.S. Group, Phase III randomized trial of CED of IL13-PE38QQR vs Gliadel wafers for recurrent glioblastoma, *Neurooncology* 12 (8) (2010) 871–881.
- [377] M. Weaver, D.W. Laske, Transferrin receptor ligand-targeted toxin conjugate (Tf-CRM107) for therapy of malignant gliomas, *J. Neurooncol.* 65 (1) (2003) 3–13.
- [378] S. Kunwar, S.M. Chang, M.D. Prados, M.S. Berger, J.H. Sampson, D. Croteau, J. W. Sherman, A.Y. Grahn, V.S. Shu, J.L. Dul, S.R. Husain, B.H. Joshi, C. Pedain, R. K. Puri, Safety of intraparenchymal convection-enhanced delivery of cintredekin besudotox in early-phase studies, *Neurosurg. Focus* 20 (4) (2006), E15.
- [379] Z. Lidar, Y. Mardor, T. Jonas, R. Pfeffer, M. Faibel, D. Nass, M. Hadani, Z. Ram, Convection-enhanced delivery of paclitaxel for the treatment of recurrent malignant glioma: a phase I/II clinical study, *J. Neurosurg.* 100 (3) (2004) 472–479.
- [380] E. Allard, C. Passirani, J.P. Benoit, Convection-enhanced delivery of nanocarriers for the treatment of brain tumors, *Biomaterials* 30 (12) (2009) 2302–2318.
- [381] UCSF Brain Tumor Center. Convection enhanced delivery. <https://braintumorcenter.ucsf.edu/treatment/experimental-diagnoses-therapies/convection-enhanced-delivery>.
- [382] M.M. Souweidane, K. Kramer, N. Pandit-Taskar, Z. Zhou, S. Haque, P. Zanzonico, J.A. Carrasquillo, S.K. Lyashchenko, S.B. Thakur, M. Donzelli, R.S. Turner, J. S. Lewis, N.V. Cheung, S.M. Larson, I.J. Dunkel, Convection-enhanced delivery for diffuse intrinsic pontine glioma: a single-centre, dose-escalation, phase 1 trial, *Lancet Oncol.* 19 (8) (2018) 1040–1050.
- [383] J.H. Sampson, G. Archer, C. Pedain, E. Wembacher-Schroder, M. Westphal, S. Kunwar, M.A. Vogelbaum, A. Coan, J.E. Herndon, R. Raghavan, M.L. Brady, D. A. Reardon, A.H. Friedman, H.S. Friedman, M.I. Rodriguez-Ponce, S.M. Chang, S. Mittermeyer, D. Croteau, R.K. Puri, P.T. Investigators, Poor drug distribution as a possible explanation for the results of the PRECISE trial, *J. Neurosurg.* 113 (2) (2010) 301–309.
- [384] J.A. Finbloom, I.L. Aanei, J.M. Bernard, S.H. Klass, S.K. Elledge, K. Han, T. Ozawa, T.P. Nicolaides, M.S. Berger, M.B. Francis, Evaluation of three morphologically distinct virus-like particles as nanocarriers for convection-enhanced drug delivery to glioblastoma, *Nanomaterials* 8 (12) (2018).
- [385] R. Patil, A. Galstyan, T. Sun, E.S. Shatalova, P. Butte, A.N. Mamelak, C. Carico, D. S. Kittle, Z.B. Grodzinski, A. Chiechi, H. Ding, K.L. Black, J.Y. Ljubimova, E. Holler, Poly malic acid chlorotoxin nanoconjugate for near-infrared fluorescence guided resection of glioblastoma multiforme, *Biomaterials* 206 (2019) 146–159.
- [386] C. Lee, G.R. Kim, J. Yoon, S.E. Kim, J.S. Yoo, Y. Piao, In vivo delineation of glioblastoma by targeting tumor-associated macrophages with near-infrared fluorescent silica coated iron oxide nanoparticles in orthotopic xenografts for surgical guidance, *Sci. Rep.* 8 (1) (2018) 11122.
- [387] A. Morgenroth, A.T. Vogg, K. Ermert, B. Zlatopolskiy, F.M. Mottaghy, Hedgehog signaling sensitizes glioma stem cells to endogenous nano-irradiation, *Oncotarget* 5 (14) (2014) 5483–5493.
- [388] M.A. Miller, R. Chandra, M.F. Cuccarese, C. Pfirschke, C. Engblom, S. Stapleton, U. Adhikary, R.H. Kohler, J.F. Mohan, M.J. Pittet, R. Weissleder, Radiation therapy primes tumors for nanotherapeutic delivery via macrophage-mediated vascular bursts, *Sci. Transl. Med.* 9 (2017) 392.
- [389] B. Yang, Y. Chen, J. Shi, Reactive oxygen species (ROS)-based nanomedicine, *Chem. Rev.* 119 (8) (2019) 4881–4985.
- [390] S.B. Yong, J.Y. Chung, Y. Song, J. Kim, S. Ra, Y.H. Kim, Non-viral nano-immunotherapeutics targeting tumor microenvironmental immune cells, *Biomaterials* 219 (2019), 119401.
- [391] S. Zanganeh, G. Hutter, R. Spitzer, O. Lenkov, M. Mahmoudi, A. Shaw, J. S. Pajarinen, H. Nejadnik, S. Goodman, M. Moseley, L.M. Coussens, H.E. Daldrup-Link, Iron oxide nanoparticles inhibit tumour growth by inducing pro-inflammatory macrophage polarization in tumour tissues, *Nat. Nanotechnol.* 11 (11) (2016) 986–994.
- [392] A.A. Kamath, D.D. Friedman, C.D. Hacker, M.D. Smyth, D.D. Limbrick, A.H. Kim, A.H. Hawasli, E.C. Leuthardt, MRI-guided interstitial laser ablation for intracranial lesions: a large single-institution experience of 133 cases, *Stereotact. Funct. Neurosurg.* 95 (6) (2017) 417–428.
- [393] J. Shao, N.R. Radakovitch, M. Grabowski, H. Borghei-Razavi, K. Knusel, K.C. Joshi, B.A. Muhsen, L. Hwang, G.H. Barnett, A.M. Mohammadi, Lessons learned in using laser interstitial thermal therapy (LITT) for treatment of brain tumors: a case series of 238 patients from a single institution, *World Neurosurg.* (2020).
- [394] G.L. Ceresoli, J.G. Aerts, R. Dziadziuszko, R. Ramlau, S. Cedres, J.P. van Meerbeek, M. Mencoboni, D. Planchard, A. Chella, L. Crino, M. Krzakowski, J. Russel, A. Maconi, L. Gianoncelli, F. Grossi, Tumour Treating Fields in combination with pemetrexed and cisplatin or carboplatin as first-line treatment for unresectable malignant pleural mesothelioma (STELLAR): a multicentre, single-arm phase 2 trial, *Lancet Oncol.* 20 (12) (2019) 1702–1709.
- [395] S.H. Burri, V. Gondi, P.D. Brown, M.P. Mehta, The evolving role of tumor treating fields in managing glioblastoma: guide for oncologists, *Am. J. Clin. Oncol.* 41 (2) (2018) 191–196.
- [396] E.D. Kirson, V. Dbalý, F. Tovaryš, J. Vymazal, J.F. Soustiel, A. Itzhaki, D. Mordechovich, S. Steinberg-Shapira, Z. Gurvich, R. Schneiderman, Y. Wasserman, M. Salzberg, B. Ryffel, D. Goldsher, E. Dekel, Y. Palti, Alternating electric fields arrest cell proliferation in animal tumor models and human brain tumors, *Proc. Natl. Acad. Sci. U. S. A.* 104 (24) (2007) 10152–10157.
- [397] R. Stupp, A. Idbaih, D.M. Steinberg, W. Read, S. Toms, G. Barnett, G. Nicholas, C.-Y. Kim, K. Fink, A. Salmaggi, F. Lieberman, J. Zhu, L. Taylor, G. Stragliotto, A. Hottinger, E.D. Kirson, U. Weinberg, Y. Palti, M.E. Hegi, Z. Ram, LTBK-01: prospective, multi-center phase III trial of tumor treating fields together with temozolamide compared to temozolamide alone in patients with newly diagnosed glioblastoma, *Neurooncology* 18 (Suppl 6) (2016) 11.
- [398] E. Chang, C.B. Patel, C. Pohling, C. Young, J. Song, T.A. Flores, Y. Zeng, L. M. Joubert, H. Arami, A. Natarajan, R. Sinclair, S.S. Gambhir, Tumor treating fields increases membrane permeability in glioblastoma cells, *Cell Death Disco* 4 (2018) 113.
- [399] E. Chang, C. Pohling, N. Beygui, C.B. Patel, J. Rosenberg, D.H. Ha, S.S. Gambhir, Synergistic inhibition of glioma cell proliferation by Withaferin A and tumor treating fields, *J. Neurooncol.* 134 (2) (2017) 259–268.
- [400] D.N. Louis, A. Perry, G. Reifenberger, A. von Deimling, D. Figarella-Branger, W. K. Cavenee, H. Ohgaki, O.D. Wiestler, P. Kleihues, D.W. Ellison, The 2016 World Health Organization classification of tumors of the central nervous system: a summary, *Acta Neuropathol.* 131 (6) (2016) 803–820.
- [401] M.T.C. Poon, C.L.M. Sudlow, J.D. Figueiroa, P.M. Brennan, Longer-term (>= 2 years) survival in patients with glioblastoma in population-based studies pre- and post-2005: a systematic review and meta-analysis, *Sci. Rep.* 10 (1) (2020) 11622.
- [402] W. Wick, M. Weller, M. van den Bent, M. Sanson, M. Weiler, A. von Deimling, C. Plass, M. Hegi, M. Platten, G. Reifenberger, MGMT testing—the challenges for biomarker-based glioma treatment, *Nat. Rev. Neurology* 10 (7) (2014) 372–385.
- [403] L. Saadatpour, E. Fadaee, S. Fadaei, R. Nassiri Mansour, M. Mohammadi, S. M. Mousavi, M. Goodarzi, J. Verdi, H. Mirzaei, Glioblastoma: exosome and microRNA as novel diagnosis biomarkers, *Cancer Gene Ther.* 23 (12) (2016) 415–418.
- [404] S.W. Huang, N.D. Ali, L. Zhong, J. Shi, MicroRNAs as biomarkers for human glioblastoma: progress and potential, *Acta Pharm. Sin.* 39 (9) (2018) 1405–1413.
- [405] D. Osti, M. Del Bene, G. Rappa, M. Santos, V. Matafora, C. Richichi, S. Faletti, G. V. Beznoskenko, A. Mironov, A. Bachi, L. Fornasari, D. Bongetta, P. Gaetani, F. DiMeco, A. Lorico, G. Pellicci, Clinical significance of extracellular vesicles in plasma from glioblastoma patients, *Clin. Cancer Res* 25 (1) (2019) 266–276.
- [406] M. Touat, A. Duran-Pena, A. Alentorn, L. Lacroix, C. Massard, A. Idbaih, Emerging circulating biomarkers in glioblastoma: promises and challenges, *Expert Rev. Mol. Diagn.* 15 (10) (2015) 1311–1323.
- [407] S. Santagata, L.S. Eberlin, I. Norton, D. Calligaris, D.R. Feldman, J.L. Ide, X. Liu, J. S. Wiley, M.L. Vestal, S.H. Ramkissoon, D.A. Orringer, K.K. Gill, I.F. Dunn, D. Dias-Santagata, K.L. Ligon, F.A. Jolesz, A.J. Golby, R.G. Cooks, N.Y. Agar, Intraoperative mass spectrometry mapping of an onco-metabolite to guide brain tumor surgery, *Proc. Natl. Acad. Sci. U. S. A.* 111 (30) (2014) 11121–11126.
- [408] J. Qian, E.B. Rankin, Hypoxia-induced phenotypes that mediate tumor heterogeneity, *Adv. Exp. Med. Biol.* 1136 (2019) 43–55.
- [409] N. Schafer, G.H. Gielen, L. Rauschenbach, S. Kebir, A. Till, R. Reinartz, M. Simon, P. Niehusmann, C. Kleinschmitz, U. Herrlinger, T. Pietsch, B. Scheffler, M. Glas, Longitudinal heterogeneity in glioblastoma: moving targets in recurrent versus primary tumors, *J. Transl. Med.* 17 (1) (2019) 96.
- [410] E. Le Rhun, M. Preusser, P. Roth, D.A. Reardon, M. van den Bent, P. Wen, G. Reifenberger, M. Weller, Molecular targeted therapy of glioblastoma, *Cancer Treat. Rev.* 80 (2019), 101896.
- [411] A.K. Pradhan, S. Maji, S.K. Das, L. Emdad, D. Sarkar, P.B. Fisher, MDA-9/Syntenin/SDCBP: new insights into a unique multifunctional scaffold protein, *Cancer Metastasis Rev.* 39 (3) (2020) 769–781.
- [412] S. Talukdar, A.K. Pradhan, P. Bhoothpathy, X.N. Shen, L.A. August, J.J. Windle, D. Sarkar, F.B. Furnari, W.K. Cavenee, S.K. Das, L. Emdad, P.B. Fisher, Regulation of protective autophagy in anoikis-resistant glioma stem cells by SDCBP/MDA-9/Syntenin, *Autophagy* 14 (10) (2018) 1845–1846.
- [413] T.P. Kegelman, B. Wu, S.K. Das, S. Talukdar, J.M. Beckta, B. Hu, L. Emdad, K. Valerie, D. Sarkar, F.B. Furnari, W.K. Cavenee, J. Wei, A. Purves, S.K. De, M. Pellecchia, P.B. Fisher, Inhibition of radiation-induced glioblastoma invasion by genetic and pharmacological targeting of MDA-9/Syntenin, *Proc. Natl. Acad. Sci. USA* 114 (2) (2017) 370–375.
- [414] M. Hassan Mesrati, A.B. Behrooz, A.Y.A. Syahir, Understanding glioblastoma biomarkers: knocking a mountain with a hammer, *Cells* 9 (2020) 5.

- [415] C. Yu, A.M. Mannan, G.M. Yvone, K.N. Ross, Y.L. Zhang, M.A. Marton, B.R. Taylor, A. Crenshaw, J.Z. Gould, P. Tamayo, B.A. Weir, A. Tsherniak, B. Wong, L.A. Garraway, A.F. Shamji, M.A. Palmer, M.A. Foley, W. Winckler, S.L. Schreiber, A.L. Kung, T.R. Golub, High-throughput identification of genotype-specific cancer vulnerabilities in mixtures of barcoded tumor cell lines, *Nat. Biotechnol.* 34 (4) (2016) 419–423.
- [416] J. Xiu, D. Piccioni, T. Juarez, S.C. Pingle, J. Hu, J. Rudnick, K. Fink, D.B. Spetzler, T. Maney, A. Ghazalpour, R. Bender, Z. Gatalica, S. Reddy, N. Sanai, A. Idbaih, M. Glantz, S. Kesari, Multi-platform molecular profiling of a large cohort of glioblastomas reveals potential therapeutic strategies, *Oncotarget* 7 (16) (2016) 21556–21569.
- [417] I. Jovcevska, Next generation sequencing and machine learning technologies are painting the epigenetic portrait of glioblastoma, *Front Oncol.* 10 (2020) 798.
- [418] J. Valdebenito, F. Medina, Machine learning approaches to study glioblastoma: a review of the last decade of applications, *Cancer Rep.* 2 (6) (2019), e1226.
- [419] Y. Zhou, L. Yang, X. Zhang, R. Chen, X. Chen, W. Tang, M. Zhang, Identification of potential biomarkers in glioblastoma through bioinformatic analysis and evaluating their prognostic value, *Biomed. Res Int.* 2019 (2019), 6581576.
- [420] Z.Q. Pan, S.J. Zhang, X.L. Wang, Y.X. Jiao, J.J. Qiu, Machine learning based on a multiparametric and multiregional radiomics signature predicts radiotherapeutic response in patients with glioblastoma, *Behav. Neurol.* 2020 (2020), 1712604.
- [421] F. Andreatta, G. Beccaceci, N. Fortuna, M. Celotti, D. De Felice, M. Lorenzoni, V. Foletto, S. Genovesi, J. Rubert, A. Alaimo, The organoid era permits the development of new applications to study glioblastoma, *Cancers* 12 (11) (2020).
- [422] H. Ruiz-Garcia, K. Alvarado-Estrada, P. Schiapparelli, A. Quinones-Hinojosa, D.M. Trifiletti, Engineering three-dimensional tumor models to study glioma cancer stem cells and tumor microenvironment, *Front. Cell Neurosci.* 14 (2020), 558381.
- [423] L.K. Infinger, C.B. Stevenson, Re-examining the need for tissue diagnosis in pediatric diffuse intrinsic pontine gliomas: a review, *Curr. Neuropharmacol.* 15 (1) (2017) 129–133.
- [424] K. Tang, S. Gardner, M. Snuderl, The role of liquid biopsies in pediatric brain tumors, *J. Neuropathol. Exp. Neurol.* 79 (9) (2020) 934–940.
- [425] A. Linkous, D. Balamatsias, M. Snuderl, L. Edwards, K. Miyaguchi, T. Milner, B. Reich, L. Cohen-Gould, A. Storaska, Y. Nakayama, E. Schenkein, R. Singhania, S. Cirigliano, T. Magdeldin, Y. Lin, G. Nanjangud, K. Chadalavada, D. Pisapia, C. Liston, H.A. Fine, Modeling patient-derived glioblastoma with cerebral organoids, *Cell Rep.* 26 (12) (2019) 3203–3211, e3205.
- [426] M. Ahluwalia, G.H. Barnett, D. Deng, S.B. Tatter, A.W. Laxton, A.M. Mohammadi, E. Leuthardt, R. Chamoun, K. Judy, A. Asher, M. Essig, J. Dietrich, V.L. Chiang, Laser ablation after stereotactic radiosurgery: a multicenter prospective study in patients with metastatic brain tumors and radiation necrosis, *J. Neurosurg.* 130 (3) (2018) 804–811.
- [427] S. Gandhi, A. Tayebi Meybodi, E. Belykh, C. Cavallo, X. Zhao, M.P. Syed, L. Borba Moreira, M.T. Lawton, P. Nakaji, M.C. Preul, Survival outcomes among patients with high-grade glioma treated with 5-aminolevulinic acid-guided surgery: a systematic review and meta-analysis, *Front Oncol.* 9 (2019) 620.
- [428] A.P. Michael, V.L. Watson, D. Ryan, K.R. Delfino, S.V. Bekker, J.W. Cozzens, Effects of 5-ALA dose on resection of glioblastoma, *J. Neurooncol.* 141 (3) (2019) 523–531.
- [429] A. Dubey, R. Kataria, V.D. Sinha, Role of diffusion tensor imaging in brain tumor surgery, *Asian J. Neurosurg.* 13 (2) (2018) 302–306.
- [430] M. Rahman, J. Abbatematteo, E.K. De Leo, P.S. Kubilis, S. Vaziri, F. Bova, E. Sayour, D. Mitchell, A. Quinones-Hinojosa, The effects of new or worsened postoperative neurological deficits on survival of patients with glioblastoma, *J. Neurosurg.* 127 (1) (2017) 123–131.
- [431] R. Stupp, S. Taillibert, A.A. Kanner, S. Kesari, D.M. Steinberg, S.A. Toms, L.P. Taylor, F. Lieberman, A. Silvani, K.L. Fink, G.H. Barnett, J.J. Zhu, J.W. Henson, H.H. Engelhard, T.C. Chen, D.D. Tran, J. Troube, N.D. Tran, A.F. Hottinger, J. Landolfi, R. Desai, M. Caroli, Y. Kew, J. Honnorat, A. Idbaih, E.D. Kirson, U. Weinberg, Y. Palti, M.E. Hegi, Z. Ram, Maintenance therapy with tumor-treating fields plus temozolamide vs temozolamide alone for glioblastoma: a randomized clinical trial, *JAMA* 314 (23) (2015) 2535–2543.
- [432] O. Rominiyi, A. Vanderlinden, S.J. Clenton, C. Bridgewater, Y. Al-Tamimi, S.J. Collis, Tumour treating fields therapy for glioblastoma: current advances and future directions, *Br. J. Cancer* (2020).
- [433] J. Yang, Z. Shi, R. Liu, Y. Wu, X. Zhang, Combined-therapeutic strategies synergistically potentiate glioblastoma multiforme treatment via nanotechnology, *Theranostics* 10 (7) (2020) 3223–3239.
- [434] H.H. Gustafson, D. Holt-Casper, D.W. Grainger, H. Ghandehari, Nanoparticle uptake: the phagocytose problem, *Nano Today* 10 (4) (2015) 487–510.
- [435] M. Zhao, D. van Straten, M.L.D. Broekman, V. Preat, R.M. Schiffelers, Nanocarrier-based drug combination therapy for glioblastoma, *Theranostics* 10 (3) (2020) 1355–1372.
- [436] H. Willers, H.P. Heilmann, H.P. Beck-Bornholdt, One hundred years of radiotherapy. Historical origins and development of fractionated irradiation in German speaking countries, *Strahl. Onkol.* 174 (2) (1998) 53–63.
- [437] E. Daguenet, S. Louati, A.S. Wozny, N. Vial, M. Gras, J.B. Guy, A. Vallard, C. Rodriguez-Lafrasse, N. Magne, Radiation-induced bystander and abscopal effects: important lessons from preclinical models, *Br. J. Cancer* 123 (3) (2020) 339–348.
- [438] C.I. Ene, S.A. Kreuser, M. Jung, H. Zhang, S. Arora, K. White Moyes, F. Szulzewsky, J. Barber, P.J. Cimino, H.G. Wirsching, A. Patel, P. Kong, T.R. Woodiwiss, S.J. Durfy, A.M. Houghton, R.H. Pierce, I.F. Parney, C.A. Crane, E.C. Holland, Anti-PD-L1 antibody direct activation of macrophages contributes to a radiation-induced abscopal response in glioblastoma, *Neurooncology* 22 (5) (2020) 639–651.
- [439] A.G. Junko Zenkoh, Y. Wang, Y. Miwa, T. Ohno, K. Tsuboi, The abscopal effect induced by in situ-irradiated peripheral tumor cells in a murine GL261 brain tumor model, *Transl. Cancer Res.* (2016) 6.
- [440] I.A. Khawar, J.H. Kim, H.J. Kuh, Improving drug delivery to solid tumors: priming the tumor microenvironment, *J. Control Release* 201 (2015) 78–89.
- [441] W. Jiang, C.K. Chan, I.L. Weissman, B.Y.S. Kim, S.M. Hahn, Immune priming of the tumor microenvironment by radiation, *Trends Cancer* 2 (11) (2016) 638–645.